
NATIONAL TOXICOLOGY PROGRAM Technical Report Series No. 226



NATIONAL TOXICOLOGY PROGRAM

The National Toxicology Program (NTP), established in 1978, develops and evaluates scientific information about potentially toxic and hazardous chemicals. This knowledge can be used for protecting the health of the American people and for the primary prevention of chemically induced disease. By bringing together the relevant programs, staff, and resources from the U.S. Public Health Service, DHHS, the National Toxicology Program has centralized and strengthened activities relating to toxicology research, testing and test development/validation efforts, and the dissemination of toxicological information to the public and scientific communities and to the research and regulatory agencies.

The NTP is comprised of four charter DHHS agencies: the National Cancer Institute, National Institutes of Health; the National Institute of Environmental Health Sciences, National Institutes of Health; the National Center for Toxicological Research, Food and Drug Administration; and the National Institute for Occupational Safety and Health, Centers for Disease Control. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS.

NTP Technical Report

on the

CARCINOGENESIS BIOASSAY

of

C. I. SOLVENT YELLOW 14

(CAS No. 842-07-9)

IN F344/N RATS AND B6C3F1 MICE

(FEED STUDY)



NATIONAL TOXICOLOGY PROGRAM Research Triangle Park Box 12233 North Carolina 27709 and Bethesda, Maryland 20205

September 1982

NTP-80-80 NIH Publication No. 82-1782

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health

NOTE TO THE READER

This is one in a series of experiments designed to determine whether selected chemicals produce cancer in animals. Chemicals selected for testing in the NTP carcinogenesis bioassay program are chosen primarily on the bases of human exposure, level of production, and chemical structure. Selection per se is not an indicator of a chemical's carcinogenic Negative results, in which the test animals do not have a potential. greater incidence of cancer than control animals, do not necessarily mean that a test chemical is not a carcinogen, inasmuch as the experiments are conducted under a limited set of conditions. Positive results demonstrate that a test chemical is carcinogenic for animals under the conditions of the test and indicate that exposure to the chemical is a potential hazard to humans. The determination of the risk to humans from chemicals found to be carcinogenic in animals requires a wider analysis which extends beyond the purview of this study.

This study was initiated by the National Cancer Institute's Carcinogenesis Testing Program, now part of the National Institute of Environmental Health Sciences, National Toxicology Program.

Comments and questions about the National Toxicology Program Technical Reports on Carcinogenesis Bioassays should be directed to the National Toxicology Program, located at Room A-306, Landow Building, Bethesda, MD 20205 (301-496-1152) or at Research Triangle Park, NC 27709 (919-541-3991).

Although every effort is made to prepare the Technical Reports as accurately as possible, mistakes may occur. Readers are requested to communicate any mistakes to the Deputy Director, NTP (P.O. Box 12233, Research Triangle Park, NC 27709), so that corrective action may be taken. Further, anyone who is aware of related ongoing or published studies not mentioned in this report is encouraged to make this information known to the NTP.

These NTP Technical Reports are available for sale from the National Technical Information Service, U.S. Department of Commerce, 5285 Port Royal Road, Springfield, VA 22161 (703-487-4650).

Single copies of this carcinogenesis bioassay technical report are available without charge (and while supplies last) from the NTP Public Information Office, National Toxicology Program, P.O. Box 12233, Research Triangle Park, NC 27709.

TABLE OF CONTENTS

Page

Con	tract
	r Review Panel and Comments
Ι.	Introduction
II.	Materials and Methods
A.	Chemical
В.	Dietary Prepartion
С.	Animals
D.	Animal Maintenance
Ε.	Single-Day Dosing and Fourteen-Day Repeated Dose
	Studies
F.	Subchronic Studies
G.	Chronic Studies
н.	Clinical Examinations and Pathology
Ι.	Data Recording and Statistical Analyses
111.	Results - Rats
Α.	Body Weights and Clinical Signs (Rats)
В.	
С.	
D.	Statistical Analyses of Results (Rats)
IV.	Results - Mice
Α.	Body Weights and Clinical Signs (Mice)
В.	Survival (Mice)
C.	Pathology (Mice)
D.	Statistical Analyses of Results (Mice)
v.	Discussion
VI.	Conclusion
VII.	Bibliography
	TABLES
Table 1	Specifications and Sources of Materials Used for Animal Maintenance
Table 2	Dosage and Survival of Rats and Mice Fed Diets Containing C. I. Solvent Yellow 14 for 2 Weeks

Page

Table 3	Dosage, Survival, and Mean Body Weights of Rats Fed Diets Containing C. I. Solvent Yellow 14 for 91 Days	9
Table 4	Dosage, Survival, and Mean Body Weight of Mice Fed Diets Containing C. I. Solvent Yellow 14 for 91 Days	10
Table 5	Experimental Design of Chronic Feeding Studies with C. I. Solvent Yellow 14 in Rats and Mice	12
Table 6	Mean Body Weight Change (Relative to Controls) of Rats Fed Diets Containing C. I. Solvent Yellow 14	19
Table 7	Analyses of the Incidence of Primary Tumors in Male Rats Fed Diets Containing C. I. Solvent Yellow 14	24
Table 8	Analyses of the Incidence of Primary Tumors in Female Rats Fed Diets Containing C. I. Solvent Yellow 14	29
Table 9	Mean Body Weight Change (Relative to Controls) of Mice Fed Diets Containing C. I. Solvent Yellow 14	37
Table 10	Analyses of the Incidence of Primary Tumors in Male Mice Fed Diets Containing C. I. Solvent Yellow 14	41
Table 11	Analyses of the Incidence of Primary Tumors in Female Mice Fed Diets Containing C. I. Solvent Yellow 14	45
Table 12	Comparison of Results of Chronic Feeding Studies of Water-Soluble and Water-Insoluble Monoazo Dyes and Related Compounds	52
	FIGURES	
Figure l	Growth Curves for Rats Fed Diets Containing C. I. Solvent Yellow 14	18
Figure 2	Survival Curves for Rats Fed Diets Containing C. I. Solvent Yellow 14	20
Figure 3	Growth Curves for Mice Fed Diets Containing C. I. Solvent Yellow 14	36
Figure 4	Survival Curves for Mice Fed Diets Containing C. I. Solvent Yellow 14	38
Figure 5	Infrared Absorption Spectrum of C. I. Solvent Yellow 14 (Lot No. PY112075)	147
Figure 6	Nuclear Magnetic Resonance Spectrum of C. I. Solvent Yellow 14 (Lot No. PY112075)	149

APPENDIXES

.

Appendix A	Summary of the Incidence of Neoplasms in Rats Fed Diets Containing C. I. Solvent Yellow 14	59
Table Al	Summary of the Incidence of Neoplasms in Male Rats Fed Diets Containing C. I. Solvent Yellow 14	61
Table A2	Summary of the Incidence of Neoplasms in Female Rats Fed Diets Containing C. I. Solvent Yellow 14	66
Table A3	Individual Animal Tumor Pathology in Male Rats Fed Diets Containing C. I. Solvent Yellow 14	70
Table A4	Individual Animal Tumor Pathology in Female Rats Fed Diets Containing C. I. Solvent Yellow 14	76
Appendix B	Summary of the Incidence of Neoplasms in Mice Fed Diets Containing C. I. Solvent Yellow 14	83
Table Bl	Summary of the Incidence of Neoplasms in Male Mice Fed Diets Containing C. I. Solvent Yellow 14	85
Table B2	Summary of the Incidence of Neoplasms in Female Mice Fed Diets Containing C. I. Solvent Yellow 14	89
Table B3	Individual Animal Tumor Pathology in Male Mice Fed Diets Containing C. I. Solvent Yellow 14	94
Table B4	Individual Animal Tumor Pathology in Female Mice Fed Diets Containing C. I. Solvent Yellow 14	100
Appendix C	Summary of the Incidence of Nonneoplastic Lesions in Rats Fed Diets Containing C. I. Solvent Yellow 14	107
Table Cl	Summary of the Incidence of Nonneoplastic Lesions in Male Rats Fed Diets Containing C. I. Solvent Yellow 14	109
Table C2	Summary of the Incidence of Nonneoplastic Lesions in Female Rats Fed Diets Containing C. I. Solvent Yellow 14	119

Page

Appendix D	Summary of the Incidence of Nonneoplastic Lesions in Mice Fed Diets Containing C. I. Solvent Yellow 14
Table Dl	Summary of the Incidence of Nonneoplastic Lesions in Male Mice Fed Diets Containing C. I. Solvent Yellow 14
Table D2	Summary of the Incidence of Nonneoplastic Lesions in Female Mice Fed Diets Containing C. I. Solvent Yellow 14
Appendix E	Analysis of C. I. Solvent Yellow 14 (Lot No. PY112075) Midwest Research Institute
Appendix F	Analysis of Formulated Diets for Stability of C. I. Solvent Yellow 14
Appendix G	Analysis of Formulated Diets for Concentrations of C. I. Solvent Yellow 14
Table Gl	Analysis of Formulated Diets for Concentrations of C. I. Solvent Yellow 14
Appendix H	Feed Consumption by Rats and Mice Receiving C. I. Solvent Yellow 14
Table Hl	Feed Consumption by Male Rats Receiving C. I. Solvent Yellow 14
Table H2	Feed Consumption by Female Rats Receiving C. I. Solvent Yellow 14
Table H3	Feed Consumption by Male Mice Receiving C. I. Solvent Yellow 14
Table H4	Feed Consumption by Female Mice Receiving C. I. Solvent Yellow 14

.

ABSTRACT

A carcinogenesis bioassay of C. I. Solvent Yellow 14 (94.1% pure), a widely used monoazo dye, was conducted by feeding diets containing 250 or 500 ppm of C.I. Solvent Yellow 14 to groups of 50 F344 rats of either sex for 103 weeks. Similar groups of 50 B6C3F1 mice received diets containing 500 or 1,000 ppm of C. I. Solvent Yellow 14 for 103 weeks. Groups of 50 untreated rats and mice of either sex served as controls.

Throughout the bioassay, mean body weights of dosed rats and mice were slightly lower than those of controls. No compound-related clinical signs or effects on survival were observed.

Increases in nonneoplastic lesions included cardiac valve fibrosis for male and female rats, lymphoid hyperplasia of the lung for male rats, and for female rats, bile duct hyperplasia, focal atrophy of the pancreatic acinus, and nephropathy. None of these effects were observed in mice.

Neoplastic nodules of the liver occurred in rats of either sex with a dose-related trend that was significant (male, P<0.001; female, P=0.005), and the incidences in the high-dose groups were significantly higher than those in the controls (male: control, 5/50; low-dose, 10/50; high-dose, 30/50, P<0.001 and female: control, 2/50; low-dose, 3/49; high-dose, 10/48, P=0.011).

Lymphomas or leukemias occurred in low-dose female mice at an incidence significantly (P<0.05) higher than that in the controls (12/50, 23/50, 17/50). Because of the lack of a dose-related trend and because the incidence in the high-dose group was not significant, the association between the increased incidence of hematopoietic tumors in the low-dose group and the administration of C. I. Solvent Yellow 14 is not clearly established. The incidence of lymphomas or leukemias in male mice was higher (not statistically significant) than that in the corresponding controls (5/49, 10/50, 10/50); in both low- and high-dose rats of either sex the incidence was significantly (P<0.001) lower than that in controls.

Under the conditions of this bioassay, C. I. Solvent Yellow 14 was carcinogenic in male and female F344/N rats, as evidenced by increased incidences of neoplastic nodules of the liver. C. I. Solvent Yellow 14 was not carcinogenic for B6C3F1 mice of either sex.

vii

CONTRIBUTORS

This bioassay was conducted at Battelle Columbus Laboratories, Columbus, Ohio, under a subcontract to Tracor Jitco, Inc., Rockville, Maryland, prime contractor for the NCI Bioassay Program. The prechronic studies were started on June 24, 1976, and finished on December 12, 1976; the chronic studies were begun in March 1977, and completed in April 1979.

Dr. A. Peters (1) was the principal investigator for this study. Ms. T. Voss (1) was the Bioassay Coordinator). Doses of the test chemical were selected by Drs. A. Peters and J. Robens (2,3). Drs. A. Peters, H. Harroff (1), and P. Stromberg (1) were in charge of animal care. Necropsies were directed by Drs. G. S. Dill (1), R. Persing (1), R. Everett (1,4), and D. Thake (1). Histopathologic evaluations were performed by Drs. G. S. Dill (mice) and R. Persing (rats). The pathology report and selected slides were evaluated in August 1980 by the NCI Pathology Working Group as described by Ward et al. (1978). The NCI Pathology Working Group was composed of Drs. G. Reznik (5), S. Stinson (5), and M. Stedham (2). The diagnoses represent a consensus of contracting pathologists and the NCI Pathology Working Group, with final approval by the NCI Pathology Working Group.

Animal pathology tables and survival tables were compiled at EG&G Mason Research Institute (6). Statistical analyses were performed by Dr. J. R. Joiner (2) and Mr. J. Warner (2) using methods selected for the bioassay program by Dr. J. J. Gart (7). Chemical analyses were conducted at Midwest Research Institute (8). Dosage analysis was supervised by Drs. R. Freudenthal (1) and P. Leber (1,9) and by Mr. D. Emmerling (1).

This report was prepared at Tracor Jitco (2) under the direction of Dr. C. Cueto, Director of the Bioassay Program; Dr. C. R. Angel, Associate Director; Dr. J. E. Tomaszewski, chemist; Dr. R. M. Kovatch, pathologist; Dr. W. D. Theriault, reports manager; and Dr. A. C. Jacobs, bioscience writer.

The following scientists at NCI/NTP (5) were responsible for evaluating the bioassay experiment, interpreting the results, and reporting the findings: Dr. Michael P. Dieter, Dr. J. Fielding Douglas, Dr. Charles Grieshaber, Dr. William V. Hartwell, Dr. Joseph Haseman, Dr. James Huff, Dr. Richard Irwin (Chemical Manager), Dr. Ernest E. McConnell, Dr. John A. Moore, Dr. Sherman F. Stinson, and Dr. Jerrold M. Ward.

- (1) Battelle Columbus Laboratories, 505 King Avenue, Columbus, Ohio 43201
- (2) Tracor Jitco, Inc., 1776 East Jefferson Street, Rockville, Maryland 20852
- (3) Now with National Program Staff, U.S. Department of Agriculture, Beltsville, Maryland 20705
- (4) E. I. duPont de Nemours & Co., Wilmington, Delaware 19898

- (5) Carcinogenesis Testing Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205; National Toxicology Program, Research Triangle Park, Box 12233, North Carolina 27709
- (6) EG&G Mason Research Institute, 1530 East Jefferson Street, Rockville, Maryland 20852
- (7) Mathematical Statistics and Applied Mathematics Section, Biometry Branch, Field Studies and Statistics, Division of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205
- (8) Midwest Research Institute, 425 Volker Boulevard, Kansas City, Missouri 64110
- (9) Now with PPG Industries, Inc., One Gateway Center, Pittsburgh, Pennsylvania 15222

REVIEWERS

National Toxicology Program Board of Scientific Counselors' Technical Reports Review Subcommittee

> Margaret Hitchcock, Ph.D. (Chairperson) John B. Pierce Foundation Laboratory New Haven, Connecticut

Alice S. Whittemore, Ph.D.* Stanford University School of Medicine Palo Alto, California Curtis Harper, Ph.D. Associate Professor of Pharmacology University of North Carolina, Chapel Hill, North Carolina

Subcommittee Panel of Experts

Norman Breslow, Ph.D.* University of Washington Seattle, Washington

Joseph H. Highland, Ph.D. (Principal Reviewer) Environmental Defense Fund Washington, D.C.

Frank Mirer, Ph.D. International Union United Auto Workers Detroit, Michigan

Sheldon D. Murphy, Ph.D. (Principal Reviewer) Professor of Toxicology University of Texas Medical School Houston, Texas

Svend Nielsen, D.V.M., Ph.D. Professor of Pathology The University of Connecticut Storrs, Connecticut Bernard A. Schwetz, Ph.D. Toxicology Research Laboratory Dow Chemical U.S.A. Midland, Michigan

Roy Shore, Ph.D. New York University Medical Center New York, New York

James Swenberg, D.V.M., Ph.D. Chief of Pathology Chemical Industry Institute of Toxicology Research Triangle Park, North Carolina

Gary M. Williams, M.D. Chief of Experimental Pathology American Health Foundation Valhalla, New York

^{*} Unable to attend February 18, 1981 meeting

PEER REVIEW PANEL AND COMMENTS

On February 18, 1981, this carcinogenesis bioassay report on C. I. Solvent Yellow 14 underwent peer review by the National Toxicology Program Board of Scientific Counselors' Technical Reports Review Subcommittee and associated Panel of Experts at public meeting held in Building 31C, National Institutes of Health, Bethesda, Maryland.


Dr. Highland, a principal reviewer for the report on the bioassay of C. I. Solvent Yellow 14, agreed with the conclusion in the report that there was a clear association between ingestion of the chemical and a significantly increased incidence of neoplastic nodules of the liver in F344 rats of both sexes. However, he felt the conclusion was weak and not reflective of the discussion section; he stated that the nodules are true neoplasms, and hence, are indicative of potential carcinogenic risk to humans. He mentioned that the dose levels in rats were less than maximum tolerated doses (MTDs), but were based on an indication of possible toxicity to the kidneys at higher doses in the subchronic studies.

As a second principal reviewer, Dr. Murphy agreed with the conclusions in the report; because there was no evidence of carcinogenicity in mice and because of the difficulty in classifying nodules as neoplasms, he said there was "limited evidence" for carcinogenicity. He agreed that an MTD had not been achieved in the studies on rats. He stated that certain neoplastic and nonneoplastic pathologic effects observed should be cited: for instance, in the chronic studies, a significantly lower incidence of lymphomas and leukemias in male and female rats; dose-related increases in incidence of cardiac valve fibrosis in rats and in bile duct hyperplasia, focal atrophy of the pancreas, and nephropathy in female rats; and in the subchronic studies, hepatic degeneration and renal cortical pigment deposition in rats, and hemosiderosis in the liver, spleen, and kidneys of mice. Dr. Murphy praised the discussion section but said that the suggested correlation of lipid solubility of the monoazo dyes with carcinogenicity was purely speculative.

Dr. Williams said that even though such discussion may be speculative, it should be expanded, since with the monoazo dyes, the proposed correlation may be a reasonable hypothesis for why some of the dyes are carcinogenic and others are not. He also stated that this chemical is negative in <u>Salmonella</u> assays because the bacteria have an azo reductase which cleaves the azo bond. Dr. Murphy agreed that the paragraph should be retained and expanded to clarify the possible correlations between lipid solubility, metabolism, and toxicity.

Dr. Moore stated and Dr. Highland agreed that the conclusion and summary statement should be strengthened to say "that this compound was found to be a carcinogen as evidenced by an increased incidence of hepatic neoplastic nodules in rats of both sexes." Dr. Highland moved that the report on the bioassay of C. I. Solvent Yellow 14 be accepted with more emphasis being given to the nonneoplastic effects in the summary, expansion of the discussion of azo dye solubilitytoxicity correlation, and of the positive carcinogenic response in rats. Dr. Murphy seconded the motion and the report was approved unanimously by the Peer Review Panel.

I. INTRODUCTION



C.I. SOLVENT YELLOW 14

CAS NO. 842-07-9

COLOUR INDEX NO. 12055

C. I. Solvent Yellow 14 -- 1-(phenylazo)-2-naphthol -- is a waterinsoluble monoazo dye used to color hydrocarbon solvents, oils, fats, waxes, shoe and floor polishes, cellulose ester varnishes, styrene resins, gasoline, and soap (Society of Dyers and Colourists, 1971). In the 1940's, C. I. Solvent Yellow 14 was used as a colorant for margarine (Childs and Clayson, 1966; and Kirby and Peacock, 1949), but at present it is not used in food, drugs, or cosmetics (IARC, 1975). In 1978, 381,000 pounds were produced in the United States (USITC, 1979).

Several studies indicated that C. I. Solvent Yellow 14 As carcinogenic for mice (Kirby and Peacock, 1949; Bonser et al., 1956; Bonser et al., 1963; Clayson and Bonser, 1965; Clayson et al., 1968; and Jul1, 1979).

Hepatomas were observed in 6/12 male mice 14 months after they were given 17 to 20 subcutaneous injections of 0.25 ml of a 3% solution of C. I. Solvent Yellow 14 in arachis oil at 3-week intervals. Hepatomas were reported by the authors to be very rare among the same (unspecified) strain of mouse (Kirby and Peacock, 1949). This study was not considered adequate because no vehicle controls were used.

Implantation of paraffin wax pellets containing C. I. Solvent Yellow 14 into the bladders of albino, $(C57 \times IF)F_1$, and $(C57B1/6J \times A/J)$ mice resulted in increased bladder tumors, compared with controls (Bonser et al., 1956; Bonser et al., 1963; Clayson and Bonser, 1965; Clayson et al., 1968;

and Jull, 1979). However, implantation of the wax pellet alone is associated with an increased incidence of bladder tumors (Clayson et al., 1968), and the pellet may stimulate the proliferation of epithelial cells of the bladder in mice (Jull, 1979).

No compound-related effects were observed when CBA mice, mice of unspecified strain, and rats were fed diets containing 1,000 ppm C. I. Solvent Yellow 14 for 1 to 2 years (Clayson et al., 1965; and Hackmann, 1951). These studies are not considered to be adequate because small numbers of animals were used and the dosage may not have been at the maximum tolerated level.

C. I. Solvent Yellow 14 was not mutagenic for <u>Salmonella</u> <u>typhimurium</u> TA 98, TA 100, TA 1535, TA 1537, or TA 1538, with or without prior metabolic activation (Garner and Nutman, 1977; Busk and Albanus, 1978; and Brown et al., 1978).

Three metabolites (1-amino-2-naphthyl hydrogen sulfate, 1-amino-2naphthyl glucuronide, and the glucuronide of 1-phenylhydrazo-2-naphthol) have been identified in the urine of albino rats of either sex given C. I. Solvent Yellow 14 by gavage (Childs et al., 1967).

C. I. Solvent Yellow 14 was one of several azo dyes (C.I. Disperse Yellow No. 3, D & C Red No. 9, C.I. Acid Red 14, C.I. Acid Orange 10, and FD & C Yellow No. 6) assigned for testing by the Bioassay Program as part of a class study, because humans are exposed to these dyes and because previous tests described above were considered to be inadequate.

II. MATERIALS AND METHODS

A. Chemical

Technical grade C. I. Solvent Yellow 14 (CAS No. 842-07-9) was obtained from Pylam Products Company (Queen's Village, NY). Lot No. PY 112075 was used for all subchronic and chronic studies.

Purity and identity analyses were performed at Midwest Research Institute (Kansas City, MO) (Appendix E). Results of titration of the azo function with titanous chloride indicated that the test material was 94.1% 1-(phenylazo)-2-naphthol. According to the manufacturer, the remaining 6% of the test material was comprised of various chemical intermediates used in the manufacturing process; no inorganic salts were present. The results of the elemental analysis for carbon were approximately 1% less than the theoretical value and those for nitrogen and hydrogen agreed with the theoretical values. Four trace impurities were detected by thin-layer chromatography. Two minor impurities with areas 0.2% and 0.5% of the the major peak were detected by high-pressure liquid chromatography. The infrared and ultraviolet/visible spectra matched the published spectra for this azo dye. The nuclear magnetic resonance spectrum was qualitatively consistent with the structure, although integration of the proton peri to the azo group was lower than expected.

All lots of technical grade C. I. Solvent Yellow 14 must meet a defined color standard. Since the manufacturer stated that the lot used in the present study was representative of the C. I. Solvent Yellow 14 used for industrial purposes, it was deemed suitable for the present bioassay.

The chemical was periodically analyzed at Battelle Columbus Laboratories using high-pressure liquid chromatography (Appendix E) and infrared spectroscopy. Results from these analyses indicated no change in composition throughout the study.

B. Dietary Preparation

Diets were formulated by mixing weighed amounts of Purina[®] Laboratory Chow animal meal (Table 1) and the test chemical for 15 minutes in a Patterson-Kelly[®] twin-shell blender equipped with an intensifier bar. Formulated diets were stored at 23[°]C for no longer than 10 days.

Diets containing 100,000 ppm C. I. Solvent Yellow 14 were analyzed at Midwest Research Institute and were found to be stable for 2 weeks at temperatures up to 45° C (Appendix F). The analytical concentrations of C. I. Solvent Yellow 14 in randomly selected batches of formulated diets containing target levels of 250, 500, or 1,000 ppm were within $\pm 10\%$ of the desired concentrations (Appendix G).

C. Animals

Four-week-old F344 rats and B6C3F1 mice of either sex were obtained from NCI Frederick Cancer Research Center (Frederick, MD), maintained in separate quarters for approximately 2 weeks, and randomly assigned to cages according to a table of random numbers. The cages were then randomly assigned to control or dosed groups.

D. Animal Maintenance

Rats and mice were housed by species, five per cage, in solid-bottom polycarbonate cages (Table 1) supplied with hardwood chip bedding. Cages and bedding were changed twice per week. Control and test diets were available <u>ad libitum</u> in feed hoppers that were changed weekly. Tap water, supplied and analyzed by the Columbus, Ohio, water department, was available <u>ad libitum</u> via an automatic watering system.

Temperature in the animal rooms was 21^o to 23^oC and the relative humidity was 40%-60%. Room air was changed 15 times per hour. Standard white fluorescent lighting provided illumination 12 hours per day.

Item	Description	Source	
Bedding	Absorb-dri [®] hardwood chips	Lab Products, Inc. (Garfield, NJ)	
Cages	Solid bottom, polycarbonate	Lab Products, Inc. (Garfield, NJ)	
Feed	Purina [®] Laboratory Chow	Ralston Purina Co. (Richmond, IN)	
Watering System	Edstrom Automatic	Edstrom Industries (Waterford, WI)	
Rack Filters	Dupon 2024 Spun-Bonded polyester filters	Snow Filtration (Cincinnati, Ohio)	

Table 1. Specifications and Sources of Materials Used for Animal Maintenance

Rats and mice fed C. I. Solvent Yellow 14 were housed by species in separate rooms, but they shared rooms with animals of the same species on feeding studies of D and C Red No. 9 (CAS 5160-02-1) and C. I. Disperse Yellow 3 (CAS 2832-40-8).

E. Single-Day Dosing and Fourteen-Day Repeated Dose Studies

Single-day dosing and 14-day repeated dose studies were conducted using F344 rats and B6C3F1 mice to determine the toxicity of C. I. Solvent Yellow 14 and the concentrations to be used in the 13-week subchronic studies. In the single-day dosing study, groups of five males and five females of each species were fed diets containing 6,000, 12,500, 25,000, 50,000, or 100,000 ppm C. I. Solvent Yellow 14 for 24 hours and then laboratory chow for the remainder of the study. Feed consumption and weight gain were not determined. All animals were killed on day 15. No deaths occurred among the rats or mice and no signs of toxicity were observed.

Groups of five males and five females of each species were fed diets containing 6,000, 12,500, 25,000, 50,000, or 100,000 ppm C. I. Solvent Yellow 14 for 2 weeks. Surviving animals were killed with carbon dioxide on day 15 (Table 2).

One of five male rats and 1/5 female rats receiving 6,000 ppm and all rats and mice receiving more than 6,000 ppm died. All mice receiving 6,000 ppm survived. Dark red intestines and mildly congested livers were found at necropsy in rats and mice at all doses, but these effects were more severe at higher doses. Histopathologic examinations were not conducted. Doses selected for the subchronic studies were less than those at which deaths occurred in the 14-day study.

Dose		Survival(a)		
(ppm)	Male	Female		
lats				
6,000	4/5	4/5		
12,500	0/5	0/5		
25,000	0/5	0/5		
50,000	0/5	0/5		
100,000	0/5	0/5		
lice				
6,000	5/5	5/5		
12,500	0/5	0/5		
25,000	0/5	0/5		
50,000	0/5	0/5		
00,000	0/5	0/5		

Table 2.	Dosage and Survival of Rats	and Mice Fed Diets Containing
	C. I. Solvent Yellow 14 for	2 Weeks

(a) Number surviving/number per group.

F. Subchronic Studies

Subchronic studies were conducted to determine the concentrations to be used in the chronic studies. Diets containing 0, 250, 500, 1,000, 2,000, or 4,000 ppm C. I. Solvent Yellow 14 were fed for 13 weeks to groups of 10 male and 10 female rats (Table 3), an groups of 10 male and 10 female mice received diets with 0, 500, 1,000, 2,000, 4,000, or 8,000 ppm (Table 4).

Mortality checks were made twice daily and individual animals were weighed weekly. At the end of the 91-day study, survivors were killed with carbon dioxide, necropsies were performed on all animals, and tissues (see section H) were taken for histopathologic analysis from control animals and from animals of the highest dose group in which at least 60% survived. The liver, spleen, kidneys, testicles, thymus, prostate, and seminal vesicles were examined in rats administered 250 or 500 ppm and the liver, spleen, kidneys, and thymus were examined in mice in the 250- and 500-ppm groups.

<u>Rats</u>: None of the rats died. Mean body weights of animals receiving 1,000 ppm or more were depressed by more than 10% when compared with the controls. Feed consumption by rats fed 2,000 or 4,000 ppm was 80% and 60%, respectively, that of the controls.

Hepatic degeneration was observed in all rats receiving 4,000 ppm. The hepatocellular degeneration was characterized by increased basophilia and a granular appearance of hepatocytes adjacent to the portal areas, while centrilobular hepatocytes had a hazy, almost vacuolated appearance. Pigment deposition in the tubular epithelium of the kidney cortex was observed in all females receiving 500 ppm or more and in all males receiving 1,000 ppm or more. The pigment was granular, golden brown, iron negative material and was not further characterized. In males, the pigment was associated with nephrosis.

Because of the kidney effects, doses selected for rats in the chronic study were 250 and 500 ppm.

					Weight Change Relative to
Dose	Survival		Weights (gra		Controls (d)
(ppm)	(a)	<pre>Initial(SE)(b)</pre>	Final(SE)	Change(SE)	(%)
MALE					
0	10/10	115.3 (3.5)	302.6 (6.9)	+187.3 (5.0)	
250	10/10	117.7 (2.4)	299.9 (4.0)	+182.2 (3.0)	-2.7
500	10/10	111.6 (4.3)	297.1 (6.1)	+185.5 (4.5)	-1.0
1,000	10/10	120.9 (3.4)	278.1 (5.1)	+157.2 (4.3)	-16.1
2,000	10/10	122.9 (3.2)	230.6 (4.6)	+107.7 (3.3)	-42.5
4,000	10/10	108.1 (1.9)	120.1 (4.7)	+ 12.0 (4.8)	-93.6
FEMALE					
0	10/10	106.1 (2.7)	189.6 (3.0)	+83.5 (3.7)	
250	10/10	100.1 (2.2)	179.1 (2.7)	+79.0 (2.6)	-5.4
500	10/10	102.0 (2.7)	181.4 (3.3)	+79.4 (2.8)	-4.9
1,000	10/10	96.4 (4.6)	167.5 (4.2)	+71.1 (2.3)	-14.9
2,000	10/10	97.0 (2.0)	148.6 (2.8)	+51.6 (2.7)	-38,2
4,000	10/10	.94.6 (2.4)	115.4 (3.4)	+20.8 (2.5)	-75.1

Table 3.	Dosage, Survival	, and Mean Body	Weights of Rats	Fed Diets
	Containing C. I.	Solvent Yellow	14 for 91 Days	•

(a) Number surviving/number per group.

(b) Standard error.

(c) Weight stratification of animals for randomization into dosed groups was not part of the protocol.

(d) Weight Change Relative to Controls = <u>Weight Change (Dosed Group) - Weight Change (Control Group)</u> X 100 Weight Change (Control Group)

Dose (ppm)	Survival (a)	Mean Body Initial(SE)(b)	Weights (gram Final(SE)	ns)(c) Change(SE)	Weight Change Relative to Controls (d) (%)
			· · · · · · · · · · · · · · · · · · ·		
MALE					
0	10/10	23.5 (0.43)	31.7 (0.56)	+8.2 (0.66)
500	10/10	22.7 (0.45)	31.3 (0.70)	+8.6 (0.50) +4.9
1,000	10/10	23.7 (0.60)	32.2 (0.82)	+8.5 (0.40) +3.7
2,000	10/10	24.0 (0.49)	30.1 (0.67)	+6.1 (0.57) -25.6
4,000	10/10	21.9 (0.31)	28.3 (0.56)	+6.4 (0.78) -22.0
8,000	0/10	16.8 (0.47)			
FEMALE					
0	10/10	18.7(e) (0.26)	23.6 (0.40)	+4.9 (0.23)
500	10/10	18.7(e) (0.26)	24.1 (0.23)	+5.4 (0.22) +10.2
1,000	10/10	18.3(e) (0.26)	23.6 (0.50)	+5.3 (0.50) +8.2
2,000	10/10	18.6(e) (0.27)	24.6 (0.22)	+6.0 (0.39) +22.4
4,000	10/10	18.3(e) (0.42)	24.0 (0.61)	+5.7 (0.47) +16.3
8,000	5/10	15.0(e) (0.45)	24.6 (0.40)	+9.6 (0.37) +95.9

(a) Number surviving/number per group.

(b) Standard error.

(c) Weight stratification of animals for randomization into dosed groups was not part of the protocol.

(d) Weight Change Relative to Controls =
 <u>Weight Change (Dosed Group) - Weight Change (Control Group)</u> X 100
 Weight Change (Control Group)

(e) Weight at day 3.

<u>Mice</u>: Ten of ten male mice and 5/10 female mice receiving 8,000 ppm died. Mean body weight gain was depressed 22% or more in male mice receiving 2,000 ppm or more. Feed consumption data were not interpretable because of urine and fecal material in the feed containers and the scattering of feed by the animals.

Histopathologic examinations were not performed on tissues of mice fed 8,000 ppm because of the large number of deaths in these groups. Splenic, renal, and hepatic hemosiderosis and splenic congestion were found in all mice receiving 2,000 and 4,000 ppm. Splenic hemosiderosis was also found in all mice receiving 1,000 ppm.

Necrosis and regeneration of the renal cortical tubular epithelium were observed in 5/10 males receiving 4,000 ppm, and lymphoid depletion of the thymus was found in 3/9 males in the same dose group.

Due to the compound-related effects seen in the kidney, spleen, and liver, doses selected for mice for the chronic study were 500 and 1,000 ppm.

G. Chronic Studies

The test groups, concentrations of dye in the diet, and durations of the chronic studies are shown in Table 5. Dosed groups were given dosed feed for 103 consecutive weeks, followed by 1 or 2 weeks on basal feed before the terminal kill.

H. Clinical Examinations and Pathology

All animals were observed twice daily to discern morbidity or mortality. Clinical examinations and palpation for masses were performed each month, and the animals were weighed every 4 to 5 weeks. Moribund animals and animals that survived to the end of the bioassay were killed by suffocation in carbon dioxide and necropsied.

	Initial	C. I.	Weeks	on Study
Test Group	No. of Animals	Solvent Yellow 14 (ppm)	Dosed	Not Dosed
Male Rats				
Untreated-Control	50	0	0	104
Low-Dose	50	250	103	1
High-Dose	50	500	103	1
Female Rats				
Untreated-Control	50	0	0	104
Low-Dose	49	250	103	1
High-Dose	50	500	103	1
Male Mice				
Untreated-Control	50	0	0	105
Low-Dose	50	500	103	2
High-Dose	50	1,000	103	2
Female Mice				
Untreated-Control	50	0	0	105
Low-Dose	50	500	103	2
High-Dose	50	1,000	103	2

Table 5. Experimental Design of Chronic Feeding Studies with C. I. Solvent Yellow 14 in Rats and Mice

Gross and microscopic examinations were performed on major tissues, major organs, and all gross lesions from killed animals and from animals found dead, unless precluded in whole or in part by autolysis or cannibalization. Thus, the number of animals from which particular organs or tissues were examined microscopically varies and does not necessarily represent the number of animals that were placed on study in each group. The tissues were preserved in 10% neutral buffered formalin, embedded in paraffin, sectioned. and stained with hematoxylin and eosin. The following were examined microscopically: skin (abdominal), lungs and bronchi, trachea, bone, bone marrow (femur), thigh muscle, spleen, lymph nodes, thymus, heart, salivary glands, liver, pancreas, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, kidney, urinary bladder, pituitary, adrenal, thyroid, parathyroid, testis, prostate, mammary gland, uterus, ovary, brain, epididymus, and all tissue masses.

I. Data Recording and Statistical Analyses

Data on this experiment were recorded in the Carcinogenesis Bioassay Data System (Linhart et al., 1974). The data elements include descriptive the chemicals, animals, experimental design, clinical information on observations, survival, body weight, and individual pathologic results, as recommended by the International Union Against Cancer (Berenblum, 1969). Probabilities of survival were estimated by the product-limit procedure of Kaplan and Meier (1958) and are presented in this report in the form of graphs. Animals were statistically censored as of the time that they died of other than natural causes or were found to be missing; animals dying from natural causes were not statistically censored. Statistical analyses for a possible dose-related effect on survival used the method of Cox (1972) for testing two groups for equality and Tarone's (1975) extensions of Cox's method for testing for a dose-related trend. One-tailed P values have been reported for all tests except the departure from linearity test, which is reported only when its two-tailed P value is less than 0.05.

The incidence of neoplastic or nonneoplastic lesions has been given as the ratio of the number of animals bearing such lesions at a specific anatomic site (numerator) to the number of animals in which that site is examined (denominator). In most instances, the denominators included only those animals for which that site was examined histologically. However, when macroscopic examination was required to detect lesions (e.g., skin or mammary tumors) before histologic sampling or when lesions could have appeared at multiple sites (e.g., lymphomas), the denominators consist of the numbers of animals necropsied.

The purpose of the statistical analyses of tumor incidence is to determine whether animals receiving the test chemical developed a significantly higher proportion of tumors than did the control animals. As a part of these analyses, the one-tailed Fisher exact test (Cox, 1970) was used to compare the tumor incidence of a control group with that of a group of dosed animals at each dose level. When the results from two dosed groups are compared simultaneously with that for a control group, a correction to ensure an overall significance level of 0.05 may be made. The Bonferroni inequality criterion (Miller, 1966) requires that the P values for any comparison be less than or equal to 0.025. When this correction was used, it is discussed in the narrative section. It is not presented in the tables, where the Fisher exact P values are shown.

The Cochran-Armitage test for linear trend in proportions, with continuity correction (Armitage, 1971), was also used. Under the assumption of a linear trend, this test determines if the slope of the dose-response curve is different from zero at the one-tailed 0.05 level of significance. Unless otherwise noted, the direction of the significant trend is a positive dose relationship. This method also provides a two-tailed test of departure from linear trend.

When a time-adjusted analysis was used, deaths that occurred before the first tumor was observed were excluded by basing the statistical tests on animals that survived at least 52 weeks, unless a tumor was found at the anatomic site of interest before week 52. When such a tumor was found,

comparisons were based exclusively on animals that survived at least as long as the animals in which the first tumor were found. Once this reduced set of data was obtained, the standard procedures for analyses of the incidence of tumors (Fisher exact tests, Cochran-Armitage tests, etc.) were followed.

Life table methods were used to analyze the incidence of tumors. Curves of the proportions surviving without an observed tumor were computed as in Saffiotti et al. (1972). The week during which an animal died naturally or was killed was entered as the time point of examination for tumors. The methods of Cox and of Tarone were used for the statistical tests of the groups.

The approximate 95 percent confidence interval for the relative risk of each dosed group compared with its control was calculated from the exact interval on the odds ratio (Gart, 1971). The lower and upper limits of the confidence interval of the relative risk have been included in the tables of statistical analyses. The interpretation of the limits is that, in approximately 95% of a large number of identical experiments, the true ratio of the risk in a dosed group of animals to that in a control group would be within the interval calculated from the experiment. When the lower limit of the confidence interval is greater than one, it can be inferred that a statistically significant result has occurred (P less than 0.025 one-tailed test when the control incidence is not zero, P less than 0.050 when the control incidence is zero). When the lower limit is less than unity but the upper limit is greater than unity, the lower limit indicates the absence of a significant result while the upper limit indicates that there is a theoretical possibility of the induction of tumors by the test chemical, which could not be detected under the conditions of this test.

.

III. RESULTS - RATS

A. Body Weights and Clinical Signs (Rats)

Mean body weights of dosed rats of either sex were lower than those of the controls after week 16 for males and after week 50 for females (Figure 1 and Table 6). No compound-related clinical signs or effects on feed consumption were observed (Appendix H).

B. Survival (Rats)

Estimates of the probabilities of survival of male and female rats administered C. I. Solvent Yellow 14 in the diet at the concentrations of this bioassay, together with those of the control group, are shown by the Kaplan and Meier curves in Figure 2. No significant differences in survival were found between any group of rats. One female rat in the high-dose group was accidentally killed.

In male rats, 28/50 (56%) of the controls, 34/50 (68%) of the low-dose, and 34/50 (68%) of the high-dose group lived to the end of the study at 104 weeks. In female rats, 39/50 (78%) of the controls, 42/49 (86%) of the lowdose, and 38/50 (76%) of the high-dose group lived to the end of the study at 104 weeks. A sufficient number of rats were at risk for the development of late appearing tumors.

C. Pathology (Rats)

Histopathologic findings on neoplasms in rats are summarized in Appendix A, Tables Al and A2; Tables A3 and A4 give the survival and tumor status for each individual animal in the male and female rat studies. Findings on nonneoplastic lesions are summarized in Appendix C, Tables C1 and C2.




Figure 1. Growth Curves for Rats Fed Diets Containing C.I. Solvent Yellow 14

		Mean B	Weight Change Relative to Controls (a) %			
	Week No.	Contro1	(grams) Low Dose	High Dose	Low Dose	High Dose
	0	131(Ъ)	133(Ъ)	133(b)		
Male	5	97	100	99	+3	+2
Rats	26	240	226	231	-6	-4
	46	275	260	261	-5	-5
	67	297	282	278	-5	-6
	88	282	265	261	-6	-7
	103	283	251	259	-11	-8
	0	103(Ъ)	104(Ъ)	102(Ъ)		<u></u>
Female	3	38	35	24	-8	-37
Rats	24	104	100	100	-4	4
	44	122	115	120	-6	-2
	65	144	134	138	-7	-4
	86	163	145	156	-11	-4
	103	183	181	176	-1	-4
						· · · · · · · · · · · · · · · · · · ·
	ht Change R					
<u> </u>	leight Chang		oup) - Weig ght Change		ontrol Group	<u>)</u> X 100

Table 6.	Mean Body Weight	Change (Relative to Controls) of Rats Fed Diets
	Containing C. I.	Solvent Yellow 14

(b) Initial weight.




Figure 2. Survival Curves for Rats Fed Diets Containing C.I. Solvent Yellow 14

A variety of neoplasms are represented among both dosed and control animals. Many of the types of tumors represented have been encountered previously as spontaneous lesions in the rat (Goodman et al., 1979).

Neoplastic nodules of the liver were observed at an increased incidence in all dosed groups (males: controls, 5/50; low-dose, 10/50; high-dose 30/50; females: controls, 2/50; low-dose, 3/49; high-dose, 10/48). Many of the nodules within the liver were small and multiple. They were usually composed of eosinophilic or basophilic hepatocytes and were accompanied by an angiectactic or cystic change. Basophilic and clear cell changes were also generally dose related.

Nonneoplastic lesions considered associated with administration of C. I. Solvent Yellow 14 include: multifocal fibrosis of the cardiac valve (male: 3/50, 6%; 8/50, 16%; 11/50, 22%; female: 10/50, 20%; 17/49, 35%; 18/48, 38%), lymphoid hyperplasia of the lung in male rats (12/50, 24%; 28/50, 56%; 23/50, 46%), and in female rats: bile duct focal hyperplasia (23/50, 46%; 37/49, 76%; 38/48, 79%), atrophy of the pancreatic acinus (4/49, 8%; 22/49, 44%; 25/48, 52%), and nephropathy (11/50, 22%; 16/49, 33%; 25/48, 52%).

A variety of other nonneoplastic lesions were seen in dosed rats. These were the ususal types seen in aging F344 rats (Goodman et al., 1979) and were not considered to be associated with chemical administration.

The histopathologic examination provided evidence that C. I. Solvent Yellow 14 caused an increased incidence of neoplastic nodules of the liver in dosed F344 rats under the conditions of this bioassay.

D. Statistical Analyses of Results (Rats)

Tables 7 and 8 contain the statistical analyses of those primary tumors that met both of the following criteria: (1) At least two animals in one group had the tumor, and (2) The incidence in one or more groups was at least 5%. Leukemia or lymphoma in male rats was observed in decreased incidence in the dosed groups compared with the control group (25/50, 50% in the controls; 2/50, 4% in the low-dose; and 4/50, 8% in the high-dose). The Cochran-Armitage test for linear trend was statistically significant in the negative direction (P less than 0.001), and the Fisher exact tests were significant (P less than 0.001 for both dosed groups). The historical incidence of untreated male F344 rats at this laboratory with lymphoma or leukemia is 93/240 (38.8%). Leukemia or lymphoma in female rats was also observed in decreasing incidence (11/50, 22% in the controls; 2/49, 4% in the low-dose; and 0/49, 0% in the high-dose). The Cochran-Armitage test for linear trend was statistically significant in the negative direction (P less than 0.001) and the Fisher exact tests were significant. The historical incidence of leukemia or lymphoma in untreated female control rats at this laboratory is 50/238 (21%).

Neoplastic nodules in male rats were observed in a statistically significant positive relation to dosage (5/50, 10% in the controls; 10/50, 20% in the low-dose; and 30/50, 60% in the high-dose). The Cochran-Armitage test for linear trend was statistically significant in the positive direction (P less than 0.001), and the Fisher exact test between the high-dose group and the control group was significant (P less than 0.001). The historical incidence of rats with neoplastic nodules is 11/239 (4.6\%) in male controls and 8/238 (3.4\%) in female controls at this laboratory. Neoplastic nodules in female rats were observed in a statistically significant positive relation (2/50, 4% in the controls; 3/49, 6% in the low-dose; 10/48, 21% in the highdose). The Cochran-Armitage test for linear trend was statistically significant in the positive direction (P=0.005), and the Fisher exact test between the high-dose and the control group was significant (P=0.011). Several rats of either sex had carcinoma of the liver.

Chromophobe adenomas or carcinomas of the pituitary in female rats were observed in a statistically significant negative relation in the dosed groups compared with the control group. The Cochran-Armitage test for linear trend was statistically significant in the negative direction (P=0.023). The

values for the Fisher exact test between the high-dose group and the control group (P=0.028), and between the low-dose group and the control (P=0.035) are both above the value of P=0.025 required by the Bonferroni inequality criterion for an overall significance of P=0.05 when two dosed groups are compared with a common control group. In male rats, this tumor was not observed in a statistically significant proportion.

Topography: Morphology	Untreated Control	Low Dose	High Dose
Subcutaneous Tissue: Fibroma (b)	3/50(6)	2/50(4)	6/50(12)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.667 0.058 5.570	2.000 0.454 11.761
Weeks to First Observed Tumor	95	78	97
Hematopoietic System: Lymphocytic Leukemia (b)	19/50(38)	1/50(2)	3/50(6)
P Values (c),(d)	P<0.001(N)	P<0.001(N)	P<0.001(N)
Departure from Linear Trend (f)	P=0.002		
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.053 0.001 0.308	0.158 0.032 0.492
Weeks to First Observed Tumor	89	92	72
Hematopoietic System: All Leukemias (b)	23/50(46)	1/50(2)	3/50(6)
P Values (c),(d)	P<0.001(N)	P<0.001(N)	P<0.001(N)
Departure from Linear Trend (f)	P<0.001		
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.043 0.001 0.248	0.130 0.027 0.393
			72

Table 7. Analyses of the Incidence of Primary Tumors in Male Rats Fed Diets Containing C. I. Solvent Yellow 14 (a)

Topography: Morphology	Untreated Control	Low Dose	High Dose
Hematopoietic System: All Lymphomas or Leukemias (b)	25/50(50)	2/50(4)	4/50(8)
P Values (c),(d)	P≪0.001(N)	P<0.001(N)	P<0.001(N)
Departure from Linear Trend (f)	P<0.001		
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.080 0.010 0.294	0.160 0.044 0.418
Weeks to First Observed Tumor	89	92	72
Liver: Neoplastic Nodule (b)	5/50(10)	10/50(20)	30/50(60)
P Values (c),(d)	P<0.00 1	N.S.	P≪0.001
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		2.000 0.675 6.944	6.000 2.595 17.463
Weeks to First Observed Tumor	95	103	95
Liver: Hepatocellular Carcinoma (b)	1/50(2)	0/50(0)	2/50(4)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.000 0.000 18.658	2.000 0.108 115.621
Weeks to First Observed Tumor	104		103

Table 7. Analyses of the Incidence of Primary Tumors in Male Rats Fed Diets Containing C. I. Solvent Yellow 14 (a)

Table 7.	Analyses of the Incidence of Primary Tumors in Male Rats
	Fed Diets Containing C. I. Solvent Yellow 14 (a)

Topography: Morphology	Untreated Control	Low Dose	High Dose
Liver: Neoplastic Nodule or Hepatocellular Carcinoma (b)	6/50(12)	10/50(20)	31/50(62)
P Values (c),(d)	P<0.001	N.S.	P<0.001
Departure from Linear Trend (f)	P=0.030		
Relative Risk (Untreated Control) (e Lower Limit Upper Limit)	1.667 0.597 5.164	5.167 2.408 13.155
Weeks to First Observed Tumor	95	103	95
Pituitary: Chromophobe Adenoma (b)	5/44(11)	5/45(11)	4/43(9)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e Lower Limit Upper Limit)	0.978 0.242 3.960	0.819 0.173 3.545
Weeks to First Observed Tumor	92	104	76
Adrenal: Pheochromocytoma (b)	6/50(12)	6/49(12)	6/50(12)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e Lower Limit Upper Limit)	1.020 0.293 3.556	1.000 0.287 3.489
Weeks to First Observed Tumor	101	79	104

Table 7.	Analyses of the Incidence of Primary Tumors in Male Rats
	Fed Diets Containing C. I. Solvent Yellow 14 (a)

Topography: Morphology	Untreated Control	Low Dose	High Dose
Thyroid: C-Cell Carcinoma (b)	3/50(6)	4/49(8)	2/50(4)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		1.361 0.243 8.854	0.667 0.058 5.570
Weeks to First Observed Tumor	97	104	104
Pancreatic Islets: Islet-Cell Adenoma (b)	4/50(8)	3/48(6)	0/46(0)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.781 0.120 4.374	0.000 0.000 1.170
Weeks to First Observed Tumor	81	104	
Pancreatic Islets: Islet-Cell Adenoma or Carcinoma (b)	4/50(8)	3/48(6)	1/46(2)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.781 0.120 4.374	0.272 0.006 2.613
Weeks to First Observed Tumor	81	104	104

Table 7. Analyses of the Incidence of Primary Tumors in Male Rats Fed Diets Containing C. I. Solvent Yellow 14 (a)

Topography: Morphology	Untreated Control	Low Dose	High Dose
Testis: Interstitial-Cell Tumor (b)	48/50(96)	46/50(92)	47/50(94)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.958 0.890 1.071	0.979 0.910 1.076
Weeks to First Observed Tumor	78	68	72

(Continued)

(a) Dosed groups received doses of 250 or 500 ppm in the diet.

(b) Number of tumor-bearing animals/number of animals examined at site (percent).

- (c) Beneath the incidence of tumors in the control group is the probability level for the Cochran-Armitage test when P is less than 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a dosed group is the probability level for the Fisher exact test for the comparison of that dosed group with the untreated control group when P is less than 0.05; otherwise, not significant (N.S.) is indicated.
- (d) A negative trend (N) indicates a lower incidence in a dosed group than in a control group.
- (e) The 95 percent confidence interval of the relative risk between each dosed group and the control group.
- (f) The probability level for departure from linear trend is given when P is less than 0.05 for any comparison.

Topography: Morphology	Untreated Control	Low Dose	High Dose
Subcutaneous Tissue: Fibroma (b)	0/50(0)	0/49(0)	3/49(6)
P Values (c),(d)	P=0.036	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		 	Infinite 0.614 Infinite
Weeks to First Observed Tumor			97
Hematopoietic System: Lymphocytic Leukemia (b)	9/50(18)	0/49(0)	0/49(0)
P Values (c),(d)	P<0.001(N)	P=0.001(N)	P=0.001(N)
Departure from Linear Trend (f)	P=0.029		
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.000 0.000 0.388	0.000 0.000 0.388
Weeks to First Observed Tumor	76		
Hematopoietic System: All Leukemia (b)	9/50(18)	1/49(2)	0/49(0)
P Values (c),(d)	P<0.001(N)	P=0.009(N)	P=0.001(N)
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.113 0.003 0.771	0.000 0.000 0.388

Table 8. Analyses of the Incidence of Primary Tumors in Female Rats Fed Diets Containing C. I. Solvent Yellow 14 (a)

(Continued)			
Topography: Morphology	Untreated Control	Low Dose	High Dose
Hematopoietic System: All Lymphomas or Leukemias (b)	11/50(22)	2/49(4)	0/49(0)
P Values (c),(d)	P<0.001(N)	P=0.008(N)	P<0.001(N)
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit	1	0.186 0.021 0.793	0.000 0.000 0.307
Weeks to First Observed Tumor	76	103	
Liver: Neoplastic Nodule (b)	2/50(4)	3/49(6)	10/48(21)
P Values (c),(d)	P=0.005	N.S.	P=0.011
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit)	1.531 0.183 17.671	5.208 1.189 46.803
Weeks to First Observed Tumor	104	104	91
Liver: Hepatocellular Carcinoma (b)	0/50(0)	0/49(0)	2/48(4)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit)		Infinite 0.308 Infinite
Weeks to First Observed Tumor			104

.

Table 8. Analyses of the Incidence of Primary Tumors in Female Rats Fed Diets Containing C. I. Solvent Yellow 14 (a)

Table 8.	Analyses of the Incidence of Primary Tumors in Female Rats Fed
	Diets Containing C. I. Solvent Yellow 14 (a)

Topography: Morphology	Untreated Control	Low Dose	High Dose
Liver: Neoplastic Nodule or			
Hepatocellular Carcinoma (b)	2/50(4)	3/49(6)	11/48(23)
P Values (c),(d)	P=0.003	N.S.	P=0.006
Relative Risk (Untreated Control) (e)		1.531	5.729
Lower Limit		0.183	1.342
Upper Limit		17.671	50.869
Weeks to First Observed Tumor	104	104	91
Pituitary: Chromophobe			
Adenoma (b)	28/44(64)	19/45(42)	18/46(39)
P Values (c),(d)	P=0.014(N)	P=0.035(N)	P=0.017(N)
Relative Risk (Untreated Control) (e)		0.663	0.615
Lower Limit		0.430	0.392
Upper Limit		1.029	0.968
Weeks to First Observed Tumor	96	94	87
Pituitary: Chromophobe			
Adenoma or Carcinoma (b)	28/44(64)	19/45(42)	19/46(41)
P Values (c),(d)	P=0.023(N)	P=0.035(N)	P=0.028(N)
Relative Risk (Untreated Control) (e)		0.663	0.649
Lower Limit		0.430	0.420
Upper Limit		1.029	1.009
Weeks to First Observed Tumor	96	94	87

Table 8. Analyses of the Incidence of Primary Tumors in Female Rats Fed Diets Containing C. I. Solvent Yellow 14 (a)

Topography: Morphology	Untreated Control	Low Dose	High Dose
Adrenal: Pheochromocytoma (b)	0/49(0)	1/48(2)	3/48(6)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		Infinite 0.555 Infinite	Infinite 0.614 Infinite
Weeks to First Observed Tumor		104	86
Thyroid: C-Cell Carcinoma (b)	2/50(4)	3/49(6)	3/48(6)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		1.531 0.183 17.671	1.563 0.187 18.028
Weeks to First Observed Tumor	104	104	104
Mammary Gland: Fibroadenoma (b)	7/50(14)	8/49(16)	7/49(14)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit	1	1.166 0.401 3.489	1.020 0.330 3.155
Weeks to First Observed Tumor	97	77	86

Table 8. Analyses of the Incidence of Primary Tumors in Female Rats Fed Diets Containing C. I. Solvent Yellow 14 (a)

(Continued)

-

Topography: Morphology	Untreated Control	Low Dose	High Dose
Mammary Gland:			<u></u>
Cystfibroadenoma (b)	4/50(8)	2/49(4)	3/49(6)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.510 0.048 3.383	0.765 0.118 4.288
Weeks to First Observed Tumor	104	101	102
Mammary Gland: Adenoma, NOS or Adenocarcinoma, NOS (b)	2/50(4)	3/50(6)	0/50(0)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		1.500 0.180 17.329	0.000 0.000 3.381
Weeks to First Observed Tumor	104	103	
Uterus: Endometrial Stromal Polyp (b)	18/49(37)	20/47(43)	11/48(23)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		1.158 0.672 2.002	0.624 0.300 1.238
Weeks to First Observed Tumor	97	94	104

.

- Table 8. Analyses of the Incidence of Primary Tumors in Female Rats Fed Diets Containing C. I. Solvent Yellow 14 (a)
- (Continued)
- (a) Dosed groups received doses of 250 or 500 ppm in the diet.
- (b) Number of tumor-bearing animals/number of animals examined at site (percent).
- (c) Beneath the incidence of tumors in the control group is the probability level for the Cochran-Armitage test when P is less than 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a dosed group is the probability level for the Fisher exact test for the comparison of that dosed group with the untreated control group when P is less than 0.05; otherwise, not significant (N.S.) is indicated.
- (d) A negative trend (N) indicates a lower incidence in a dosed group than in a control group.
- (e) The 95 percent confidence interval of the relative risk between each dosed group and the control group.
- (f) The probability level for departure from linear trend is given when P is less than 0.05 for any comparison.

IV. RESULTS - MICE

A. Body Weights and Clinical Signs (Mice)

Mean body weights of all dosed mice were slightly lower than those of the controls after week 30 in males and after week 50 in females (Figure 3 and Table 9). No compound-related clinical signs or effects on feed consumption were observed (Appendix H).


B. Survival (Mice)

Estimates of the probabilities of survival of male and female mice administered C. I. Solvent Yellow 14 in the diet at the concentrations of this bioassay, together with those of the control group, are shown by the Kaplan and Meier curves in Figure 4. No significant differences in survival were observed between any of the groups of either sex of mice. One male control animal was reported missing.

In male mice, 44/50 (88%) of the controls, 42/50 (84%) of the low-dose, and 39/50 (78%) of the high-dose group lived to the end of the study at 105 weeks. In female mice, 36/50 (72%) of the controls, 41/50 (82%) of the lowdose, and 37/50 (74%) of the high-dose group lived to the end of the study at 105 weeks.

C. Pathology (Mice)

Histopathologic findings on neoplasms in mice are summarized in Appendix B, Tables B1 and B2; Tables B3 and B4 give the survival and tumor status for each individual animal in the male and female mouse studies. Findings on nonneoplastic lesions are summarized in Appendix D, Tables D1 and D2.





		Mean B	Cumulati ody Weight		Weight Cha	nge Relative
			(grams)		to Contr	ols (a) %
	Week No.	Control	Low Dose	High Dose	Low Dose	High Dose
	0	21(b)	21(Ъ)	21(Ъ)		
Male	5	6	7	6	+17	0
Mice	23	13	13	13	0	0
	42	17	16	15	-6	-12
	62	19	17	16	-11	-16
	84	15	15	14	0	-7
	100	17	15	14	-12	-18
	0	19(Ъ)	19(Ъ)	19(Ъ)	······	
Female	4	3	3	3	0	0
Mice	26	9	8	9	-11	0
	45	13	13	13	0	0
	65	15	14	14	-7	-7
	87	16	15	14	-6	-13
	99	16	15	16	-6	0
	ght Change R					
V	Veight Chang		oup) - Wei ght Change	ght Change (C	Control Group	<u>)</u> X 100

Table 9.	Mean Body Weight	Change (Relative to Controls) of Mice Fed Diets
	Containing C. I.	Solvent Yellow 14

(b) Initial weight.




Figure 4. Survival Curves for Mice Fed Diets Containing C.I. Solvent Yellow 14

A variety of neoplasms are represented among both dosed and control animals. Each type of tumor represented has been encountered previously as a spontaneous lesion in aging B6C3F1 mice (Ward et al., 1979).

A number of female mice from both dosed groups and control groups were diagnosed as having leukemia or malignant lymphomas of various types and in various locations (12/50 in the controls, 23/50 in the low-dose, and 17/50 in the high-dose). There was no corresponding increased incidence of lymphoid hyperplasias.

A variety of nonneoplastic lesions are represented among both control and dosed animals. Such lesions have been encountered previously in aging B6C3F1 mice (Ward et al., 1979), and they are not considered to be compound related.

D. Statistical Analyses of Results (Mice)

Tables 10 and 11 contain the statistical analyses of those primary tumors that occurred in at least two animals of one group and with an incidence of at least 5% in one or more groups.

Lymphomas or leukemias in female mice were observed in a statistically significant positive association in the low-dose group compared with the controls (12/50, 24% in the controls; 23/50, 46% in the low-dose; and 17/50, 34% in the high-dose). The Cochran-Armitage test for linear trend was not significant, but there was a departure from linear trend (P=0.039) due to increased incidence in the low-dose group compared with the other two groups. The Fisher exact test between the low-dose group and the control group was significant (P=0.018), but no significant incidence was observed in the high-dose group. The historical incidence of female mice at this laboratory with leukemia or lymphoma is 70/300 (23.3%), ranging from 20% to 32%. In the absence of significant results in the high-dose group, the association between these tumors and administration of the test substance is not clear. Life table analysis, using the week that an animal died as the time point of

examination for tumors, indicated no significant result. In male mice, this tumor was not observed in a statistically significant proportion.

Time-adjusted tests, eliminating those animals dying before 52 weeks on study, did not materially alter the results reported above since only two control animals, three low-dose animals, and one high-dose animal died before week 52.

a.

Topography: Morphology	Untreated Control	Low Dose	High Dose
Lung: Alveolar/Bronchiolar Adenoma (b)	4/49(8)	6/50(12)	7/50(14)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		1.470 0.372 6.681	1.715 0.467 7.525
Weeks to First Observed Tumor	77	105	105
Lung: Alveolar/Bronchiolar Adenoma or Carcinoma (b)	5/49(10)	7/50(14)	7/50(14)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		1.372 0.403 5.129	1.372 0.403 5.129
Weeks to First Observed Tumor	77	105	105
Hematopoietic System: Malignant Lymphoma Lymphocytic Type (b)	0/49(0)	1/50(2)	3/50(6)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		Infinite 0.053 Infinite	Infinite 0.590 Infinite
Weeks to First Observed Tumor		105	81

Table 10. Analyses of the Incidence of Primary Tumors in Male Mice Fed Diets Containing C. I. Solvent Yellow 14 (a)

Table 10.	Analyses of the Incidence of Primary Tumors in Male Mice Fed
	Diets Containing C. I. Solvent Yellow 14 (a)

Topography: Morphology	Untreated Control	Low Dose	High Dose
Hematopoietic System: Malignant Lymphoma,		<u> </u>	
Histiocytic Type (b)	3/49(6)	8/50(16)	5/50(10)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		2.613 0.672 14.517	1.633 0.337 10.018
Weeks to First Observed Tumor	105	96	98
Hematopoietic System:		<u> </u>	
All Lymphoma (b)	5/49(10)	10/50(20)	9/50(18)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e)		1.960	1.764
Lower Limit Upper Limit		0.662 6.803	0.574 6.247
Weeks to First Observed Tumor	105	96	81
Hematopoietic System:			
All Lymphoma or Leukemia (b)	5/49(10)	10/50(20)	10/50(20)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e)		1.960	1.960
Lower Limit Upper Limit		0.662 6.803	0.662 6.803
Weeks to First Observed Tumor	105	96	69

Topography: Morphology	Untreated Control	Low Dose	High Dose
		<u> </u>	
Liver: Hepatocellular Adenoma (b)	5/49(10)	3/50(6)	7/50(14)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.588 0.096 2.851	1.372 0.403 5.129
Weeks to First Observed Tumor	105	105	105
Liver: Hepatocellular Carcinoma (b)	10/49(20)	9/50(18)	12/50(24)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.882 0.348 2.203	1.176 0.515 2.752
Weeks to First Observed Tumor	77	86	77
Liver: Hepatocellular Adenoma or Carcinoma (b)	15/49(31)	11/50(22)	19/50(38)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.719 0.334 1.500	1.241 0.681 2.302
Weeks to First Observed Tumor	77	86	77

Table 10. Analyses of the Incidence of Primary Tumors in Male Mice Fed Diets Containing C. I. Solvent Yellow 14 (a)

Table 10. Analyses of the Incidence of Primary Tumors in Male Mice Fed Diets Containing C. I. Solvent Yellow 14 (a)

(Continued)

- (a) Dosed groups received doses of 500 or 1,000 ppm in the diet.
- (b) Number of tumor-bearing animals/number of animals examined at site (percent).
- (c) Beneath the incidence of tumors in the control group is the probability level for the Cochran-Armitage test when P is less than 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a dosed group is the probability level for the Fisher exact test for the comparison of that dosed group with the untreated control group when P is less than 0.05; otherwise, not significant (N.S.) is indicated.
- (d) A negative trend (N) indicates a lower incidence in a dosed group than in a control group.
- (e) The 95 percent confidence interval of the relative risk between each dosed group and the control group.

Topography: Morphology	Untreated Control	Low Dose	High Dose
Lung: Alveolar/Bronchiolar Adenoma (b)	2/50(4)	5/50(10)	3/49(6)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		2.500 0.432 25.286	1.531 0.183 17.671
Weeks to First Observed Tumor	105	105	105
Lung: Alveolar/Bronchiolar Adenoma or Carcinoma (b)	3/50(6)	6/50(12)	4/49(8)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		2.000 0.454 11.761	1.361 0.243 8.854
Weeks to First Observed Tumor	66	76	105
Hematopoietic System: Malignant Lymphoma, Histiocytic Type (b)	5/50(10)	15/50(30)	12/50(24)
P Values (c),(d)	N.S.	P=0.011	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		3.000 1.135 9.740	2.400 0.857 8.071
Weeks to First Observed Tumor	80	73	82

Table 11. Analyses of the Incidence of Primary Tumors in Female Mice Fed Diets Containing C. I. Solvent Yellow 14 (a)

(Continued)	

Topography: Morphology	Untreated Control	Low Dose	High Dose
Hematopoietic System: All Lymphomas (b)	9/50(18)	23/50(46)	17/50(34)
P Values (c),(d)	N.S.	P=0.002	N.S.
Departure from Linear Trend (f)	P=0.014		
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		2.556 1.283 5.543	1.889 0.887 4.322
Weeks to First Observed Tumor	80	73	82
Hematopoietic System: Leukemia (b)	3/50(6)	0/50(0)	0/50(0)
P Values (c),(d)	P=0.037(N)	N.S.	N.S.
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		0.000 0.000 1.663	0.000 0.000 1.663
Weeks to First Observed Tumor	53		
Hematopoietic System Lymphoma or Leukemia (b)	12/50(24)	23/50(46)	17/50(34)
P Values (c),(d)	N.S.	P=0.018	N.S.
Departure from Linear Trend (f)	P=0.039		
Relative Risk (Untreated Control) (e) Lower Limit Upper Limit		1.917 1.040 3.693	1.417 0.716 2.892
Weeks to First Observed Tumor	53	73	82

Table 11. Analyses of the Incidence of Primary Tumors in Female Mice Fed Diets Containing C. I. Solvent Yellow 14 (a)

Topography: Morphology	Untreated Control	Low Dose	High Dose
Liver: Hepatocellular Carcinoma (b)	2/50(4)	3/50(6)	4/50(8)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) Lower Limit Upper Limit) (e)	1.500 0.180 17.329	2.000 0.301 21.316
Weeks to First Observed Tumor	105	105	101
Liver: Hepatocellular Adenoma or Carcinoma (b)	2/50(4)	4/50(8)	6/50(12)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) Lower Limit Upper Limit) (e)	2.000 0.301 21.316	3.000 0.569 29.254
Weeks to First Observed Tumor	105	105	101
Thyroid: Follicular-Cell Adenoma (b)	0/49(0)	3/47(6)	1/47(2)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Untreated Control) Lower Limit Upper Limit	(e)	Infinite 0.628 Infinite	Infinite 0.056 Infinite
Weeks to First Observed Tumor		105	104

Table 11. Analyses of the Incidence of Primary Tumors in Female Mice Fed Diets Containing C. I. Solvent Yellow 14 (a)

- (a) Dosed groups received doses of 500 or 1,000 ppm in the diet.
- (b) Number of tumor-bearing animals/number of animals examined at site (percent).
- (c) Beneath the incidence of tumors in the control group is the probability level for the Cochran-Armitage test when P is less than 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a dosed group is the probability level for the Fisher exact test for the comparison of that dosed group with the untreated control group when P is less than 0.05; otherwise, not significant (N.S.) is indicated.
- (d) A negative trend (N) indicates a lower incidence in a dosed group than in a control group.
- (e) The 95 percent confidence interval of the relative risk between each dosed group and the control group.
- (f) The probability level for departure from linear trend is given when P is less than 0.05 for any comparison.

V. DISCUSSION

During the second year of the study, mean body weights of dosed rats and mice of either sex were lower than those of the corresponding controls. No compound-related clinical signs or effects on survival were observed. Compound-related nonneoplastic lesions in the kidney were observed in rats and mice of either sex in the subchronic studies. Compound-related nonneoplastic lesions in the kidney were observed only in female rats (nephropathy: 11/50, 16/49, 25/48) in the chronic studies.

Although lymphomas occurred in low-dose female mice at an incidence significantly higher than that in the controls, neither the incidence in the high-dose group nor the results of life table analysis were significant. In addition, the results of the Cochran-Armitage test for linear trend were not significant, and thus the association between the administration of the C. I. Solvent Yellow 14 and lymphomas in the female mice was not clearly established; these lesions were elevated slightly in dosed male mice. Leukemia or lymphoma occurred in dosed rats of either sex at incidences significantly lower than those of the corresponding controls.

Neoplastic nodules of the liver occurred with a statistically significant dose-related trend in rats of either sex, and the incidences in the high-dose groups were significantly higher than those in the controls. A compoundrelated increased incidence of neoplastic nodules is considered to be indicative of the carcinogenic potential of a compound (IARC, 1980). The biological significance of neoplastic nodules of the rat liver has been the While certain studies have shown a subject of considerable discussion. regression of some neoplastic nodules when carcinogen administration was halted (Farber, 1973; Goldfarb and Zak, 1961; and Teebor and Becker, 1971), certain others have observed progression of these lesions (Reuber, 1965; Sasaki and Yoshida, 1935; and Williams and Yamato, 1972). It has been speculated that diverse results arose from use of imprecise criteria for identifying the nodules and from the different strains of rats being used. In an attempt to resolve this dilemma, a recent study using histochemically

defined criteria for neoplastic nodules in the F344 rat observed continued growth of the nodules following cessation of carcinogen administration, confirming their neoplastic nature (Hirota and Williams, 1979). No evidence to support progression of the nodules to carcinoma was found (Ohmori et al., 1980). This type of information has led several groups to conclude that, while evidence supporting the progression of neoplastic nodules to carcinoma may be inconclusive, these nodules are true neoplasms and hence are indicative of potential carcinogenic risk to humans (IARC, 1980; Squire and Levitt, 1975; Nat. Acad. Sci., 1980). In this study, the dose-related increased incidences of these liver lesions in both male and female rats are considered to be unequivocal evidence of a carcinogenic response to the dietary administration of C. I. Solvent Yellow 14.

Two other water-insoluble monoazo dyes were found to be carcinogenic in bioassays conducted by NCI/NTP. Administration of D and C Red No. 9 was associated with statistically significant increased incidences of fibrosarcomas in the spleen and neoplastic nodules in the liver of male F344 rats, and administration of C. I. Disperse Yellow 3 was associated with statistically significant increased incidences of neoplastic nodules of the liver in male F344 rats and of hepatocellular adenomas in female B6C3F1 mice. In contrast, three water-soluble monoazo dyes (FD&C Yellow No. 6, C. I. Acid Red 14, and C. I. Acid Orange 10) were not found to be carcinogenic. Details of these studies and of azobenzene and aniline hydrochloride are given in Table 12.

Water insoluble and water soluble azo dyes can be reductively cleaved by intestinal bacteria (Childs et al., 1967; Radomski, 1961; and Ryan et al., 1968). The relative toxicity of other azo dyes (Ponceau R, D&C Red No. 9, and D&C Red No. 10) has been correlated with the lipid solubility of their possible metabolites after reductive cleavage of the azo bond (Radomski, 1974). Lipid soluble compounds are generally absorbed more readily by animals than are water soluble compounds (Doull et al., 1980). The presence or absence of carcinogenic effects from the azo dyes studied in the Bioassay Program may be correlated with the extent of absorption of the dyes and their

metabolites -- absorption is greater for water insoluble dyes which yield lipid soluble metabolites and is less for water soluble dyes which yield lipid insoluble metabolites.

Test Substance	Structure	Species	Sex	Dose (ppm)	Duration (Weeks)	Site an of Lesior Liver	nd Type n Observed Spleen
C. I. Solvent Yellow 14 (a) (Present Study) Water Insoluble		Rat (F344) Mouse (B6C3F1)	M F M F	500 500 1,000 1,000	103 103 103 103	N (b) N	
C. I. Disperse Yellow No. 3 (a) (NTP, 1982a) Water Insoluble		Rat (F344) Mouse (B6C3F1)	M F M F	10,000 10,000 5,000 5,000	103 103 103 103	N N	
D & C Red No. 9 (a) (NTP, 1982b) Water Insoluble		Rat (F344) Mouse (B6C3F1)	M F M F	3,000 3,000 2,000 2,000	103 103 103 103	N	N
C. I. Acid Red 14 (c) (NTP, 1982c) Water Soluble		Rat (F344) Mouse (B6C3F1)	M F M F	12,500 25,000 6,000 6,000	103 103 103 103		
C. I. Acid Orange 10 (NTP, 1982d) Water Soluble		Rat (F344) Mouse (B6C3F1)	M F M F	3,000 (d 3,000 (d 6,000 (d 6,000 (d) 103) 103	D (e)	
FD & C Yellow (c) No. 6 (NTP, 1981) Water Soluble		Rat (F344) Mouse (B6C3F1)	H F M F	25,000 25,000 25,000 25,000	103 103 103 103		
Azobenzene (NCI, 1979)		Rat (F344) Mouse (B6C3F1)	M F M F	400 400 400 545	105-106 105-106 105-106 105-106		N N
Aniline Hydrochloride (NCI, 1978)		Rat (F344) Mouse (B6C3F1)	M F M F	6,000 6,000 12,000 12,000	103 103 103 103		N N

Table 12. Comparison of Results of Chronic Feeding Studies of Water-Soluble and Water-Insoluble Monoazo Dyes and Related Compounds

(a) C. I. Solvent Yellow 14, C. I. Disperse Yellow No. 3, and D & C Red No. 9 were on test in the same room.

(b) N = Neoplastic lesion.

(c) C. I. Acid Red 14, C. I. Acid Orange 10, and FD & C Yellow No. 6 were on test in the same room.

(d) May not be maximum tolerated dose.

(e) D = Neoplastic lesion occurred only with significant dose-related trend. Results of the Fisher exact test were not significant.

VI. CONCLUSION

Under the conditions of this bioassay, C. I. Solvent Yellow 14 was carcinogenic in male and female F344/N rats, as evidenced by increased incidences of neoplastic nodules of the liver. C. I. Solvent Yellow 14 was not carcinogenic for B6C3F1 mice of either sex.

.

VII. BIBLIOGRAPHY

Armitage, P., <u>Statistical Methods in Medical Research</u>, John Wiley & Sons, Inc., New York, 1971, pp. 362-365.

Berenblum, I., ed., <u>Carcinogenicity Testing</u>: <u>A</u> <u>Report of the Panel on</u> <u>Carcinogenicity of the Cancer Research Commission of UICC</u>, <u>Vol. 2</u>, International Union Against Cancer, Geneva, 1969.

Bonser, G., Bradshaw, L., Clayson, D., and Jull, J., A further study of the carcinogenic properties of ortho hydroxy-amines and related compounds by bladder implantation in the mouse. Br. J. Cancer 10:539-546, 1956.

Bonser, G., Clayson, D., and Jull, J., The potency of 20-methylcholanthrene relative to other carcinogens on bladder implantation. <u>Br. J. Cancer</u> 17:235-241, 1963.

Brown, J., Roehm, G., and Brown, R., Mutagenicity testing of certified food colors and related azo, xanthene and triphenylmethane dyes with the Salmonella/microsome system. Mutat. Res. 56:249-271, 1978.

Busk, L. and Albanus, L., On the mutagenicity of some azo-dyes. <u>Mutat. Res.</u> 53:161-162, 1978.

Childs, J. and Clayson, D., The metabolism of 1-phenylazo-2-naphthol in the rabbit. Biochem. Pharmacol. 15:1247-1258, 1966.

Childs, J., Nakajima, C., and Clayson, D., The metabolism of 1-phenylazo-2naphthol in the rat with reference to the action of the intestinal flora. Biochem. Pharmacol. 16:1555-1561, 1967.

Clayson, D. and Bonser, G., The induction of tumours of the mouse bladder epithelium by 4-ethylsulphonylnaphthalene-1-sulphonamide. <u>Br</u>. J. <u>Cancer</u> 19:311-316, 1965.

Clayson, D., Lawson, T., Santana, S., and Bonser, G., Correlation between the chemical induction of hyperplasia and of malignancy in the bladder epithelium. Br. J. Cancer 19:297-310, 1965.

Clayson, D., Pringle, J., Bonser, G., and Wood, M., The technique of bladder implantation: further results and an assessment. <u>Br. J. Cancer</u> 22:825, 1968.

Cox, D., <u>Analysis of Binary Data</u>, Methuen & Co., Ltd., London, 1970, pp. 48-52.

Cox, D. Regression models and life tables. J. R. Stat. Soc. <u>B34</u>:187-220, 1972.

Doull, J., Klaassen, C., and Amdur, M., eds., Casarett and Doull's <u>Toxicology</u>, <u>The Basic Science of Poisons</u>, 2nd ed., Macmillan Pub. Co., New York, 1980, p. 66.

Ernsberger, M. L., and Brode, W. R., J. Org. Chem. 6:331-340, 1941.

Farber, E., Hyperplastic liver nodules. Methods. <u>Cancer Res. 7</u>:345-375, 1973.

Garner, R. and Nutman, C., Testing of some azo dyes and their reduction products for mutagenicity using <u>Salmonella</u> <u>typhimurium</u> TA 1538. <u>Mutat</u>. <u>Res</u>. 44:9-19, 1977.

Gart, J., The comparison of proportions: a review of significance tests, confidence limits and adjustments for stratification. <u>Rev. Int. Stat. Inst.</u> <u>39</u>:148-169, 1971.

Golfarb, S., and Zak, F., Role of injury and hyperplasis in the induction of hepatocellular carcinoma. JAMA 178:729-731, 1961.

Goodman, D., Ward, J., Squire, R., Chu, K., and Linhart, M., Neoplastic and nonneoplastic lesions in aging F344 rats. <u>Toxicol</u>. <u>Appl</u>. <u>Pharmacol</u>. 48:237-248, 1979.

Hackmann, C., Untersuchungen ueber die cancerogene wirkung einiger fettloeslicher azofarbstoffe. Zeitshrift fuer Krebsforsch. 57:530-541, 1951.

Hirota, N., and Williams, G. Persistence and growth of rat liver neoplastic nodules following cessation of carcinogen exposure. J. <u>Natl. Cancer Inst.</u> 63:1257-1265, 1979.

Horwitz, W., Ed., Official Methods of Analysis of the Association of Analytical Chemists. 12th edition, Association of Official Analytical Chemists, Washington, D.C., 1975, pp. 636-637, 34.017-34.019.

IARC, Sudan I. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man: Some Aromatic Azo Compounds Vol. 8, World Health Organization, Geneva, 1975, pp. 225-231.

IARC Monographs, Long term and short-term screening assays for carcinogens: A critical appraisal, Supplement 2, World Health Organization, Geneva, 1980, p. 69.

Jull, J., The effect of time on the incidence of carcinomas obtained by the implantation of paraffin wax pellets into mouse bladder. <u>Cancer Letters</u> 6:21-25, 1979.

Kaplan, E. and Meier, P., Nonparametric estimation from incomplete observations. J. Amer. Stat. Assoc. 53:457-481, 1958.

Kirby, A. and Peacock, P., Liver tumours in mice injected with commercial food dyes. Glasgow Med. J. 30:364-372, 1949.

Linhart, M., Cooper, J., Martin, R., Page, N., and Peters, J., Carcinogenesis bioassay data system. Comp. Biomed. Res. 7:230-248, 1974.

Miller, R., Jr., <u>Simultaneous</u> <u>Statistical</u> <u>Inference</u>, McGraw-Hill Book Co., New York, 1966, pp. 6-10.

National Academy of Sciences, Histologic typing of liver tumors of the rat. J. Natl. Cancer Inst., 64:180-206, 1980.

NCI, National Cancer Institute, <u>Bioassay</u> of <u>Aniline Hydrochloride</u>, DHHS Publication No. (NIH) 78-1385, <u>Carcinogenesis</u> Testing Program, National Cancer Institute, National Institutes of Health, Bethesda, Md., 1978.

NCI, National Cancer Institute, <u>Bioassay of Azobenzene</u>, DHEW Publication No. (NIH) 79-1710, Carcinogenesis Testing Program, National Cancer Institute, National Institutes of Health, Bethesda, Md., 1979.

NTP, National Toxicology Program, Carcinogenesis Bioassay of C. I. Disperse Yellow 3, NTP TR 222, Department of Health and Human Services, Research Triangle Park, North Carolina, 1982a.

NTP, National Toxicology Program, Carcinogenesis Bioassay of D & C Red No. 9, NTP TR 225, Department of Health and Human Services, Research Triangle Park, North Carolina, 1982b.

NTP, National Toxicology Program, Carcinogenesis Bioassay of C. I. Acid Red 14, NTP TR 220, Department of Health and Human Services, Research Triangle Park, North Carolina, 1982c.

NTP, National Toxicology Program, Carcinogenesis Bioassay of C. I. Acid Orange 10, NTP TR 211, Department of Health and Human Services, Research Triangle Park, North Carolina, 1982d.

NTP, National Toxicology Program, Carcinogenesis Bioassay of FD & C Yellow No. 6, NTP TR 208, Department of Health and Human Services, Research Triangle Park, North Carolina, 1981.

Ohmori, T., Watanabe, K., and Williams, G., Absence of uniform progressive growth of long-term transplants of rat liver neoplastic nodules. J. Nat. Cancer Inst. 65:485-490, 1980.

Przybylski, W., and McKeown, G. G. Journal of the Assoc. Off. Anal. Chem. 43(4):800-804, 1960.

Radomski, J., The absorption, fate and excretion of Citrus Red No. 2 (2,5-dimethoxyphenyl-azo-2-naphthol) and ext. D&C Red No. 14 (1-xylylazo-2-naphthol). J. Pharmacol. Exp. Ther. 134:100-109, 1961.

Radomski, J., Toxicology of food colors. <u>Ann. Rev. Pharmacol.</u> <u>14</u>:127-137, 1974.

Reuber, M. D., Development of preneoplastic and neoplastic lesions of the liver in male rats given 0.025 percent N-2-fluorenyldiacetamide. J. Nat. Cancer Inst. 34:697-723, 1965.

Ryan, A., Roxon, J., and Sivaryavirojana, A., Bacterial azo reduction: a metabolic reaction in mammals. Nature 219:854-855, 1968.

Sadtler Standard Spectra, Sadtler Research Laboratories, Philadelphia, Pennsylvania, IR No. R579.

Saffiotti, U., Montesano, R., Sellakumar, A., Cefis, F., and Kaufman, D., Respiratory tract carcinogenesis in hamsters induced by different numbers of administration of benzo(a)pyrene and ferric oxide. <u>Cancer Res</u>. 32:1073-1081, 1972.

Sasaki, T., and Yoshida, T., Experimentelle erzeugung des lebercarcinoms durch fuetterung mit o-amidoazotoluol. Virchows Arch. 295:175-200, 1935.

Society of Dyers and Colourists, <u>Colour Index Vol. 3</u>, The Society of Dyers and Colourists, Bradford, England, 1971, p. 3566.

Squire, R. and Levitt, M., Report of a workshop on classification of specific hepatocellular lesions in rats. <u>Cancer Res. 35</u>:3214, 1975.

Tarone, R., Tests for trend in life table analysis. <u>Biometrika</u> 62:679-682, 1975.

Teebor, G. and Becker, F., Regression and persistence of hyperplastic hepatic nodules induced by N-2-fluorenylacetamide and their relationship to hepatocarcinogenesis. <u>Cancer Res. 31:1-3</u>, 1971.

USITC, United States International Trade Commission, <u>Synthetic Organic</u> <u>Chemicals</u> - United States Production and Sales 1978, USITC Publication 1001, U.S. Government Printing Office, Washington, D.C., 1979.

Ward, J., Goodman, D., Griesemer, R., Hardisty, J., Schueler, R., Squire, R., and Strandberg, J., Quality assurance for pathology in rodent carcinogenesis tests. J. Environ. Path. Toxicol. 2:371-378, 1978.

Ward, J., Goodman, D., Squire, R., Chu, K., and Linhart, M., Neoplastic and nonneoplastic lesions in aging B6C3F1 mice. <u>J. Nat. Cancer</u> <u>Inst.</u> 63:849-854, 1979.

Williams, G. and Yamamoto, R., Absence of stainable iron from preneoplastic and neoplastic lesions in rat liver with 8-hydroxyquinoline-induced siderosis. J. Nat. Cancer Inst. 49:685-692, 1972.

APPENDIX A

Summary of the Incidence of Neoplasms in Rats Fed Diets Containing C. I. Solvent Yellow 14

TABLE A1.

	میں شد بند بند مد بند مد مد بند بند بند مد بند مد		
	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY ANIMALS NECROPSIED ANIMALS EXAMINED HISTOPATHOLOGICALLY	50 50 50	50 50 50	50 50 50
INTEGUMENTARY SYSTEM			
*SKIN SQUAMOUS CELL CARCINOMA FIBROMA CARCINOSARCOMA	(50)	(50) 1 (2%) 1 (2%) 1 (2%)	(50)
*SUBCUT TISSUE Squamous cell carcinoma Basal-cell tumor	(50)		(50) 1 (2%) 1 (2%)
FIBROMA FIBROSARCOMA NEURILEMOMA, MALIGNANT	3 (6%) 2 (4%) 1 (2%)	2 (4%)	6 (12%)
RESPIRATORY SYSTEM			
*NASAL CAVITY Squamous cell carcinoma, invasiv	(50)	(50)	(50) 1 (2%)
#LUNG CARCINDSARCOMA, METASTATIC MESOTHELIOMA, METASTATIC	(50) 1 (2%)	(50) 1 (2%)	(50)
HEMATOPOIETIC SYSTEM			
*MULTIPLE ORGANS Malignant Lymphoma, Nos Malig Lymphoma, Lymphocytic Type	(50) 1 (2%)	(50)	(50)
MALIG.LYMPHOMA, LYMPHOCYTIC TYPE Malig.lymphoma, histiocytic type Leukemia,nos		1 (2%)	
		1 (2%)	3 (6%)
#SPLEEN FIBROSARCOMA	(50)	(50)	(50) <u>2 (4%)</u>

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS FED DIETS **CONTAINING C.I. SOLVENT YELLOW 14**

	CONTROL	LOW DOSE	HIGH DOSE
#CERVICAL LYMPH NODE Astrocytoma, metastatic	(47)	(45)	(41)
<pre>#MESENTERIC L. NODE Malig.lymphoma, histiocytic type</pre>	(47)	(45)	(41) 1 (2%)
CIRCULATORY SYSTEM			
*MULTIPLE ORGANS Angiosarcoma	(50)	(50) 1 (2%)	(50)
#SPLEEN HEMANGIOSARCOMA	(50)	(50)	(50) 1 (2%)
DIGESTIVE SYSTEM			
#LIVER NEOPLASTIC NODULE HEPATOCELLULAR CARCINOMA	(50) 5 (10%) 1 (2%)	(50) 10 (20%)	(50) 30 (60% 2 (4%)
#PANCREAS ACINAR-CELL ADENOMA	(50)	(48)	(46) 1 (2%)
#CARDIAC STOMACH Squamous cell papilloma Leiomyosarcoma	(50) 1 (2%)	(50)	(49) 2 (4%)
#JEJUNUM LEIOMYOMA	(47)	(45)	(47) 1 (2%)
#ILEUM Adenocarcinoma, nos Papillary Adenocarcinoma	(47)	(45) 1 (2%)	(47) 1 (2%)
#COLON Adenomatous Polyp, Nos	(50)	(48)	(47) 1 (2%)
JRINARY SYSTEM			
#KIDNEY TUBULAR-CELL_ADENOMA	(50) 1 (2%)	(50)	(50)

TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

•

	CONTROL	LOW DOSE	HIGH DOSE
#KIDNEY/PELVIS TRANSITIONAL-CELL PAPILLOMA	(50)	(50) 1 (2%)	(50)
#URINARY BLADDER TRANSITIONAL-CELL PAPILLOMA	(47)	(46)	(45) 1 (2%)
ENDOCRINE SYSTEM			
#PITUITARY CARCINOMA,NOS	(44)	(45) 1 (2%)	(43)
ADENOMA, NOS Chromophobe Adenoma	1 (2%) 5 (11%)	1 (2%) 5 (11%)	4 (9%)
#ADRENAL CORTICAL ADENOMA	(50)	(49)	(50) 1 (2%)
PHEOCHROMOCYTOMA GANGLIONEUROBLASTOMA	6 (12%)	6 (12%)	6 (12%) 1 (2%)
#ADRENAL MEDULLA GANGLIONEUROBLASTOMA	(50)	(49) 2 (4%)	(50) 1 (2%)
#THYROID C-CELL CARCINOMA	(50) 3 (6%)	(49) 4 (8%)	(50) 2 (4%)
#PANCREATIC ISLETS ISLET-CELL ADENOMA ISLET-CELL CARCINOMA	(50) 4 (8%)	(48) 3 (6%)	(46) 1 (2%)
REPRODUCTIVE SYSTEM			
*MAMMARY GLAND Adenoma, Nos	(50)	(50) 1 (2%)	(50)
FIBROADENOMA	2 (4%)	1 (2%)	1 (2%)
*PREPUTIAL GLAND CARCINOMA.NDS	(50) 1 (2%)	(50)	(50)
ADENOMA, NOS	1 (2%)	1 (2%)	1 (2%)
<pre>#PROSTATE PAPILLARY ADENOMA</pre>	(48)	(42) 2 (5%)	(47)
#TESTIS INTERSTITIAL-CELL TUMOR	(50) 48 (96%)	(50) 46 (92%)	(50) 47 (94%)

TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)

	CONTROL	LOW DOSE	HIGH DOSE
NERVOUS SYSTEM			
#BRAIN/MENINGES GRANULAR-CELL TUMOR, NOS	(50)	(50)	(50) 1 (2%
#BRAIN Astrocytoma	(50)	(50) 1 (2%)	(50)
#CEREBELLUM Astrocytoma	(50)	(50) 1 (2%)	(50)
#MEDULLA OBLONGATA Granular-Cell Tumor, Nos	(50) 1 (2%)	(50)	(50)
NONE MUSCULOSKELETAL SYSTEM NONE			
BODY CAVITIES			
*TUNICA VAGINALIS Mesothelioma, nos		(50) 1 (2%)	(50)
ALL OTHER SYSTEMS			
*MULTIPLE ORGANS MESOTHELIOMA, MALIGNANT	(50) 1 (2%)	(50)	(50)
ORBITAL REGION Squamous cell carcinoma, invasiv			1

TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)

TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)
and the second

	CONTROL	LOW DOSE	HIGH DOSE
NIMAL DISPOSITION SUMMARY			
	50	50	50
NATURAL DEATHƏ Moribund sacrifice	14 8	12 4	11 5
SCHEDULED SACRIFICE Accidentally killed			
TERMINAL SACRIFICE ANIMAL MISSING	28	34	34
INCLUDES AUTOLYZED ANTMALS			
UMOR SUMMARY			
TOTAL ANIMALS WITH PRIMARY TUMORS* Total primary tumors	50 112	48 97	49 120
TOTAL ANIMALS WITH BENIGN TUMORS		46	49
TOTAL BENIGN TUMORS	71	71	73
TOTAL ANIMALS WITH MALIGNANT TUMORS TOTAL MALIGNANT TUMORS	28 35	13 15	14 16
		-	1
TOTAL ANIMALS WITH SECONDARY TUMORS TOTAL SECONDARY TUMORS	# ' 1	2 2	' 2
TOTAL ANIMALS WITH TUMORS UNCERTAIN	_		
BENIGN OR MALIGNANT TOTAL UNCERTAIN TUMORS	6	11	30 31
	-	11	
TOTAL ANIMALS WITH TUMORS UNCERTAIN PRIMARY OR METASTATIC	-		
TOTAL UNCERTAIN TUMORS			
PRIMARY TUMORS: ALL TUMORS EXCEPT S SECONDARY TUMORS: METASTATIC TUMORS			

TABLE A2.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY ANIMALS NECROPSIED ANIMALS EXAMINED HISTOPATHOLOGICALLY	50 50 50 50	49 49 49 49	50 49 48
INTEGUMENTARY SYSTEM			
*SUBCUT TISSUE squamous cell carcinoma sarcoma, nos fibroma	(50) 1 (2%) 1 (2%)	(49)	(49) 3 (6%)
FIBROSARCOMA			1 (2%)
RESPIRATORY SYSTEM			
#LUNG CARCINOMA,NOS	(50)	(49)	(48) 1 (2%)
ALVEOLAR/BRONCHIOLAR CARCINOMA Cortical Carcinoma, metastatic		1 (2%)	1 (2%)
HEMATOPOIETIC SYSTEM			
*MULTIPLE ORGANS Malig.lymphoma, lymphocytic type	(50)	(49)	(49)
MALIG.LYMPHOMA, HISTIOCYTIC TYPE LEUKEMIA, NOS		1 (2%) 1 (2%)	
	9 (18%)		
CIRCULATORY SYSTEM			
NONE			
DIGESTIVE SYSTEM			
#LIVER NEOPLASTIC NODULE	(50) 2 (4%)	(49) 3 (6%)	(48) 10_(21%)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

66

	CONTROL	LOW DOSE	HIGH DOSE
HEPATOCELLULAR CARCINOMA			2 (4%)
#CARDIAC STOMACH Squamous cell papilloma	(50)	(49)	(47) 2 (4%)
URINARY SYSTEM			
#URINARY BLADDER TRANSITIONAL-CELL PAPILLOMA	(47)	(46) 2 (4%)	(47)
ENDOCRINE SYSTEM			
#PITUITARY	(44)		2 (44)
CARCINOMA,NOS CHROMOPHOBE ADENOMA CHROMOPHOBE CARCINOMA GANGLIONEUROBLASTOMA	28 (64%)	19 (42%)	18 (39%) 1 (2%) 1 (2%)
#ADRENAL Cortical Adenoma	(49)	(48) 1 (2%)	(48)
CORTICAL CARCINOMA Pheochromocytoma		1 (2%)	
GANGLIONEUROMA GANGLIONEUROBLASTOMA		1 (2%)	1 (2%)
#THYROID C-CELL CARCINOMA	(50) 2 (4%)	(49) 3 (6%)	(48) 3 (6%)
#PARATHYROID Adenoma, nos	(40)	(38)	(35) 1 (3%)
#PANCREATIC ISLETS ISLET-CELL ADENOMA	(49) 1 (2%)	(49)	(48)
REPRODUCTIVE SYSTEM			
*MAMMARY GLAND Adenoma, Nos	(50) 2 (4%)	(49) 2 (4%)	(49)
ADENOCARCINOMA, NOS FIBROSARCOMA	E (747	1 (2%)	
FIBROADENOMA CYSTFIBROADENOMA	7 (14%) 4 (8%)	8 (16%) 2 (4%)	7 (14%) 3 (6%)

TABLE A2. FEMALE RATS: NEOPLASMS (CONTINUED)

	CONTROL	LOW DOSE	HIGH DOSE
*CLITORAL GLAND CARCINOMA,NOS ADENOMA, NOS CYSTADENOMA, NOS	(50)	(49) 1 (2%) 1 (2%)	(49)
#UTERUS ENDOMETRIAL STROMAL POLYP ENDOMETRIAL STROMAL SARCOMA	(49) 18 (37%)	(47) 20 (43%) 1 (2%)	(48) 11 (23%
#OVARY ADENOCARCINOMA, NOS GRANULOSA-CELL TUMOR	(49)	(47) 1 (2%) 1 (2%)	(48)
NERVOUS SYSTEM			
#BRAIN Chromophobe carcinoma, invasive Astrocytoma	(50)	(49) 1 (2%)	(48) 1 (2%)
#CEREBELLUM ASTROCYTOMA	(50)	(49) 1 (2%)	(48)
#MEDULLA OBLONGATA Astrocytoma	(50)	(49)	(48) 1 (2%)
SPECIAL SENSE ORGANS None			
MUSCULOSKELETAL SYSTEM None			
BODY CAVITIES			
*ABDOMINAL CAVITY Mesothelioma, Nos	(50) 1 (2%)	(49)	(49)
ALL OTHER SYSTEMS			
NONE	<u></u>		

TABLE A2, FEMALE RATS: NEOPLASMS (CONTINUED)

* NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
ANIMAL DISPOSITION SUMMARY			
ANIMALS INITIALLY IN STUDY NATURAL DEATHƏ MORIBUND SACRIFICE SCHEDULED SACRIFICE	50 8 3	49 3 4	50 6 5
ACCIDENTALLY KILLED TERMINAL SACRIFICE ANIMAL MISSING	39	42	1 38
INCLUDES AUTOLYZED ANIMALS			
UMOR SUMMARY			
TOTAL ANIMALS WITH PRIMARY TUMORS* Total primary tumors	44 80	4 1 7 4	38 73
TOTAL ANIMALS WITH BENIGN TUMORS TOTAL BENIGN TUMORS	38 58	37 54	28 46
TOTAL ANIMALS WITH MALIGNANT TUMORS TOTAL MALIGNANT TUMORS	15 15	1 1 14	13 14
TOTAL ANIMALS WITH SECONDARY TUMORS TOTAL SECONDARY TUMORS	•		2 2
TOTAL ANIMALS WITH TUMORS UNCERTAIN- Benign or malignant Total uncertain tumors	7 7	6 6	13 13
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC TOTAL UNCERTAIN TUMORS			
PRIMARY TUMORS: ALL TUMORS EXCEPT SE			DUACENT ORGA

TABLE A2. FEMALE RATS: NEOPLASMS (CONTINUED)

TABLE A3.

INDIVIDUAL ANIMAL TUMOR PATHOLOGY IN MALE RATS FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

CO	мτ	D1	ור
- UUI		n١] L

NUMBER	9	2	0 3	0	5	0	2	0	0 9	_01	-1	2	3	4	5	6	뷞	8	1	0	2	2	0 2 3	24	
WEEKS ON Study	1	2	9	1	0	6 1 0	ö	8 0 8	0	0	1	9	0	8	0	9	0	8 8	0	2	1	10	1	1	
NTEGUMENTARY SYSTEM	-[-2]		-2	-9.	- 91	_21	_41			_41	-91	-21	لك		41	اه.	-81	- 71	. 91	41	4	1	41	4	
SUBCUTANEOUS TISSUE Fibroma Fibrosarcoma Neurilemoma, malignant	+	•	* x	•	•	٠	+	٠	+	+	•	+	• x	+	+	٠	•	+	+	+	•	٠	•	•	•
ESPIRATORY SYSTEM			~~~~															····				_~-	-		-
LUNGS AND BRONCHI Mesotheliona, metastatic	ŀ	•	+	+	+	+	+	•	+	•	+	+	.+	+	+	+	+	+	+	+	+	*	٠	•	_
TRACHEA	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	•
EMATOPOIETIC SYSTEM																									
BONE MARROW	+		+	_+	<u>+</u> -	+	<u>+</u>	+	- <u>+</u> -	+	+	+	+	+	+	+	+	+	+	+.	+	+	+	*	-
SPLEEN	+÷	<u>.</u>	<u>.</u>	<u>.</u>	+	•	- <u>*</u>	<u> </u>		<u>+</u>	<u>.</u>	<u>,</u>	<u>+</u>	+	<u>+</u>	<u>.</u>	<u>+</u>	<u>+</u>	•	<u>+</u>	<u>.</u>	•	+	•	
LYMPH NODES Thymus	+	• •	+	+		-		÷	+	+	+	+	+	÷	+	+	<u>.</u>	-	+	+	+	+	+		_
IRCULATORY SYSTEM	-		<u> </u>			_	<u> </u>	-	_		<u> </u>	_	<u> </u>		<u> </u>	<u> </u>		-		<u> </u>	<u> </u>		_	<u> </u>	
HEART	1.	+	+	+	÷	+	÷	+	÷	÷	÷	÷	+	•	+	÷	÷	÷	+	+	÷	+	•	•	
IGESTIVE SYSTEM	<u> </u>	·				·									•		<u> </u>	<u> </u>			<u> </u>	<u> </u>			_
SALIVARY GLAND	1.		•		+	+	+	+	÷	÷	÷	+	÷	-	÷	÷	÷	÷		÷	+	÷	÷	÷	
LIVER HEOPLASTIC NODULE HEPATOCELLULAR CARCINOMA	ŀ	+	+	٠	+	+	+	+	+	+	+	+	+	+	ŧ	+	+	+	+	+	+	+	+	+	4
BILE DUCT	+	+	+	+	+	+	+	+	+	+	+	٠	+	+	+	+	+	+	+	+	+	+	+	+	,
GALLBLADDER & COMMON BILE DUCT	N	N	н	N	N	N	N	N	N	N	N	N	N	N	N	H	N	N	N	N	N	N	N	N	
PANCREAS	1.	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		<u>.</u> t_	+	+	+	+	
ESOPHAGUS	+	+	+	+	+	+	+	+	+	•	+	+	•	+	+	+	÷	+	•	+	+	ŧ	٠	÷	
STOMACH Leighyosarcoma	ŀ	+	+	+	•	+	+	•	+	+	+	+	٠	•	+	•	٠	٠	•	٠	+	٠	٠	+	•
SMALL INTESTINE	1±	•	+	+	+	+	+	+	+	+_	+	+	-	+	t	+	+	-	+	. t _	_ <u>t</u> _		+	+	-
LARGE INTESTINE	•	+	+	٠	+	٠	٠	+	+	÷	+	+	+	+	+	+	+	٠	+	+	+	٠	+	+	1
RINARY SYSTEM								•							-										_
KIDNEY Tubular-Cell Adenoma	L.	+	+	+	•	•	+	+	+	+	+	+	+	+	+	•	+	•	+	+	+	+	+	+-	•
URINARY BLADDER	+	+	+	+	+	-	+	-	-	+	+	+	+	+	+	+	+	+	+	+	+	٠	+	+	4
NDOCRINE SYSTEM											_					_			_						
PITUITARY Adenoma, nos Chromophobe Adenoma		•	*	+	*	•	+	*	•	+ x	+ x	-	+	•	•	-	•	-	+	•	*	+ x	-	+	•
ADRENAL Pheochromocytoma	ŀ	•	+	+	+	*	+	+	+	+	+	+	+	+	+	+	+	+	* x	+	+	*	+	ż	•
THYROID C-CELL CARCINOMA	ŀ	+	•	+	+	+	•	•	+	+	•	•	+	+	+	+	•	•	+	+	+	ż	+	+	•
PARATHYROID	++	-	-	+	+	+	-	+	+	+	+	-	+	-	+	.+	+	+	-	-	+			+	
PANCREATIC ISLETS ISLET-CELL ADENOMA	+	+	*	*	*	+	+	+	*	+	•	•	+	+	+	+	+	+	•	+	+	•	+	•	1
EPRODUCTIVE SYSTEM MAMMARY GLAND								N	+	+	+	+	N	+											
FIBROADENOMA	+	+	+	+	+	+	+		-		-	<u> </u>		-	+	N	+	+ -	N	N	+	N 	×	+	
INTERSTITIAL-CELL TUMOR	Ļ.ž.	<u> </u>	<u>×</u>	x	<u>×</u>	×.	ž.	x	x	×_	x	ž.	ž.	×_	ž.	<u>×</u>	ż		×.	ž.	ż.	<u>×</u>	<u>×</u>	x	2
PROSTATE	+	+	+	+	٠	-	+	+	-	+	+	+	+	+	+	٠	٠	+	٠	+	+	٠	+	+	1
PREPUTIAL/CLITORAL GLAND Carcinoma, NOS Adenoma, NOS	H	N	N	N	N	N	H	N	H	H	N	N	N	N	N	N	N	N	N	N	N X	N	N	H	۲
ERVOUS SYSTEM		-				•																			
BRAIN GRANULAR-CELL TUMOR, NOS	+	+	٠	+	+	+	٠	* x	+	+	+	+	+	٠	+	•	+	+	٠	+	+	٠	+	٠	٠
LL OTHER SYSTEMS																									
MULTIPLE ORGANS NOS MESOTHELIOMA, MALIGNANT Malignant Lymphoma, Nos Malig.Lymphoma, Histiocytic Type Leukemia, Nos Lymphocytic Leukemia	N	N	N	N	N	N	N	N	N	H	N	M	N	N	N	N	N	N X	H	H	N X	H X	N	н	۲
LYMPHOCYTIC LEUKEMIA	_l x_		x			x						x	x	x	E IN NC	x			x					x	

¥1

.

TABLE A3. MALE RATS: TUMOR PATHOLOGY (CONTINUED) CONTROL

ANIMAL NUMBER WEEKS ON	0 2 6 1	0 2 7 0	028	2 9	3	0 3 1 0 9	0 3 2 0	0 3 3	3	3	3	3	31	3	-		2	3		5	6	4 7	4 8 1	9	5 0 1	TOTAL TISSUE TUMOR
STUDY	4	8 1	4	4	9	읽	8	0 4	3	?	4	4	4	4	9	4	4	4	4	4	2	1	4	4	0 3	TUMOR
SUBCUTANEOUS TISSUE FIBROMA FIBROSARCOMA NEURILEMOMA, MALIGNANT	.	N	٠	٠	٠	٠	• x	٠	٠	٠	٠	+	٠	٠	٠	٠	٠	٠	HX	* x	٠	+ x	٠	٠	٠	50 H 3 2 1
RESPIRATORY SYSTEM								·										•								
LUNGS AND BRONCHI Mesothelioma, metastatic	Ŀ		+	<u> </u>	*	<u>.</u>	*	•	*	•	*	<u>*</u>	+	*	*	*	•	*	*	*	+	+	•	+	+	50
TRACHEA	•	+	+	+	٠	٠	+	٠	+	+	٠	+	•	٠	+	+	٠	+	٠	٠	٠	+	٠	٠	+	49
HEMATOPOIETIC SYSTEM	1																									
BONE MARROW	+-	<u>+</u>	+	<u>+</u>	*	+	<u>+</u>	<u>+</u>	* <u>*</u>	<u>+</u>	<u>*</u>	<u>*</u>	<u>*</u>	<u>*</u>	<u>+</u>	<u>+</u>	<u>+</u>	+	<u>+</u>	<u>*</u>	<u>*</u>	+	+	+	-+	49
SPLEEN Lymph Nodes	†÷	<u>.</u>	<u>.</u>	*	<u>+</u>	•	<u>.</u>	<u>+</u>	<u>.</u>	+	÷	÷	÷	<u>+</u>	<u>.</u>	<u>.</u>	<u>*</u>	:	+	÷	•	÷.	:	÷	-	<u>50</u> 47
THYMUS	T.	<u>+</u>	+	+	+	- <u>-</u>	÷	-	- <u></u>	-	÷	-	•	+	+	+	-	•	+	+	+	-	•		-	37
CIRCULATORY SYSTEM	+																								-	
HEART	+	÷	÷	٠	٠	÷	÷	+	÷	+	٠	÷	÷	+	+	÷	+	٠	+	+	÷	÷	٠	٠	+	50
DIGESTIVE SYSTEM	1-																								-	
SALIVARY GLAND	+		+	+	•	+	+	+	+	+	+	<u>+</u>	+	-	+	<u>+</u>	<u>.</u>	<u>+</u>	<u>+</u>	<u>+</u>	<u>.</u>	<u>+</u>	+	+	+	47
LIVER Neoplastic Nodule Hepatocellular carcinoma	×	•	•	•	•	*	•	•	•	•	•	•	*	*	•	+	*	•	•	•	•	•	• x	+	+	50 5
BILE DUCT	ł۰	+	<u>+</u>	+	<u>+</u>	+	+	+	+	+		<u>+</u>		+		•	+	+	+	+	+	+	٠	+	+	50
GALLBLADDER & COMMON BILE DUCT	N	N	N	N	N	N	N	N	N	N	N	N	N		H	N	N	N	N	N	N	N	N	N	M	50×
PANCREAS ESOPHAGUS	†÷	. <u>+</u>	<u>+</u>	+		•	<u>+</u>	<u>*</u>	<u>+</u>	+	•	•	+	•	+	<u>+</u>	+	+	+	+	+	+	+	+	+	50
STOMACH	÷	÷	÷	•	*	+	+	•	+	+	• •	• •	•	÷	• •	• •	•	• •	+	÷.	÷	÷	+	÷	-	<u>50</u> 50
LEIOMYOSARCOMA	ļ				<u> </u>						<u> </u>							-				×.				1
SMALL INTESTINE	+-	<u>+</u>	+	+	•	•	+	+	+	•	<u>+</u>	<u>+</u>		<u>+</u>	+	<u>+</u>	<u>+</u>	±	<u>+</u>	+	+	+	+	+	╡	47
LARGE INTESTINE JRINARY SYSTEM	L.	*	*	+	<u>+</u>	*	*	*	*	+	+	*	+	+	•	+	+	•	+	•	+	+	•	•	4	50
KIDHEY	•	•	÷		•	•	•	÷	•	÷	•	•	÷	•	•	•	•	•	÷	•	٠	÷	•	•		50
TUBULAR-CELL ADENOMA	×																								-1	ł
URINARY BLADDER	+	*	+	+	+	+	+	<u>*</u>	*	+	•	+	+	+	•	+	•	*	*	<u>+</u>	+	+	+	+	1	47
NDOCRINE SYSTEM Pituitary Adenoma, Nos Chronophobe Adenoma	+	÷	٠	٠	٠	٠	÷	٠	-	* ×	٠	•	٠	+	•	•	•	•	+	+	+	•	٠	÷	-	44 1
ADRENAL	+	+	•	+	•	+	+	÷	+	+	+	÷	+	ŧ	+	•	•	+	÷	÷	÷	+	+	+	+	50
PHEOCHROMOCYTOMA Thyroid	×−	+	+	* *					+				+	+	•				+						-+	6
C-CELL CARCINOMA	Ľ	•		•	+	+	+	+	-	<u>×</u>	+	+	•	•		•	•	•	•	+	+	+	+	ż	1	⁵⁰ 3
PARATHYROID	<u>+</u>	<u>+</u>	+	•		+	+	+	+	+	+	<u>+</u>	+	+	<u>+ </u>	<u>+</u>	+	+	+	+	-	+	•	+	-	38
PANCREATIC ISLETS Islet-cell Adenoma	+	*	+	•	+	+	+	•	•	+	+	+	•	* ×	* x	+	+	•	+	+	+	+	•	•	+	50 4
EPRODUCTIVE SYSTEM								-														_			╉	
MAMMARY GLAND FIBROADENOMA	+	H	+	•	•	•	N	*	+	+	N	+	•	+	N	N	•	•	N	+	N	N	N	•	4	50× 2
TESTIS INTERSTITIAL-CELL TUMOR	* ×	*	*	*	* ×	<u>*</u>	<u>*</u>	<u>*</u>	<u>*</u>	<u>*</u>	*	* x	+ x	*	* x	ŧ.	*:	*	*	*	•	<u>*</u>	ż_	<u>*</u>	<u>x</u>	50 48
PROSTATE	+	÷	+	+	+	٠	÷	÷	+	•	÷	•	+	+	+	÷	•	+	•	÷	+	+	•	+	+	48
PREPUTIAL/CLITORAL GLAND Carcinoma,nos Adenoma, nos	H	N	N	N	N X	N	N	N	N	н	N	N	N	N	H I	H I	NI	N I	H	Ν	N	N	H	N	H	50× 1
ERVOUS SYSTEM																					~~~				+	
BRAIN Granular-Cell Tumor, NOS	+	+	+	+	+	+	+	+	÷	+	+	+	•	•	• •	•	•	•	+	+	÷	+	٠	+	+	50 I
LL OTHER SYSTEMS		~ ~																							+	
MULTIPLE ORGANS NOS MESOTHELIOMA, MALIGMANT MALIGNANT (YMPHOMA, NOS MALIG, LYMPHOMA, HISTIOCYTIC TYPE LEUKEMIA,NOS	N	N	N	н	H	N	N	N			N	N	N 1	N 1	N I	• •	NI	•	N	H	N	N	N	н	N	50× 1 1
MALIG.LYMPHOMA, HISTIOCYTIC TYPE Leukemia,nos Lymphocytic leukemia	_x_			×	<u>x</u>	<u>x</u>		<u>x_</u>	<u>x</u>	× 		:	× ,	<u> </u>	<u>x_</u>		x			x			×	x		1 4 19
ANIMALS NECROPSIED +: TISSUE EXAMINED MICROSCOP -: REQUIRED TISSUE NOT EXAMI X: TUMOR INCIDENCE N: NECROPSY, NO AUTOLYSIS, N	ICAL NED 9 mi	LY MIC Crd	ROS SCO	COP PIC	ICA Ex	LLY AMI	NAT	104			: A: B:	ND Ne Au An No	TI CRO TOL IMA NE	SSU PSY YSI L M CRO	E 1 5 155 P5Y	NFO O H Ing Pe	RMA IST RFO	T 1 0 0 L 0 RME	GY D	DVI	4E TO	TED Pi	ROT	oco	L	

TABLE A3.

INDIVIDUAL ANIMAL TUMOR PATHOLOGY IN MALE RATS FED DIETS CONTAINING **C.I. SOLVENT YELLOW 14**

LOW DOSE ANIMAL 0 0 0 WEEKS O INTEGUMENTARY SYSTEM SKIN Squamdus cell carcinoma Fibroma Carcinosarcoma SUBCUTANEOUS TISSUE FIBROMA RESPIRATORY SYSTEM LUNGS AND BRONCHI CARCINOSARCOMA, METASTATIC TRACHEA HEMATOPOIETIC SYSTEM BONE MARROW SPI EEN LYMPH NODES ASTROCYTOMA, METASTATIC THYMUS CIRCULATORY SYSTEM HEART DIGESTIVE SYSTEM SALTVARY GLAND LIVER NEOPLASTIC NODULE * * * * * * * * * * * * * * * * * * * BILE DUCT GALLBLADDER & COMMON BILE DUCT PANCREAS ESOPHAGUS STOMACH SMALL INTESTINE PAPILLARY ADENOCARCINOMA LARGE INTESTINE URINARY SYSTEM KIDNEY TUBULAR-CELL ADENOMA KIDNEY/PELVIS TRANSITIONAL-CELL PAPILLOMA URINARY BLADDER ENDOCRINE SYSTEM PITUITARY CARCINOMA, NOS Adenoma, Nos Chromophobe Adenoma ADRENAL PHEOCHROMOCYTOMA GANGLIONEUROBLASTOMA THYROID C-CELL CARCINOMA PARATHYROID PANCREATIC ISLETS ISLET-CELL ADENOMA REPRODUCTIVE SYSTEM MAMMARY GLAND ADENOMA, NOS FIBRGADENOMA TESTIS INTERSTITIAL-CELL TUMOR PROSTATE PAPILLARY ADENOMA PREPUTIAL/CLITORAL GLAND NERVOUS SYSTEM BRAIN ASTROCYTOMA BODY CAVITIES TUNICA VAGINALIS Mesothelioma, Nos ALL OTHER SYSTEMS

MULTIPLE ORGANS NOS Angiosarcoma Malig.lymphoma, lymphocytic type Lymphocytic leukemia

+: TISSUE EXAMINED MICROSCOPICALLY -: REQUIRED TISSUE NOT EXAMINED MICROSCOPICALLY X: Tumor Incidence H: Mecropsy, No Autolysis, No Microscopic Examination

: NO TISSUE INFORMATION SUBMITTED C: MECROPSY, NO HISTOLOGY DUE TO PROTOCOL -A: Autolysis M: Animal Missing B: No Mecropsy Performed

TABLE A3. MALE RATS: TUMOR PATHOLOGY (CONTINUED) LOW DOSE

HUMBER HEEKS ON	2	2	å	2 9 1	3 0 1	-1	2	3	3	3	3	뷖	3	ᅨ	i	븲		1	1	1	1	2	-		5	TOTAL
STUDY INTEGUMENTARY SYSTEM	لغ	:	1	•	4	\$;	3	4	1	-	-	-	ŝ		3	4	1	•	4	8	4	-	4	TUMORS
SKIN Squamdus cell carcinoma Fibrona	•	٠	٠	٠	٠	٠	٠	٠	٠	+ x	٠	٠	H	٠	٠	•	٠	•	٠	•	٠	٠	٠	٠	٠	50×
CARCIHOSARCOMA Subcutaneous tissue Fibroma	+	•	•	•	+	•	•	+	+	•	+	•	N	•	+	*	+	+	+	•	+	+	+	•	÷	1 50× 2
RESPIRATORY SYSTEM																		_	_						_	
LUNGS AND BRONCHI Carcinosarcoma, metastatic	•	•	٠	٠	•	+	٠	+	+	•	•	•	+	+	•	÷.	+	+	•	+	•	•	+	+	٠	50
TRACHEA	ŀ	*	+	*	+	+	+	•	*		+	+	+	+	•	+	+	*	•	<u>+</u> .	*	+	+	+	+	50
HEMATOPOIETIC SYSTEM Bone Marrow											_							•		_			÷			46
SPLEEN		•	+	+	+	+	+	+	+	+	+	+	+	+	+	+	ŧ.,	+	+	+	+	+	+	+	•	50
LYMPH NODES ASTROCYTOMA, METASTATIC	•	•	+	+	+	٠	+	+	+	-	•	•	+	•	+	•	+	•	•	•	•	*	+	+	·	45,
THYMUS	ŀ	•	*	*	*	, †	+	+	+	+	+	+	+	-	+	~	+	+	-	•	-	+	+	+	*	34
CIRCULATORY SYSTEM HEART	+	+	•	+	•	+	+	+	+	+	+	+	+	+	+	+	+	•	٠	٠	+	+	•	+	٠	50
DIGESTIVE SYSTEM SALIVARY GLAND	Ι.									÷	•	•	÷	•		_	•									42
LIVER	+	+	+	+	÷	+	+	+	+	•	+	+	+	+	+	+		+	÷	+	+	+	•	+	÷,	50
NEOPLASTIC NODULE		+	<u>×</u>	•	•			<u>×</u>	+	×	+	+	+	+	× +	•	•	+	+	×	•	•	+	× +	-	<u>10</u> 50
BILE DUCT Gallbladder & Common Bile Duct	N.	N.	N	Ň	н	H	N	Ň	ň	ĸ	H	Ň	Ň	N	H	H	т н	N	T.N.	H	ч	Ň	т н	H	Ţ	50×
PANCREAS	+	+	+	-	•	+	+	+	+	. +	+	+	+	+	+	+	+	÷	٠	<u>+</u>	+	•	÷	÷	٠	48
ESOPHAGUS	ŀ	•	+	+	+	+	+	+	٠	+	+	+	+	•	٠	+	+	•	•	+	+	٠	+	+	•	50
STOMACH	↓ +	+	+	<u>+</u>	+	+	+	+		+	+	+	+	+	.+	+	+	+	-	+	+	+	+	+	┵	50
SMALL INTESTINE Papillary Adenocarcinoma		+	+	+	+	+	<u> </u>			<u>+</u>	*	<u>+</u>	<u>+</u>	+	<u>+</u>	*	+	*	ż.	*	<u>*</u>	*	<u>+</u>	*		45
LARGE INTESTINE	+	٠	٠	٠	+	٠	٠	٠	+	+	+	٠	٠	+	٠	٠	+	+	+	+	+	+	+	٠	٠	48
URINARY SYSTEM KIDNEY	•	+	+	•	+	+	+	+	+	•	+	•	+	÷	+	÷	+	+	+	+	•	•	+	+	t	50
TUBULAR-CELL ADENOMA . KIDNEY/PELVIS	+	+	+	•	+	+	•	+	+	+	•	+	+	+	•	•	+	+	+	+	•	+	•	+	4	50
TRANSITIONAL-CELL PAPILLOMA	+		+	•	•	+	•	+	+	•	•	+	•	+	-×	•	•	•	+	+	+	•	•	•	-	<u> </u>
ENDOCRINE SYSTEM	ĺ−		-	<u> </u>					-		-				-		·	-	-			<u> </u>	-		-	
PITUITARY Carcinoma.nos Adenoma. Nos Chromophobe Adenoma	+	٠	٠	٠	•	٠	٠	٠	٠	• x	٠	٠	• ×	•	-	÷	• x	٠	•	•	-	* x	+	٠	•	45
ADRENAL PHEOCHROMOCYTOMA GANGLIONEUROBLASTOMA	•	+	+	+	+ +	+	+	+	+	+	* x	+	÷	+	+	÷	+	÷	•	* ×	+	+	+	+	•	49 49
THYROID C-CELL CARCINOMA	+	+	+	+	+	٠	*	*	•	•	٠	+	+	÷	÷	٠	•	•	÷ ×	÷	+	٠	•	÷	·	49
PARATHYROID	+	+	-	+	+	+	-	+	٠	+	+	+	•	+	-	+	•	+	+	+	<u>+</u>	•	. <u>+</u>	+		- 41
PANCREATIC ISLETS ISLET-CELL ADENOMA	•	•	+	-	×	•	•	+	•	٠	•	+	•	*	•	•	•	•	•	•	•	+	•	•	•	48 ₃
REPRODUCTIVE SYSTEM Mampiary Gland Adenoma, Mos Fibroadenoma	•	٠	Ņ	٠	* X	H	N	٠	н	٠	٠	•	H	٠	٠	н	N	٠	٠	• × _	٠	H	+	٠	ĸ	50× 1 1
TESTIS INTERSTITIAL-CELL TUMOR	* ×	* ×	* x	* ×	* ×	* ×	*	÷.	*	*	*	*	* x	ţ.	* ×	ż	; x	* x		÷ x	* ×	•	* ×	* x	÷	50 46
PROSTATE PAPILLARY ADENOMA	+	-	+	٠	٠	٠	+	٠	+	٠	+	٠	+	٠	-	-	*	•	+	+	+	+	+	-	+	42 2
PREPUTIAL/CLITORAL GLAND ADENOMA, NOS	N	N	N	N	N	N	н	N	N	н	H	H	N	N	H	H	N	H	H	H	H	н	н	H	M	50×
NERVOUS SYSTEM BRAIN ASTROCYTOMA	+	+	٠	٠	+	+	+	+	٠	•	٠	*	•	٠	٠	•	٠	÷	•	÷	+	*	٠	٠	•	50 2
BODY CAVITIES Tunica Vaginalis	 •	•	•	+	•	+	•	+	•	+	+		•	+	•	•	•	•	+	+	•	•	+	+	+	50×
MESOTHELIOMA, NOS																	_									1
ALL OTHER SYSTEMS Multiple organs nos Angiosarodma Malig.lymphoma, lymphocytic type	N	N	N	N X	N	N	H	H	H	H	N	H	H	N	H		N X	N	N	H	H	N	N	H	H	50×

TABLE A3.

INDIVIDUAL ANIMAL TUMOR PATHOLOGY IN MALE RATS FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

						HI	GI		D()S	Ē					`										
AN IMAL NUMBER	0		0	0	0	0	0	0	0	0	0	0	01	3	2	0	0	01	0	2	01	0	4	0	0	
WEEKS ON	++	- 2	-1	2 9 0 9	-9			귀	-+	- 8	-6	-7	휘	-#	+	ᇷ	귀	귀	-	- 1	4	뀨	8	- 1		TOTAL TISSUES
STUDY	0	7 2	0	?	9 4	0 4	0 4	4	4	2	8 _6	9 7	4	4	2	8	4	4	4	8	읽	2	6	4	4	TUMORS
INTEGUMENTARY SYSTËM Subcutanegus tissue Squamous cell carcinoma Basal-cell tunor	•	٠	÷	٠	•	٠	•	+	+	٠	٠	٠	٠	+	÷	٠	٠	٠	* x	÷	+	٠	٠	٠	÷	50× t
FIBROMA	1		×	×	×			_x	x			×					•									6
RESPIRATORY SYSTEM	.																									50
LUNGS AND BRONCHI	<u> </u>		-	<u>,</u>	-	÷						<u> </u>	-		<u>.</u>		<u>.</u>	÷	÷	•	<u>*</u>	Ť	<u> </u>	÷	Ť	<u>50</u> 50
TRACHEA NASAL CAVITY Squamous cell carcingma, invasive	N	N	N	N	N	N	_ <u>+</u> N	N	N	N	N	N	N	N	N	N	N	N	N X	N	N	N	N	N	N	50× 1
HEMATOPOIETIC SYSTEM	t-																				-					
BONE MARROW	∔∸	+	+	+	+	+	<u>t</u>	+	t.	+	<u>+</u>	<u>+</u>		+	+	+	+	+	+	+	+	+	_ <u>t</u>	+	-+	50
SPLEEN FIBROSARCOMA HemangIosarcoma	• 	•	+	+	•	•	•	+	+	+	•	•	•	+	+	•	•	•	+	+	•	•	•	×	•	50 2 1
LYMPH NODES Malig.lymphoma, histiocytic type	ŀ	٠	+	+	+	+	+	-	+	-	+	+	-	+	-	+	+	+	+	-	•	•	•	+	+	41 1
THYMUS	+	-	-	-	-	+	+	+	+		+	-	+	-	•	•	+	+	+	+	+	•	+	+	_+	35
CIRCULATORY SYSTEM	Γ																									
HEART	+	+	*	+	+	+	+	•	+	•	*	+	*	+	*	*	•	*	+	•	+	*	•	*	+	50
DIGESTIVE SYSTEM																										
SALIVARY GLAND	++	+	+	<u>+</u>	+		<u>.</u>	·	<u>+</u>	<u>+</u>		+		+	-	*	+	+		-	+	+	+	+	-+	46
LIVER NEOPLASTIC NODULE HEPATOCELLULAR CARCINOMA	×	•	* ×	•	* x	* x	* x	* ×	•	* ×	•	+	•	+	* x	+	* X	* ×	•	•	* ×	+	•	* x	×	50 30 2
BILE DUCT	∔ •	+	+	+	+	+	+	+	+	+	+	+	•	+	*	+	+	•	+	+	•	+	+	+	-1	50
GALLBLADDER & COMMON BILE DUCT	N	N	N	N	N	N	N	N	N	M	N	N	N	N	N	N	N	H	N	N	N	N.	<u>N</u>	N		50×
PANCREAS ACINAR-CELL ADENOMA	+	. +	*	•	+	+	+	* x	+	+	+	+	+	+	-	•	+	+	-	+	+	+	+	+	+	46
ESOPHAGUS	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	•	٠	+	50
STOMACH	•	+	+	٠	٠	+	+	٠	٠	+	+	+	+	+	+	+	+	+	+	+	+	÷	٠	+	+	49
SQUAMOUS CELL PAPILLOMA Small intestine Adenocarcinoma, hos	•	+	-	•	٠	٠	+	•	٠	+	٠	+	•	•	•	•	•	*	•	•	+	•	-	•	+	47 47
LEIOMYOMA LARGE INTESTINE ADENOMATOUS POLYP, NOS	<u> </u> .	+	•	+	+	•	+	+	+	•	•	•	+	•	•	+	•	+	+	+	+	+	•	•	+	47
JRINARY SYSTEM	<u> </u>																								_	
KIDNEY	١.	+	•	•	+	•	•		•	•	+				•	+	÷	•	•	•	÷	÷				50
URINARY BLADDER TRANSITIONAL-CELL PAPILLOMA	ŀ	•	÷	+	+	+	٠	+	•	+	+	+	+	•	+	+	+	+	-	+	-	+	+	+	•	45 ₁
NDOCRINE SYSTEM																										
PITUITARY Chromophobe Adenoma	+	-	٠	+	+	٠	٠	٠	+	-	-	•	•	•	+	+	٠	+	+	*	+	+	*	-	+	43
ADRENAL CORTICAL ADENOMA PHEOCHROMOCYTOMA GANGLISDHEURDBLASTOMA	•	•	٠	٠	* x	+	•	+	•	•	+	+	+	•	•	•	+	+	+	+	•	•	+	+	•	50 1 6
THYROID C-CELL CARCINOMA	•	٠	٠	+	٠	+	•	٠	•	+	٠	٠	ŧ	٠	•	•	+	•	٠	٠	÷	* x	+	٠	·	50 2
PARATHYROID	·	+	+	-	+		+		•	+	+	+	+	÷	+	÷	÷	+	+	÷	+	-	•	+	+	42
PANCREATIC ISLETS ISLET-CELL CARCINOMA	•	•	٠	•	٠	٠	٠	٠	٠	٠	٠	٠	*	•	-	٠	+	•	-	•	•	+	•	+	·	46 ₁
EPRODUCTIVE SYSTEM	Γ																									
MAMMARY GLAND FIBROADENOMA TESTIS	Ŀ		N	N	+	•	•	•	N	H	H	N	N	N .	N .	•	•	•	•		N .	н	N	+	+	50× 1.
INTERSTITIAL-CELL TUMOR	×.	×	×	<u>×</u> .	×	×	ž	×	×	×	×	× •	×.	<u>×</u>	ž.	<u>×</u> _	ž	*	<u>*</u>	<u>*</u>	<u>*</u>	× •	• •	ž	×	50 47 47
PREPUTIAL/CLITORAL GLAND ADENOMA, NOS	N	N	N	N	H	H X	H	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	50× 1
ERVOUS SYSTEM Brain Granular-Cell Tumdr, NDS	+	+	•	•	•	•	•	•	•	•	•	+	•	•	•	+	+	•	•	•	•	•	•	•	•	50
LL OTHER SYSTEMS	-						~				~															
MULTIPLE ORGANS NOS Lymphocytic leukemia Orbital Region	-	X				4			-		н			H			-		R				N	N	┦	50× 3
SQUAMOUS CELL CARCINOMA. INVASIVE	L																		X	-						

A NIMALS SEE SUBJECT SET OF CONTROL OF CONTR

TABLE A3. MALE RATS: TUMOR PATHOLOGY (CONTINUED) HIGH DOSE

ÁNIMÁL NUMBER	0	0	0	0	ě	0	0	0	0	1	1	1	1	1	1	i	;	1	1	2	2	2	2	24	l
WEEKS ON Study		1	0	1	1	1	1	1	1	0	9	0	8	1	-	1	-	0	0	0	0	8	i	0	Γ
INTEGUMENTARY SYSTEM	41	4	4	4	.4	4	4	4	4	4	نغ	- 41	. 91	31	61	- 61	- 61	_9	_4	_4	. 4	L_7	نع		-
SUBCUTANEOUS TISSUE Squamous Cell Carcinoma Basal-Cell Tumor Fibroma	+	M	+	٠	• ×	٠	+	٠	•	•	٠	٠	٠	٠	•	•	٠	•	٠	٠	•	•	+	•	
RESPIRATORY SYSTEM					-						-						•								-
LUNGS AND BRONCHI	+	+	•	+	+	+	+	•	•	+	+	+	+	+	*	+	+	+	+	+.	+	•	•	+	-
TRACHEA	+	*	*	+	+		+	+	<u>+</u>	+	- + N	+	+	.+	<u>+</u>	<u>.</u>	<u>+</u>	+ N	+ N	+ H		+ N	+ N	 N	
NASAL CAVITY Squamous cell carcinoma, invasive	н	N	N	N	N	N	N	N	N	Ν	M	N	N	н	N	N			п		"	"		"	
IEMATOPOIETIC SYSTEM																									
BONE MARROW	+	+	+	+	+	*	+	+	<u>+</u>	*	+	+	+	+	+	+	+	•		<u>+</u>	+	*	*	*	-
SPLEEN FIBROSARCOMA HEMANGIOSARCOMA	•	•	•	• 	•	•	•	-	•	•	* 	•	• _	÷	•	-	•	×	•	•	•	•		-	
LYMPH NODES Malig.lymphoma, histiocytic type	+	+	+	•	+	+	-	•	+	+	+	*	•	*	+	•	-	*	+	-	+	+	•	+	
THYMUS	+	-	+	+	+	+	-	*	+	+	-	-	+	-	+	•	-	+	+	<u> </u>	-	-	*	+	_
CIRCULATORY SYSTEM											,			,			,								
HEART DIGESTIVE SYSTEM	+	+	+	+	+	+	+	+	•	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	_
SALIVARY GLAND	+	+	÷	٠	+	+	٠	-	٠	+	+	+	÷	•	+	•	+	+	+.	-	+		+	+	
LIVER NEOPLASTIC NODULE HEPATOCELLULAR CARCINOMA	* ×	•	+	+	* ×	* x	* ×	*	*	* x	* ×	* ×	+	+ X	* X	+	+	*x	+ ×	* ×	* x	٠	* ×	* ×	
BILE DUCT	+	+_	+	+	. +	+	•	÷	÷	+	+	÷	÷	,	+	+	+	+	Ŷ	+	+	. +	.+	+	
GALLBLADDER & COMMON BILE DUCT	N.	N	N.	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
PANCREAS ACINAR-CELL ADENOMA	+	+	-	•	+	+	+	+	+	+	+	+	٠	٠	•	+	•	•	-	+	•	•	+	+	
ESOPHAGUS	+	+	+	+	+	+	.+		<u>+</u>	+	+	+	+	+	+	•	•	+	.*	+	+	+	+	+	_
STOMACH Squamous cell papilloma	+	*	•	* x	*	+	*	+	*	*	+	+	*	+	+	*	+	+	*	+	+	+	+	+	
SMALL INTESTINE Adenocarcinoma, nos Leiomyoma	+	+	-	+	+	+	+	+	+	+	+	•	•	+	•	•	+	+	+	+ X	+	+	+	+	
LARGE INTESTINE Adenomatous Polyp, Nos	+	+	-	-	٠	٠	+	٠	+	+	٠	* ×	+	+	•	+	+	+	+	٠	٠	٠	٠	+	
RÎNARY SYSTEM																						•••••			
KIDNEY	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	<u>+</u>	+	+	
URINARY BLADDER TRANSITIONAL-CELL PAPILLOMA	+	+	-	-	+	+	+	+	+	+	+	•	+	+	+	+	+	•	•	*	+	-	•	•	
NDOCRINE SYSTEM																									-
PITUITARY Chromofhobe Adenoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	* ×	+	<u>*</u>	-	+		-	+	
ADRENAL Cortical Adenoma Pheochromocytoma	+	+	٠	٠	•	+	٠	* x	٠	+	+	٠	+	٠	٠	٠	٠	٠	+ x	+	+ × ×	+	٠	+ x	
GANGLIONEUROBLASTOMA Thyroid	+	+	+	•	+	+	÷	+	+	+	+	+	•	•	+	+	+	+	+	•	+	+	+	+	-
C-CELL CARCINOMA																			x				-		_
PARATHYROID		*	+	-	+	+	+	+	+	<u>+</u>	+	<u>+</u>	-	<u>+</u>		+		<u>+</u>	<u>+</u>	. <u>+</u> .	<u>+</u>	+	- <u>+</u> -	- <u>+</u>	
PANCREATIC ISLETS ISLET-CELL CARCINOMA	•	•	-	•	•	+	•	•	•	*	•	*	•	•	*	*	*	•	-	*	•	•	*	•	
EPRODUCTIVE SYSTEM				-			-										-								-
MAMMARY GLAND FIBROADENOMA	+	N	+	+	+	+	*	+	+	+	N	N	+	+	N	N	+	+	+	+	+	+	N	*	_
TESTIS INTERSTITIAL-CELL TUMOR	* x	* ×	+	* ×	* ×	*	* x	* ×	* ×	* ×	* ×	* x	* x	* ×	* ×	* x	٠	* ×	* ×	* x	*	* ×	* ×	* ×	
PROSTATE	+	+	+	-	+	+	+	+	+	+	+	+	+	-	+	+	÷	+	+	+	+		+	+	_
PREPUTIAL/CLITORAL GLAND ADENOMA, NOS	N	N	N	N	N	N	N	N	N	H	N	N	М	N	N	H	H	N	N	N	H	N	N	N	,
ERVOUS SYSTEM																									
BRAIN GRANULAR-CELL TUMOR, NOS	+	+	+	+	+	+	*	+	+	+	+	•	+	•	•	*	+	+	+	+	+	•	+	+	
LL OTHER SYSTEMS Multiple organs nos Lymphocytic leukemia	м	н	N	N	N	N	н	N	N	N	N	н	Ň	N	N	N	N	N	N	N	N	Ņ	N	N	-
ETHIOUCITIC LEOKEMIA						• · · ·		_					<u>×</u>									<u>×</u>			-

TISSUE EXAMINED MICROSCOPICALLY
 REQUIRED TISSUE NOT EXAMINED MICROSCOPICALLY
 TUMOR INCIDENCE
 NECROPSY, NO AUTOLYSIS, NO MICROSCOPIC EXAMINATION

: NO TISSUE INFORMATION SUBMITTED C: NECROPSY: NO HISTOLOGY DUE TO PROTOCOL A AUTOLISIS M: ANIHAL MISSING B: NO NECROPSY PERFORMED

TABLE A4.

INDIVIDUAL ANIMAL TUMOR PATHOLOGY IN FEMALE RATS FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

					C	DN	IT	R	OL	-															
ANIMAL		0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	2	0	0
WEEKS ON	++	2	1	4	5	6	1	-8	9	0		2	-3	-4		-6	-11	8	- 9	-	-1	-2	-3	4	1
STUDY	4	0 2	0 4	9	0 4	0 4	4	0 4	0	0	0	0	0 4	0 4	0	4	4	0	0 4	0 4	0 4	9 8	0 4	8 2	0 4
SUBCUTANEOUS TISSUE SQUAMOUS CELL CARCINOMA SARCOMA, NOS	•	+	٠	٠	+ x	÷	٠	٠	٠	÷	٠	٠	٠	٠	÷	+	٠	٠	٠	+	+	٠	٠	٠	٠
RESPIRATORY SYSTEM	+						•••••		-													-			
LUNGS AND BRONCHI	1+	+	+	+	+	+	+	+	+_	+	+	+	+	+	+	ŧ.	+	+	+	+	+	+	+	•	+
TRACHEA	+	٠	÷	+	÷	÷	٠	+	+	٠	+	+	÷	+	٠	+	+	+	+	٠	+	+	+	-	+
HEMATOPOIETIC SYSTEM	-			~		-																			_
BONE MARROW	ŀ	+	+	+	+	+	+	+	+	+	+	•	+	+	+	+	+	•	+	+	-	+	+	-	+
SPLEEN	+	+	+	+	+	+	.+	+	+	ţ.	+	+	+	_+_		+	+	+	+	+	+	+	+	+	+
LYMPH NODES	+	+	+	+	+	+	t	+	+			+	+		+	+	+	+	•	ŧ	+	+	÷	÷	+
THYMUS	+	•	+	+	+	+	+	٠	٠	٠	+	-	+	+	+	+	-	+	+	+	٠	+	٠	+	+
CIRCULATORY SYSTEM	+								~			•													_
HEART	+	٠	+	+	+	÷	٠	٠	+	+	+	+	+	+	+	+	٠	٠	+	÷	٠	٠	+	٠	+
DIGESTIVE SYSTEM	+																	-						-	
SALIVARY GLAND	+		+	+	+	+	+	<u>+</u>	+		<u>+</u>	+	•		+	+	+	+	+	+	+	+	+	+.	+
LIVER NEOPLASTIC HODULE	ļ.	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	*	+	+
BILE DUCT	Ļ٠	+	+	+	+	+		.+	+	<u>.</u>	+	+	٠	+	*	÷	+	+	+	+	+	+	.+	+	+
GALLBLADDER & COMMON BILE DUCT	<u>N</u>	N	N	N	N	N	N	N	N	N	N	N	N	N	N	Ν_	N	N	N	N	N.	N	N	N	N
PANCREAS	+	+	. +	+	+	+	+	+	+		•	+	+	+	+	+	<u>+</u>	_ <u>+</u>	+	+	+	<u>+</u>	+	+	+
ESOPHAGUS	+	+	٠	+	٠	٠	٠	+	٠	+	+	٠	٠	+	+	+	٠	٠	٠	+	+	+	+	+	+
STOMACH	1.	<u>+</u>	+	+	. +	. +	+	+	÷	+	÷	٠	+	+	+	+	÷	+	+	.+	ŧ.	+	÷	+	+
SMALL INTESTINE	+	-	+	+	+	+	+	+	+		+	+	+	+	+	t	+	+	+	+	+		+	+	٠
LARGE INTESTINE	+	٠	+	+	٠	٠	٠	+	+	÷	+	٠	٠	+	+	٠	+	٠	٠	٠	+	+	+	+	٠
URINARY SYSTEM	1		-																						
KIDNEY	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	٠	+	+	<u>+</u>	+	+	+_	+	+	+	<u>+</u>
URINARY BLADDER	+	+	٠	+	+	+.	+	٠	٠	+	+	+	+	+	+	+	+	+	+	٠	+	+	+	+	٠
ENDOCRINE SYSTEM	!				· ·						•														
PITUITARY Chromophobe Adenoma	1 ×	-	* x	* ×	<u>*</u>	+	* x	-	•	<u>*</u> .	+	+	+	×	•	+	* x	-	* x	×	+	* x	* *	+	* x
ADRENAL Cortical Adenoma	+	+	+	•	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	٠	+	+	+	+	. +
THYROID C-CELL CARCINOMA	+	+	+	+	+	+	+	+	*	+	+	+	+	+	+	+	* ×	+	+	+	+	•	+	+	+
PARATHYROID	L	+	+	+	+	+	+	+	-	-	÷	+	+	+	+	+	+	+	+	-	÷	+	-	+_	+
PANCREATIC ISLETS ISLET+CELL ADENOMA	•	+	+	+	٠	+	٠	+	+	٠	٠	+	+	+	٠	+	+	+	+	٠	٠	+	+	٠	+
REPRODUCTIVE SYSTEM												-													
MAMMARY GLAND Adenoma, Nos Fibroadenoma Cystfibroadenoma	•	+	+ . x	+ x	+ X	٠	+	+	+	N	N	+	+	٠	+	N	+	+	* x	٠	٠	+	+ x	+	+ X
PREPUTIAL/CLITORAL GLAND CYSTADENOMA, NOS	н	N	N	N	N	N X	N	N	N	N	N	N	N	N	N	N	н	N	N	N	H	н	N	N	N
UTERUS Endometrial stromal polyp	+ X	* ×	+	* X	+	+	* x	+	+	+	*	•	* x	+	٠	•	+	+	+	٠	* x	٠	÷	٠	* x
OVARY	+	t	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	÷	+	+
BODY CAVITIES															_										
PERITONEUM MESOTHELIOMA, NOS	N	N	н	N	N	H	N	N	н	N	N	H	N	N	N	H	H	N	N	H .	H	N	N	N	H
ALL OTHER SYSTEMS																			•••						-
MULTIPLE ORGANS NOS Malig.lymphodna, lymphocytic type Lymphocytic leukemia	N	N X	N X	н	N	н	N	N	N	N X	н	N	N	N X	N	н	N	N	N	N X	N	N X	м	N	N

CONTROL

: NO TISSUE INFORMATION SUBMITTED C: NECROPSY, NO HISTOLOGY DUE TO PROTOCOL A: Autolysis M: Animal Missing B: No Necropsy Performed

+: TISSUE EXAMINED MICROSCOPICALLY -: REQUIRED TISSUE NOT EXAMINED MICROSCOPICALLY X: Tumor Incidence N: Necropsy, No Autolysis, No Microscopic Examination

TABLE A4. FEMALE RATS: TUMOR PATHOLOGY (CONTINUED) CONTROL

AN IMAL NUMBER	0 2 6	27	0 2 8 0	2	3	3	3	3	3	3	3	3	3	3	4	4	2	3	4	4	4	2	0 4 8	4 9	5	TOTAL
WEEKS ON Study	0	0	71	0	0 9 7	0	9	0	4 9 9	81	0				0	2	0 71 61	ġ.		ġ		0	0			TUMO
NTEGUMENTARY SYSTEM	1																									-
SUBCUTANEDUS TISSUE Squamdus cell carcinoma Sarcoma, nos	+	+	+	+	+	٠	+	•	+	* ×	•	٠	+	•	+	•	+	+	+	+	H	•	•	+	+	50)
ESPIRATORY SYSTEM	1				-																				1	
LUNGS AND BRONCHI	++	+	+	+	. +	+	+	+	+	+	+	+	+	+	<u>+</u>	+	+.	*	<u>+</u>	+	+	+	<u>+</u>	+	+	
TRACHEA	-	٠	+	+	+	+	+	+	+	٠	+	+	+	+	*	•	+	•	+	+	+	•	+	+	+	48
EMATOPOIETIC SYSTEM																									T	
BONE MARROW	++	÷	<u>+</u> .	+	+	<u>+</u>	+	+	+	+	+	+	+	+	+	+ .	+	+	<u>+</u>	+	-	+	+	+	4	47
SPLEEN	<u>+-</u>	+	+	_+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	t	+	+	+	+	50
LYMPH NODES	+	+	+	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	<u>+</u>	+	+	+	+	*	╧╋	49
THYMUS	+	٠	+	٠	+	+	+	+	٠	٠	-	+	+	+	+	+	-	-	-	+	٠	+	+	+	+	43
IRCULATORY SYSTEM																										
HEART	+	+	+	+	+	+	+	+	+	+	+	+	٠	+	+	+	+	+	+	+	+	٠	+	+	+	50
IGESTIVE SYSTEM	1															-										
SALIVARY GLAND	++-	•	+	+	+	•	+	+	+	+	+	+	+	•	+	+	+	+	+	+	+	+	+	+	4	50
LIVER NEOPLASTIC NODULE	+	+	+	+	+	÷	+	*	+	+	+	+	+	+	+	+	+	•	+	+	+	+	+	+	+	50
BILE DUCT	1.	+	+	•	•	<u>.</u>	+	+	•	•	+	+		•	•	+	+	•	+	•	•	•	•	•	1	50
GALLBLADDER & COMMON BILE DUCT	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	H	N	N	N	N	N	N	50
PANCREAS	1.	+	+	+	+	+	+	+	+	•	+	+	+		+	•		•	•	•	•	+	•	•	-	49
ESOPHAGUS	1.	•	+	•	+	+		+	+	+	•	•	+			+		+	•	•	•	•	+	•	.†	50
STOMACH		÷	•		÷	÷	•	•	÷	•	•		÷	•		•			•	•					1	50
SMALL INTESTINE	1.	+	+	•	+	+	+	+	•	*	•	•	+	+	+	+		•	•	•	•	•	*	•		49
LARGE INTESTINE	1.	<u>`-</u>	 +	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	÷	+	•	÷	Ť	49
RINARY SYSTEM	<u> </u>	<u>.</u>					·														·	<u>.</u>		•	4	
KIDNEY								L	÷		+	+	÷	÷	÷	•										
URINARY BLADDER	1	+	- <u>-</u> -	- <u>-</u> -	+	+	+	+	+	+		+				+ +		*	+	+	*	<u>.</u>	+	+	Ť	<u>50</u> 47
	Ľ				_	<u> </u>	· ·	<u> </u>	<u> </u>	-	<u> </u>	<u>.</u>	<u> </u>	-	·	·	-	•	•	•	<u> </u>	_	•		4	4/
NDOCRINE SYSTEM																										
PITUITARY Chromophobe Adenoma	±×_	<u>.</u>	+		<u>x</u>	+	×	+	<u>×</u>	<u> </u>	<u>×</u>	ż.	<u>*</u>	<u>*</u>		<u>*</u>	*	-	* x	<u>*</u>	<u>*</u>	<u>*</u>	.*	×.	-	44
ADRENAL Cortical Adenoma	+	+	+	+	•	+	+	+	+	+	+	+	+	+	•	+	+	* x	+	+	+	•	+	+	٠	49
THYROID	+	٠	+	٠	+	+	+	+	٠	+	+	+	*	٠	+	•	٠	•	+	•	÷	+	•	•	+	50
C-CELL CARCINOMA	†																								+	
PARATHYROID	<u>†.</u>	÷	<u> </u>		- <u>*</u>	- <u>*</u>	· ·		+	+	<u>*</u>	<u>.</u>	+	+	+	<u>.</u>	-	<u>.</u>	•	•	÷	<u>*</u>	Ţ	÷	+	40
PANCREATIC ISLETS ISLET-CELL ADENOMA	1	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•		•	*	•	-	49
EPRODUCTIVE SYSTEM														-											╉	
MAMMARY GLAND	+	+	N	+	+	+	+	+	+	٠	N	+	+	+	+	÷	N	•	•	+	+	+	+	+	+	50
ADENOMA, NOS FIBROADENOMA					x							x			x	x			x			x			x	
CYSTFIBRDADENOMA PREPUTIAL/CLITORAL GLAND CYSTADENOMA, NOS	N	N	н	н	N	N	N	N	N	N	N	н	N	N	N	N	N	н	N	N	N	H	N	N	N	50
UTERUS ENDOMETRIAL STROMAL POLYP	+	+	-	*	*	÷	*	+	÷	+	+	*	*	÷	+	+ x	+	•	+ ×	•	+	*	*	÷	*	49
OVARY	Γ.	+	-	+	+	÷	+	4	+	+	+	+	+	+	•	+	+	+	+	÷	+	•		•		49
DY CAVITIES	 																· ·								-	.,
PERITONEUM	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	н	N	N I	N	N	N	N	N	N	N	50)
MESOTHELIOMA, NOS	<u> </u>		x																				••		1	507
LL OTHER SYSTEMS	-																								T	
MULTIPLE ORGANS NOS MALIG.LYMPHOMA, LYMPHOCYTIC TYPE LYMPHOCYTIC LEUKEMIA	H	N	N	N	N X	N	N	N X	N	N	N	N	N	н Х	N	N	N X	N	н	N	N	N	н	N	N	50
ANIMALS NECROPSIED +: TISSUE EXAMINED MICROSCO -: REQUIRED TISSUE NOT EXAM X: TUMOR INCIDENCE N: NECROPSY, NO AUTOLYSIS, I	PICAU INED No Mi	MI	CRO: DSCI	5C0 0P1(Р I С.	ALL' XAMI	Y I NA	T I OI	N		: A: M: B:	H A A	ECR UTO NTM	DPS LYS AL	UE 1 Y, # IS MISS 0P51	10 1 N	H15' G	IOLO	JGY	SUB DU	MIT E T	1 E D 0 P	R01	000)L	

TABLE A4.

INDIVIDUAL ANIMAL TUMOR PATHOLOGY IN FEMALE RATS FED DIETS CONTAINING **C.I. SOLVENT YELLOW 14**

				l	.0	W	D	0	SE													_			
ANIMAL NUMBER	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	2	2	2	0	0
WEEKS ON STUDY	ġ	-2	1	5	8	i	1	1	1	-	1	0	1	귀	1	í	-11	1				譋	1	5	
RESPIRATORY SYSTEM	11	Š	4	Å	6	4	Å	4	4	4	4	ا ف	4	4	4	4	4	4	41	Å	4	4	4	š.	_
LUNGS AND BRONCHI Alveolar/Bronchiolar Carcinoma	Ŀ	•	٠	+	+	×	•	•	+	+	٠	٠	+	٠	٠	•	٠	٠	٠	٠	•	٠	٠	+	1
TRACHEA	+	+	٠	٠	·+	٠	+	+	٠	٠	÷	÷	+	+	٠	÷	٠	+	+	+	+	+	+	٠	
HEMATOPOIETIC SYSTEM	+												-												-
BONE MARROW	₽÷	+	+	+	÷	•	+	+	+	+	+	+	•	ŧ	+	+	+	+	÷	+	+	٠	+	+	
SPLEEN	<u>↓</u> •	•	•	+	+	.+	•	+		+	+	+	+	+	+	+	٠	+	+	+	+	+	+	+	_
LYMPH NODES	<u>+</u> +	+	+	+	-	.+	+	+	+	+	+	•	+	+	+	+	+	+	+	+	+	+	+	.+	_
THYMUS	+	•	+	+	+	•	+	-	+	*	+	*	•	+	-	+	-	-	+	+	+	+	+	+	
CIRCULATORY SYSTEM	Γ																								
HEART	1.	+	٠	+	+	*	+	+	+	+	+	+	+	+	+	+	+	+	+	+	٠	+	+	+	•
DIGESTIVE SYSTEM																									
SALIVARY GLAND	H	+	+	+	+	+	+	+	+	+	•	<u>+</u>	+	+	+	+	+	+	+	<u>+</u>	+	*	•	+	-
NEOPLASTIC NODULE	Ľ	+	+	+	*	* x	*	+	<u>+</u>	+	+	+	+	+	+	+	+	+	*	•	+	+	+	+	_
BILE DUCT	Ĺ≁	•	+	+	٠	•	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	
GALLBLADDER & COMMON BILE DUCT	N	_N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	<u>N</u>	N	1
PANCREAS	Ĺ≁	. +	+	+	٠	+	+	+	+	+	+	÷	+	÷	+	+	+	+	+	+	+	+	+	+	•
ESOPHAGUS	ŀ	+	÷	+	+	+	+	+	+	+	.+	÷	+	.+	+	+	+	+	+	+	+	+	+	+	
STOMACH	ŀ	+	÷	+	+	+	+		+	+	+	•	+	+	. +	+	<u>+</u>	+	+	+	+	+	+	+.	
SMALL INTESTINE	+	٠	٠	٠	+	+	٠	+	٠	٠	٠	-	+	+	٠	٠	+	٠	٠	٠	+	٠	٠	٠	•
LARGE INTESTINE	+	+	+	•	+	٠	+	+	+	+	+	+	٠	+	+	+	+	+	+	٠	٠	٠	+	٠	
JRINARY SYSTEM	1																								
KIDNEY	┝	<u>+</u>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	.+	+	+	+	-
URINARY BLADDER TRANSITIONAL-CELL PAPILLOMA	1.	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	•	+	+	+	+	+	+	
ENDOCRINE SYSTEM	+																								
PITUITARY CHROMOPHOBE ADENOMA	Ŀ	* x	+	+	•	+	* x	+	+	<u>*</u>	* x	* x	-	* x	* ×	+	* x	* x	* x	+	•	+	+	-	
ADRENAL Cortical Adenoma Pheochromocytoma Ganglioneuroblastoma	ŀ	+	+	+	•	+	+	+	•	+	+	+	•	+	+	•	+	+	* ×	+	-	+	+	•	
THYROID C-CELL CARCINOMA	ŀ	+	+	+	٠	+	•	٠	+	•	+	+	* *	+	+	+	+	+	•	٠	•	•	+	+	
PARATHYROID	+	٠	-	+	٠	-	٠	٠	٠	+	-	+	+		+	+	-	+	+	٠	-	٠	+	٠	
REPRODUCTIVE SYSTEM	1																								
MAMMARY GLAND Adenoma, Nos Adenocarcinoma, Nos Fibrosarcuma Fibrosarcuma	•	* ×	٠	•	+ x	N	٠	+ x	+	•	+ x	+	٠	•	+ x	•	•	•	•	•	•	•	N	•	
CYSTFIBROADENOMA	N	N	N	N	N	N	N	N	N		N	N	N	N	N	N	N	н	N	N	N	<u>х</u> N	N	N	
PREPUTIAL/CLITORAL GLAND CARCINOMA,NOS ADENOMA, NOS	Ĺ	м <u>х</u>		п	N	н 	n	N			n				N			-					n	N	-
UTERUS Endometrial stromal Polyp Endometrial stromal sarcoma	Ľ	* ×	×	+	•	-	×	•	*	+	*	*	×	*	*	*	+	+	+	*	+	+	*	•	
OVARY Adenocarcinoma, nos granulosa-cell tumor	+	+	+	+	+	-	+	+	+	+	+ x	٠	٠	٠	٠	٠	+	٠	٠	+	+	٠	٠	٠	
ERVOUS SYSTEM																									-
BRAIN Astrocytoma	ŀ	٠	+	٠	+	٠	+	٠	+	+	+	٠	٠	٠	+	٠	٠	+	٠	٠	+	•.	+	+	
LL OTHER SYSTEMS MULTIPLE ORGANS NOS Malig.lymphoma, histiocytic type Leukemia, Nos	N	H X	N	N	N	N	H	N	N	N	N	N	N X	N	N	N	N	H	N	N	N	N	H	H	1
MALIG.LYMPHOMA, HISTIOCYTIC TYPE LEUKEMIA.NOS +: TISSUE EXAMINED MICROSCOP -: REQUIRED TISSUE NOT EXAMI X: TUMOR INCIDENCE N: NECROPSY, NO AUTOLYSIS, N	NED	MIC	ROS	SCOF	ICA		NAT	ION			: C: M: B:	NO NE AU AN	CRO TOL IMA	PSY 751 L M	, N 5 ISS	0 H TNG	157	TIO	GY	UBM DUE		ED PR	010	COL	

I OW DOGE

TABLE A4. FEMALE RATS: TUMOR PATHOLOGY (CONTINUED) LOW DOSE

ANIMAL HUMBER	27	2	2	0 3	03	3	0 3	0 3	0	3	3	3	3	0 4 0	4	2	4		4	ŝ	4	0 4 8	049	5	TOT	A I.
WEEKS ON Study	17	1	1	1 0 4	104		1	1	1 0 4	1	1	-1	0	0	0	2	3	4 0 9 9		-1 01 4	-1	11	- i	0	TISS	UĒ
RESPIRATORY SYSTEM	T																									
LUNGS AND BRONCHI Alveolar/Bronchiolar Carcinoma	<u> </u>	+	+	•	•	•	+	+	•	+	+	•		•	•	+	•	+	•	+	•	•	+	•	- 41	1
TRACHEA	+	+	+	+	٠	+	٠	٠	٠	•	+	+	•	+	+	+	+	٠	+	+	٠	+	+	+	4	9
HEMATOPOIETIC SYSTEM																										
BONE MARROW	++	+	+	+	+	+	+	+	•		t	+	+	+	+	+	+	+	+	+	+	+	+	+		9
SPLEEN	+	÷	+	+	+	•	+			+		+	+	+	+	+	+	+	4	t		+	<u> </u>	+		9
LYMPH NODES	<u></u>	+	+	+		•		+	.+	+	•	+_	•	+	•	*	<u>+</u>	+	+	٠	+	+	+		<u>•</u> e	6
THYMUS	-	٠	٠	+	+	٠	-	٠	+	-	-	-	+	٠	+	٠	+	+	٠	٠	+	+	٠	٠	40	0
CIRCULATORY SYSTEM	1				•																					_
HEART	+	+	٠	+	+	+	+	٠	+	٠	٠	+	٠	٠	٠	+	+	٠	٠	٠	٠	+	+	+	61	9
DIGESTIVE SYSTEM	+																	-		_		_			+	-
SALIVARY GLAND	1.	+	+	٠	+	+	÷	÷	+	•	÷	<u>+</u>	+	+	+	<u>+</u>	+	<u>.</u>	+		•	<u>+</u>	<u>+</u>	+	- 49	<u>9</u>
LIVER NEOPLASTIC NODULE	ŀ	•	٠	+	+	•	•	•	•	•	•	ż	•	•	•	+	*	٠	•	٠	•	٠	+	•	49	°3
BILE DUCT	1.	+	•	<u>t</u>	+	+	+	+	<u>.</u>	+		+	+	+	+	+	+		+	+	٠	+	+	+	45	9
GALLBLADDER & COMMON BILE DUCT	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	49	
PANCREAS	I.	+	+	÷	+	÷	•	÷	+	÷	+	+	÷	+	+	÷	•	+	÷	+	+	+	•	+	49	9
ESOPHAGUS	•	+	+	+_		+.	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49	9
STOMACH	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	÷	49	,
SMALL INTESTINE	1.	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•	+	+	÷	+	+	+	+	+	48	3
LARGE INTESTINE	1.	+	+	٠	+	÷	٠	+	+	+	÷	+	٠	÷	+	٠	٠	÷	+	÷	+	+		٠	4 4 4	
URINARY SYSTEM	+																									
KIDNEY	1.	÷	+	÷	+	+	+	•	+	+	•	+	+	+	•	÷	÷	+ .	÷	+	+	+	+	+.	49	9
URINARY BLADDER TRANSITIONAL-CELL PAPILLOMA	+	+	÷	÷	+	÷	+	+	÷	+	÷	+	÷	÷	-	+	÷	÷	-	٠	* x	* x	÷	+	46	62
ENDOCRINE SYSTEM	+																		_							
PITUITARY Chromophobe Adenoma	ŀ	٠	*	+	+	-	+	+	•	+	* x	+	÷.	+	+	* ×	* ×	* ×	+	*	-	+	*	+	49	5
ADRENAL Cortical Adenoma Pheochrdmocytoma Ganglioneuroblastoma	+	٠	٠	٠	•	+ ×	٠	٠	+	٠	+	+	•	+	•	٠	•	٠	٠	٠	+	٠	+	٠	48	;
THYROID C-Cell Carcindma	•	٠	÷	٠	•	+	+	* *	÷	+	+	+	* ×	+	+	+	+	+	÷	+	٠	+	+	+	49	, ,
PARATHYROID	•	+	÷	÷	+	+	-	+	+	÷	+	-	+	+	-	+	+	+	+	+	-	+	-	+	38	;
REPRODUCTIVE SYSTEM	+																								+	
MAMMARY GLAND Adenoma, Nos Adenocarcinoma, Nos	•	٠	٠	N	٠	٠	٠	٠	٠	٠	٠	* ×	+	٠	+	+ x	٠	÷	٠	٠	N	٠	٠	ĸ	49	2
FIBROSARCOMA FIBROADENOMA Cystfibroadenoma	×							x							x x						x					1 8 2
PREPUTIAL/CLITORAL GLAND Carcinoma, Nos Adenoma, Nos	N	H	н	N	N	N	N	N	N X	N	N	N	N	H	N	N	N	N	N	·N	N	N	N	м	49	1
UTERUS Endometrial stromal Polyp Endometrial stromal sarcoma	ŀ	+	+	*	×	+	*	+	* ×	* ×	*	* ×	•	+		* x	+	+	+	•	* ×	+	+	•	47 2	20 1
OVARY Adenocarcinoma, nos granulosa-cell tumor	+	٠	٠	٠	٠	٠	٠	+	٠	+	•	•	٠	٠	-	•		+ X	٠	٠	٠	٠	•	٠	47	1
ERVOUS SYSTEM	1-									_															+ -	_
BRAIN Astrocytoma	+	+	٠	+	٠	٠	÷	*	٠	٠	+	٠	+	٠	* x	+	٠	•	+	٠	٠	٠	٠	٠	49	2
LL OTHER SYSTEMS	t—			-								_														
MULTIPLE ORGANS NOS Malig.lymphoma, histiocytic type Leukemia.nos	N	N	N	N	N	N	N	N	N	H	N	H	N	H	N	N	N	N	N	N	N	N	N	м	49	¥ 1

* ANMALS NECROPSIED +: TISSUE EXAMINED MICROSCOPICALLY -: REQUIRED TISSUE NOT EXAMINED MICROSCOPICALLY X: TUMOR INCIDENCE H: NECROPSY, NO AUTOLYSIS, NO MICROSCOPIC EXAMINATION

: NO TISSUE INFORMATION SUBMITTED C: NECROPSY, NO MISTOLOGY DUE TO PROTOCOL A: Autolysis N: Animal Missing B: No Necropsy Performed

TABLE A4.

INDIVIDUAL ANIMAL TUMOR PATHOLOGY IN FEMALE RATS FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

+ + + + +	0 2 1 0 4 + + + + + + + +	0 3 0 1 8 8 8 8 8 8 8 8 8 8 8 8	+ + +	+	0 0 1 0 4 1 0 4 1 0 1 4 1 0 1 4 1 0 1 4 1 0 1 4 1	8 9 7 1 0 4 + +	0 8 1 9 4 + +	0 9 9 1 1 +	+	+	0 1 2 4 4 +	+	0 1 4 1 0 2 + *	¢ 1 5 0 4 +	0 1 6 8 7 7	+	0 1 8 0 4 +	0 1 9 0 4 +	0 2 0 7 6 + X +	+	0 2 2 9 7 7	+	0 2 4 1 0 4 +
• • • • • •	+ + + + +	B B B B B B B B	8 6 + +	0 41 +	1 01 4 N	+	+	+	+	41	4	+ +	+	+	+ +	+ +	1	41	71 6 +	104	9	+	-11
41 + + + + + + +	+ + + + +	B B B B B B B	+	+	41 N	• • •	4 + +	+ +	+ + +	41	4	41 + +	21 +	4 + +	* + +	* * *	4 + +	41	<u>6</u>] +	41	71	4 + +	4 +
• • •	+	8 8 8 8 8 8	+ + + + + + + + +	+ + +	N + +	• •	+ + +	• •	•	•	Ņ. +	•	* *	+	•	•	•	+ 		•	•	•	•
• • •	+	B 8 8 8	+	+ + + + + + +	+ + +	•	+	+	•	•	÷	÷	* ×	+	÷	÷	•	+	+	•	÷	+	+
• • •	+	B 8 8 8	+ + +	+	+ + +	•	+	•	•	•	٠	٠	* X	٠	٠	÷	٠	+	+	÷	٠	٠	٠
• • •	+	8 - R - B	+ + + +	+	•	•	+	٠													X		
		8 8 8 8	+ + .+	+	•				•	+	÷	+	•	+	+	÷	+	+	+	÷	•	+	+
		8 	+	+	+																		
		<u>в</u> В	+	+		+	+	+	+	•	÷	+	+	-	•	÷	+ .	+	+	÷	+ .	+.	+
		B	.+		+	•	+	+	+	+	+	+	+	+	+	÷	+	+	+	÷	+	+	+
		8		-		-				+	•		•	•	•	•		÷	+		•	•	
			+	+	+	-	+	-	•	+	+	+	-	+	+	+	•	+	+	•	-	•	+
•			•									•											
																							÷
÷				· ·					. <u> </u>	•	•	•	·		•	·		<u> </u>		<u> </u>		<u> </u>	<u> </u>
	- <u>*</u> -			•	•	-		-	*	<u>.</u>	<u>.</u>	-	<u>.</u>	<u>•</u>	•	<u>.</u>	<u>.</u>	<u> </u>	<u> </u>	-	•	-	<u> </u>
×	×							×					·						_		×		
+	. <u>+</u>	В	+	+	+.	.+	. <u>+</u>	*	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
N	N	В	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	Ν.	.N.	N	N	N.	<u>N</u>
+	+	B	+	+	+	+	+	+	+	+	+	+	+	<u>+</u>	+	+	+	+	+	+	+	+	+
+	+	В	+	+	+	+	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
+	+	B	٠	•	+	•	•	+	•	•	•	+	-	+	•	+	+	•	•	•	•	٠	*
+	+	В	+	+	+	+	+	.+	+	+.	+	+	-	+	+	+	+	+	*	+	<u>+</u>	+	+
+	٠	B	٠	+	٠	+	٠	٠	+	•	+	+	٠	+	+	+	+	٠.	•	+	+	+	+
				-				-															
+	+	B	+	٠	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	٠	+	+
٠	+	в	+	+	+	+	+	+	+	+	+	+	+	+	•	÷	+	+	٠	÷	+	+	+
			-																				
•	٠	В	•	٠	* X	+ x	•	•	+	•	* x		*	•	• x :	• x	٠	* ×	•	•	* x	٠	٠
+	+	8	+	:	+	+	+	+	٠	•	+	+	÷	+	+ -	+	+	+	+	•	+	÷	+
			×			×		<u>x</u>													×		
+	+	8	+	+	+	+	+	+	+	٠	+	+	+	+	•	•	*	<u>*</u>	+	•	٠	+	+
•	•	B	+	-	•	-	-	٠	٠	+	+	•	+	-	•	•	•	+	٠	-	+	+	•
٠	*	8	×	+	N	ż	N	•	٠	+	×	H	н <u>х</u>	+	N ·	•	•	+	•	+	*	•	+
* ×	٠	8	٠	+	* ×	٠	٠	٠	٠	* ×	٠	÷	٠	+			٠	* x	٠	+	٠	+	* x
+	+	B	٠	+	٠	٠	٠	٠	٠	+	٠	÷	÷	•	•	٠	÷	•	+	٠	÷	+	•
																							<u></u>
•	•	B	٠	•	•	•	٠	٠	٠	+	•	+	٠	+	•	٠	+	+	+	+	+	٠	٠
	+ + X + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ B + + B	• • B • * * B + * * B + * * B + * * B + * * B + * * B + * * B + * * B + * * B + * * B + * * B + * * B + * * B + * * B + * * * B + * * * * * * * * * * * * * * *	• B • + + B + + + B + + B + + + B + + + B + + + B + + + B + + + B + + + B + + + B + + + B + + + B + + + B + + + B + + + B + + + B + + - X B + + A B + - X B + + X B +	• B • • • B • • • • B • • • • • B • • • • • • B • • • • • • • B • • • • • • • • B •	• B •	• B •	• B •	• B •	• B •	• B •	• B •	• B •	• •	• •	• •	• •	• •	• •	• •	• •	• •

 +: TISSUE EXAMINED MICROSCOPICALLY
 : NO TISSUE INFORMATION SUBMITTED

 -: REQUIRED TISSUE NOT EXAMINED MICROSCOPICALLY
 C: NECROPSY, NO NISTOLOGY DUE TO PROTOCOL

 X: TUMOR INCIDENCE
 AUTOLYSIS

 M: MECROPSY, NO AUTOLYSIS, NO MICROSCOPIC EXAMINATION
 MICROSCOPIC EXAMINATION

80

TABLE A4. FEMALE RATS: TUMOR PATHOLOGY (CONTINUED) HIGH DOSE

AN ÍMÁL NUMBER	026	0 2 7	0 2 8	029	0	0 3 1	3	03	034	0 3 5	0 3 6	31	0 3 8	3	0 4 0	4	4	4	044	4	0	647	4	4	51	TOTAL
WEEKS ON STUDY	1	0	0	0	8	0	2	9	8	0	0	1	1	0	0	0	1	3	3	0	0	0	8	1	8	TOTAL TISSUE TUMOR
INTEGUMENTARY SYSTEM	- 41	41		41	4	41	51	.71	41	41	4	41	41	91	4	4	.11	41	41	-91	91	-91	31	-91	-	
SUBCUTANEOUS TISSUE Fibroma Fibrosarcoma	+	+	+	٠	+	* ×	N	* ×	* x	+	+	٠	+	٠	•	٠	٠	+	•	•	+	•	+	٠	+	49× 3 1
ESPIRATORY SYSTEM											·															
LUNGS AND BRONCHI Carcinoma,nos Alveolar/bronchidlar carcinoma Cortical carcinoma, metastatic	ŀ	•	+	•	•	+	•	•	+	+	•	+	+	•	•	•	•	+	•	•	+ ×	+	٠	*	٠	48
TRACHEA	1.	+	+	٠	٠	+	A	٠	+	+	•	+	٠	٠	+	÷	•	٠	÷	+	+	+	٠	+	+	48
EMATOPOIETIC SYSTEM	-			-																				-	-	
BONE MARROW	<u> -</u>	+	+	÷	+	+	A	÷	+	٠	+	٠	+	+	+	÷	+	+	+	•	÷	+	+	•	+	46
SPLEEN	+	+	+		+	+	<u>A</u>	+	+	<u>.</u>	+	+		+	+	+	÷	•	+	+	+	+	÷	+	+	48
LYMPH NODES	+	٠	+	÷	+	+	A	+	+	+	+	+	+	+	+	÷	+	+	÷	+	٠	+	•	+	÷	46
THYMUS	+	٠	+	+	+	٠	A	٠	+	+	÷	+	٠	+	-	٠	٠	+	-	+	٠	+	+	+	+	40
TRCULATORY SYSTEM	+				-																					
HEART .	+	٠	٠	٠	+	٠	A	٠	+	+	÷	+	+	+	+	+	٠	+	+	+	٠	٠	+	٠	+	48
DIGESTIVE SYSTEM																									-	
SALIVARY GLAND	L.	+	+	+	+	. +	A	+	+	+	+	+	+	+	+	+	+	+	<u>+</u>	+	•	+	+	+.	+	48
LIVER Neoplastic Nodule Hepatocellular carcinoma	ŀ	* x	* x	•	+	+		•	*	٠	+	*	+	+	+	+	•	•	•	• x	٠	•	٠	* x	×	48 10 2
BILE DUCT	+	•	+	+	+	+	A	+	+	+	+	÷	+	+		÷	+	+	+	+	+	÷	+	+	+	48
GALLBLADDER & COMMON BILE DUCT	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	н	N	N	N	N	N	N	49×
PANCREAS	+	÷	+	+	+	•		+	٠	+	÷	÷	+	+	+	÷	÷	+	+	<u>+</u>	+	<u>+</u>	+	٠	•	48
ESOPHAGUS	L.	+	+	+	+	+	A	+	•	÷	+	+	+	t	+	÷	+	+	٠	+	÷	+	+	+	•	48
STOMACH Squamous cell papilloma	ŀ	+	+	+	•	+		+	+	•	•	* x	+	+	•	•	•	•	•	•	+	+	•	٠	+	47
SMALL INTESTINE	+	+	•	+	÷	+	A	+	+	+	+	÷	+	<u>+</u>	+	+	+	+	+	+	+	+	+	+	-1	47
LARGE INTESTINE	1.	+	٠	٠	+	٠	A	٠	٠	+	+	٠	+	+	٠	+	٠	+	+	٠	٠	+	٠	٠	+	48
RINARY SYSTEM											_															
KIDHEY	++	+	+	+	+	•	A	٠	+	+	•	٠	+	+	+	+	•	+	+	+	+	+	+	+	-+	48
URINARY BLADDER	+	+	-	٠	٠	•	A	٠	+	٠	+	+	+	+	•	٠	٠	+	٠	٠	+	+	٠	+	+	47
NDOCRINE SYSTEM	1																									
PITUITARY Carcinoma, Hos Chromophobe Adenoma Chromophobe Carcinoma Ganglioneurobiasiona	-	•	* ×	* ×	•	* ×	A	×	×	•	* ×	+	•	-	* ×	* ×	×	•	* ×	* ×	* x	•	+	•	•	46 2 18 1
ADRENAL Cortigal Carcinoma Pheochromogytoma Ganglioneuroma	+ ×	•	٠	٠	٠	٠	A	٠	+	٠	+	٠	•	•	٠	+	٠	٠	٠	٠	٠	•	٠	٠	•	48 1 3
THYROID C-CELL CARCINOMA	ŀ	+	+	٠	÷	٠	٨	٠	+	٠	+	+	+	+	+	+	+	*	+	٠	+	+	+	٠	٠	48 ₃
PARATHYROID Adenoma, Nos	+	+	+	* x	•	-	٨	-	-	+	+	+	+	-	-	•	+	+	٠	+	+	-	•	+	·	35
EPRODUCTIVE SYSTEM	1			_			-																		-	
MAMMARY GLAND Fibroadenoma Cystfibroadenoma	Ľ	+	+	+	•	N	N	•	•	•	×	•	•	*	* x	•	•	•	+ x	•	•	•	N	M	•	49¥ 7 3
UTERUS Endomftrial stromal polyp	+	٠	* x	٠	٠	*	۸	٠	*	٠	+	+	+	+	٠	٠	٠	٠	* x	* ×	•	٠	٠	٠	·	48 11
OVARY ERVOUS SYSTEM	+	+	٠	•	+	•	A	+	•	•	•	+	٠	+	•	٠	•	•	•	•	+	•	•	+	·	48
BRAIN Chromophobe Carcinoma, Invasive Astrocytoma	+	٠	٠	٠	٠	٠	A	٠	٠	٠	٠	٠	٠	٠	*	٠	٠	٠	٠	•	٠	+	+ ¥	٠	+	48
A ANIMALS NECROPSIED + IISSUE EXAMINED MICROSCO - Reguired Tissue not exam X: Tunge Incidence N: Necropsy, no Autolysis,								TIO	 N		C: A: A: B:	N N A A A	ID T IECR UTO NIM	ISS OPS ILYS	UE Y, MIS OPS	INF NO SIN	ORT HIS	IAT I	ON OG1 ED	SUI r Di	JE 1	TTEI TO I	PRO	TOC		

.

82

•

APPENDIX B

.

Summary of the Incidence of Neoplasms in Mice Fed Diets Containing C. I. Solvent Yellow 14

TABLE B1.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE FED DIETS **CONTAINING C.I. SOLVENT YELLOW 14**

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY ANIMALS MISSING	50 1	50	50
ANIMALS HISSING ANIMALS NECROPSIED ANIMALS EXAMINED HISTOPATHOLOGICALLY	49	50 50	50 50
INTEGUMENTARY SYSTEM			
	(49)	(50)	(50)
SARCOMA, NOS FIBROSARCOMA RHABDOMYOSARCOMA		1 (2%) 1 (2%)	2 (4%) 1 (2%)
RESPIRATORY SYSTEM			
*NASAL CAVITY Olfactory neuroblastoma	(49)	(50) 1 (2%)	(50)
#LUNG HEPATOCELLULAR CARCINOMA, METAST ALVEOLAR/BRONCHIOLAR ADENOMA	(49)	(50)	(50) 3 (6%)
ALVEOLAR/BRONCHIOLAR ADENOMA ALVEOLAR/BRONCHIOLAR CARCINOMA	4 (8%)	6 (12%)	7 (14%)
FIBROSARCOMA, METASTATIC			1 (2%)
HEMATOPOIETIC SYSTEM			
<pre>*MULTIPLE ORGANS MALIGNANT LYMPHOMA, NOS</pre>	(49)	(50) 1 (2%)	(50)
MALIG.LYMPHOMA, LYMPHOCYTIC TYPE MALIG.LYMPHOMA, HISTICCYTIC TYPE	3 (6%)	1 (3 /)	1 (2%) 5 (10%)
MALIGNANT LYMPHOMA, MISTICTIC TYPE GRANULOCYTIC LEUKEMIA	1 (2%)	((174)	1 (2%)
#SPLEEN	(49)	(50)	(50)
MALIGNANT LYMPHOMA, NOS MALIG.LYMPHOMA, HISTIOCYTIC TYPE		1 (2%)	1 (2%)
#LYMPH NODE FIBROSARCOMA, INVASIVE	(41)	(46)	(43)

TABLE B1. MALE MICE: NEOPLASMS (CONTINUED)

	CONTROL	LOW DOSE	HIGH DOSE
<pre>#MESENTERIC L. NODE FIBROSARCOMA MALIG.LYMPHOMA, LYMPHOCYTIC TYPE</pre>	(41)	(46) 1 (2%)	(43) 1 (2%)
<pre>#RENAL LYMPH NODE Malig.lymphoma, lymphocytic type</pre>	(41)	(46)	(43) 1 (2%)
<pre>#PEYER'S PATCH MALIGNANT LYMPHOMA, MIXED TYPE</pre>	(48) 1 (2%)	(49)	(45)
IRCULATORY SYSTEM			
*SUBCUT TISSUE Hemangioma Hemangiosarcoma	(49) 1 (2%)	(50) 1 (2%)	(50)
#SPLEEN HEMANGIOSARCOMA	(49)	(50)	(50) 1 (2%)
#LIVER HEMANGIOMA HEMANGIOSARCOMA	(49) 1 (2%)	(50) 1 (2%) 1 (2%)	(50) 1 (2%) 1 (2%)
#KIDNEY/PELVIS HEMANGIOMA	(48)	(50) 1 (2%)	(50)
DIGESTIVE SYSTEM			
#LIVER HEPATOCELLULAR ADENOMA HEPATOCELLULAR CARCINOMA	(49) 5 (10%) 10 (20%)	(50) 3 (6%) 9 (18%)	(50) 7 (14% 12 (24%
#STOMACH Squamous cell carcindma	(47)	(48)	(49) 2 (4%)
#CARDIAC STOMACH Squamous cell papilloma	(47)	(48)	(49) 1 (2%)
#JEJUNUM Adenocarcinoma, nos	(48)	(49)	(45)

NONE

	CONTROL	LOW DOSE	HIGH DOSE
ENDOCRINE SYSTEM			
#PITUITARY Chromophobe Adenoma	(38)	(37)	(41) 2 (5%)
#ADRENAL Cortical Adenoma Pheochromocytoma	(48) 2 (4%)	(50)	(49) 1 (2%)
#THYROID Follicular-cell Adenoma Follicular-cell Carcinoma	(49)	(48) 1 (2%)	(50) 1 (2%) 1 (2%)
REPRODUCTIVE SYSTEM			
*MAMMARY GLAND Adenocarcinoma, nos	(49)	(50)	(50) 1 (2%)
#TESTIS INTERSTITIAL-CELL TUMOR	(48)	(50) 1 (2%)	(49)
NERVOUS SYSTEM			
NONE			
SPECIAL SENSE ORGANS			
*EYE/LACRIMAL GLAND Adenoma, Nos	(49) 1 (2%)	(50)	(50) 2 (4%)
MUSCULOSKELETAL SYSTEM			
NONE			
BODY CAVITIES			
*MEDIASTINUM <u>Hepatocellular carcinoma, metast</u>	(49)	(50)	(50) <u>1 (2%)</u>
NUMBER OF ANIMALS WITH TISSUE EXAMI NUMBER OF ANIMALS NECROPSIED	NED MICROSCOPI	CALLY	

TABLE B1. MALE MICE: NEOPLASMS (CONTINUED)

87

TABLE B1, MALE MICE: NEOPLASMS (CONTINUED)

	CONTROL	LOW DOSE	HIGH DOSE
ALL OTHER SYSTEMS			
ADENUCARCINUMA, NUS, METASTATIC SARCOMA, NOS, METASTATIC		(50) 1 (2%) 1 (2%)	(50) 1 (2%)
ANIMAL DISPOSITION SUMMARY			
ANIMALS INITIALLY IN STUDY NATURAL DEATHƏ MORIBUND SACRIFICE SCHEDULED SACRIFICE	50 4 1	50 8	50 10 1
ACCIDENTALLY KILLED TERMINAL SACRIFICE ANIMAL MISSING	44 1	42	39
a INCLUDES AUTOLYZED ANIMALS			
TUMOR SUMMARY			
TOTAL ANIMALS WITH PRIMARY TUMORS* Total primary tumors	24 31	30 40	37 53
TOTAL ANIMALS WITH BENIGN TUMORS Total benign tumors	13 13	12 13	20 22
TOTAL ANIMALS WITH MALIGNANT TUMORS TOTAL MALIGNANT TUMORS	15 18	23 27	25 3 1
TOTAL ANIMALS WITH SECONDARY TUMORS# Total secondary tumors	5 5	4	5 7
TOTAL ANIMALS WITH TUMORS UNCERTAIN- Benign or malignant Total Uncertain Tumors			
TOTAL ANIMALS WITH TUMORS UNCERTAIN- Primary or metastatic Total uncertain tumors			
* PRIMARY TUMORS: ALL TUMORS EXCEPT SEC # SECONDARY TUMORS: METASTATIC TUMORS			JACENT ORGAN

TABLE B2.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY ANIMALS NECROPSIED ANIMALS EXAMINED HISTOPATHOLOGICALLY	50 50 50	50 50 50	50 50 50
INTEGUMENTARY SYSTEM			
*SKIN BASAL-CELL CARCINOMA	(50) 1 (2%)	(50)	(50)
*SUBCUT TISSUE SARCOMA, NOS FIBROSARCOMA LIPOSARCOMA	(50) 1 (2%)	(50) 2 (4%)	(50) 2 (4%) 1 (2%)
RESPIRATORY SYSTEM #LUNG ALVEOLAR/BRONCHIOLAR ADENOMA ALVEOLAR/BRONCHIOLAR CARCINOMA SARCOMA, NOS, METASTATIC LIPOSARCOMA, METASTATIC		(50) 5 (10%) 1 (2%)	1 (2%)
HEMATOPOIETIC SYSTEM *MULTIPLE ORGANS MALIGNANT LYMPHOMA, NOS MALIG.LYMPHOMA, UNDIFFER-TYPE MALIG.LYMPHOMA, LYMPHOCYTIC TYPE MALIGNANT LYMPHOMA, MIXED TYPE LEUKEMIA,NOS LYMPHOCYTIC LEUKEMIA	4 (8%)	(50) 1 (2%) 1 (2%) 14 (28%) 4 (8%)	(50) 3 (6%) 1 (2%) 9 (18%) 1 (2%)
*SKIN MAST-CELL TUMOR	(50)	(50) 1 (2%)	(50)
#SPLEEN Malig.lymphoma, histiocytic type	(50)	(49)	(49) 1 (2%)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

,

	CONTROL	LOW DOSE	HIGH DOSE
MALIGNANT LYMPHOMA, MIXED TYPE		1 (2%)	
#LYMPH NODE Liposarcoma, metastatic	(45)	(45)	(46) 1 (2%)
#MANDIBULAR L. NODE Malig.lymphoma, lymphocytic type	(45)	(45) 1 (2%)	(46) 1 (2%)
#LIVER Malig.lymphoma, histiocytic type	(50)	(50)	(50) 1 (2%)
#PEYER'S PATCH Malig.lymphoma, histiocytic type	(48)	(49) 1 (2%)	(48)
#UTERUS MALIG.LYMPHOMA, HISTIOCYTIC TYPE	(49)	(47)	(49) 1 (2%)
CIRCULATORY SYSTEM			
*MULTIPLE ORGANS Hemangiosarcoma	(50)	(50) 1 (2%)	(50)
#BONE MARROW Hemangioma	(47)	(48)	(49) 1 (2%)
#SPLEEN Hemangiosarcoma	(50) 1 (2%)	(49)	(49) 1 (2%)
*MEDIASTINAL ARTERY SARCOMA, NOS, METASTATIC	(50)	(50) 1 (2%)	(50)
DIGESTIVE SYSTEM			
#LIVER HEPATOCELLULAR ADENOMA HEPATOCELLULAR CARCINOMA	(50) 2 (4%)	(50) 1 (2%) 3 (6%)	(50) 2 (4%) 4 (8%)
#ESOPHAGUS Squamous cell papilloma	(50)	(47) 1 (2%)	(49)
#STOMACH Squamous cell papilloma	(49)	(49)	(49) 1 (2%)
#CARDIAC STOMACH SQUAMOUS_CELL_PAPILLOMA	(49)	(49)	(49) <u>1 (2%)</u>

TABLE B2. FEMALE MICE: NEOPLASMS (CONTINUED) ______

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

•

	CONTROL	HIGH DOS					
#JEJUNUM ADENOCARCINOMA, NOS	(48)	(49)	1 (2%)				
JRINARY SYSTEM							
NONE		·					
ENDOCRINE SYSTEM							
#PITUITARY Chromophobe Adenoma Chromophobe Carcinoma	(43) 1 (2%) 1 (2%)	(38)	(46) 2 (4%)				
#ADRENAL Pheochromocytoma	(49)	(48)	(48) 1 (2%)				
#THYROID ADENOMA, NOS Follicular-cell Adenoma	(49) 1 (2%)	(47) 3 (6%)					
#PANCREATIC ISLETS ISLET-CELL ADENOMA	(47)		(49) 1 (2%)				
REPRODUCTIVE SYSTEM							
*MAMMARY GLAND Adenocarcinoma, nos	(50) 1 (2%)	(50) 1 (2%)	(50)				
#UTERUS FIBROMA	(49)	(47)	(49)				
LEIOMYOMA Endometrial stromal polyp		1 (2%) 1 (2%)	1 (2%) 1 (2%)				
#ENDOMETRIAL GLAND Adenocarcinoma, Nos	(49) 1 (2%)	(47)	(49)				
#OVARY Papillary Adenoma Papillary Cystadenoma, Nos	(46) 1 (2%) 1 (2%)	(46)	(48)				
CHORIOCARCINOMA		1 (2%)					

TABLE B2. FEMALE MICE: NEOPLASMS (CONTINUED)

.

NERVOUS SYSTEM

NONE

	CONTROL	LOW DOSE	HIGH DOSE
SPECIAL SENSE ORGANS			
*EYE Malignant Melanoma	(50) 1 (2%)	(50)	(50)
*EYE/LACRIMAL GLAND ADENOMA, NOS	(50)	(50)	(50)
*EXTERNAL EAR SARCOMA, NOS	(50)		(50) 1 (2%)
MUSCULOSKELETAL SYSTEM			
*VERTEBRAL COLUMN Sarcoma, nos, invasive	(50)	(50)	(50) 1 (2%)
*RIB SARCOMA, NOS, INVASIVE	(50)	(50) 1 (2%)	(50)
BODY CAVITIES			
*ABDOMINAL CAVITY SARCOMA, NOS	(50) 1 (2%)	(50)	(50)
ALL OTHER SYSTEMS			
*MULTIPLE ORGANS ADENOCARCINOMA, NOS, METASTATIC	(50) 1 (2%)	(50)	(50)
SARCOMA, NOS, METASTATIC Fibrosarcoma, Milastatic	1 (2%)	1 (2%)	1 (2%)
THORAX Sarcoma, nos Liposarcoma, metastatic	1	1	

TABLE B2, FEMALE MICE: NEOPLASMS (CONTINUED)

	CONTROL	LOW DOSE	HIGH DOS				
NIMAL DISPOSITION SUMMARY							
ANIMALS INITIALLY IN STUDY NATURAL DEATHƏ Moribund Sacrifice Scheduled Sacrifice	50 14	50 7 2	50 11 2				
ACCIDENTALLY KILLED TERMINAL SACRIFICE ANIMAL MISSING	36	4 1	37				
INCLUDES AUTOLYZED ANIMALS							
UMOR SUMMARY							
TOTAL ANIMALS WITH PRIMARY TUMORS* TOTAL PRIMARY TUMORS	27 31	34 48	36 44				
TOTAL ANIMALS WITH BENIGN TUMORS Total Benign Tumors	8 8	11 14	14 15				
TOTAL ANIMALS WITH MALIGNANT TUMORS TOTAL MALIGNANT TUMORS	21 23	29 33	25 29				
TOTAL ANIMALS WITH SECONDARY TUMORS Total Secondary Tumors	# 3 3	2 3	3 5				
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT TOTAL UNCERTAIN TUMORS	-	1					
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC TOTAL UNCERTAIN TUMORS	-						
PRIMARY TUMORS: ALL TUMORS EXCEPT SE Secondary Tumors: Metastatic Tumors			DIACENT ORG				

TABLE B2. FEMALE MICE: NEOPLASMS (CONTINUED)

TABLE B3.

INDIVIDUAL ANIMAL TUMOR PATHOLOGY IN MALE MICE FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

					υ	U		K	U	-															
ANIMAL NUMBER	8	0	0	0	0	0	8	-	8	1	1	1	1	1	1	1	1		0	2	2	2	2	0	02
WEEKS ON		-1	3	4	-1	6	7	1	퀴	┦	∄	-1	킒	+	퀴	1	;	-	긤	- 0	1	2	3	4	5
STUDY	5	0 5	0 5	5	5	0 5	0 5	5	5	3	5	5	الد	š.	5	5	5	š	5	Š	<u>s</u> i	ŝ	5	5	Š
SUBCUTANEOUS TISSUE HEMANGIOMA	•	+	+	٠	٠	+	٠	+	`+	٠	٠	٠	+	٠	٠	٠	٠	٠	٠	٠	+	+	٠	٠	٠
RESPIRATORY SYSTEM	<u> </u>																_								
LUNGS AND BRONCHI Hepatocelullar Carcinoma, metasta Alveolar/Bronchiolar Adenoma Alveolar/Bronchiolar Carcinoma	+	٠	+	•	* x	•	+	+	+	•	+	+ X	+	•	×	•	+ ×	•	+	•	+ x	+	٠	+	•
TRACHEA	+	٠	÷	٠	٠	+	٠	÷	÷	٠	٠	÷	+	٠	+	+	+	+	٠	÷	+	+	+	+	+
HEMATOPOIETIC SYSTEM	┢─																-								~
BONE MARROW	Ŀ	+	<u>+</u> _	<u>.</u>	+	•	<u>+</u>	-	<u>.</u> t	+	+		+	+	•	٠	÷	+	+.	+	+	.+	+	+	+
SPLEEN	ŀ	+	t	÷		+	<u>+</u>	+	<u>+</u>	+	+	<u>+</u>	÷	÷	•	+	+	+	+	+.	+	+	ŧ	+	+
LYMPH NODES	+	+	+	•	-	+	+	-	+	÷	•	+		+	+	+_	÷		+	.+	_ t	+	~	-	+
THYMUS	+	+	-	٠	-	٠	÷	-	+	٠	-	÷	+	÷	+	+	+	-	+	÷	-	+	+	-	+
CIRCULATORY SYSTEM	<u> </u>																	_							-
HEART	+	+	+	+	+	+	٠	٠	+	+	÷	+	+	٠	÷	+	÷	+	÷	+	٠	+	+	+	+
DIGESTIVE SYSTEM	ļ																								
SALIVARY GLAND	L.	÷	+	+	+	÷	+	-	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	. +	+
LIVER	•	+	+	+	÷	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+
HEPATOCELLULAR ADENOMA Hepatocellular carcinoma Hemangiosarcoma		x		×		×	×				x	x			x										
BILE DUCT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	±	+	+	.+	+		+		<u>+</u>	+	. +
GALLBLADDER & COMMON BILE DUCT	+	٠	+	+	+	٠	٠	٠	٠	٠	+	+	+	٠	٠	٠	٠	٠	٠	٠	٠	٠	٠	٠	+
PANCREAS	+	+	. +	+	+	-	+	+	+	٠	÷	+	+	+	+	+	÷	÷	÷	+	+	+	+	+	+
ESOPHAGUS	•	+	.+	+	+	÷	÷	+	+	+	+	+	+	÷	+	+	+	+	+		+	<u>+</u>	+	+	
STOMACH	+	+	+	+	+	+	+	+	+	+	+	+	. <u>+</u>	÷	+	+	+	+	+	+	+	+	+	+	+
SMALL INTESTINE Adenocarcinoma, Nos Malignant Lymphoma, Mixed Type	+	٠	٠	* ×	+	٠	٠	٠	+ ¥	٠	٠	٠	+	٠	٠	٠	+	+	٠	٠	+	+	٠	+	+
LARGE INTESTINE	+	+	•	+	+	+	+	•	÷	•	+	•	+	+	•	+	+	+	+	+	+	+	+	•	+
JRINARY SYSTEM	<u> </u>												·				·								
KIDNEY	١.	+	+	+	+				+	+		+	+	+	+	+	+	•	+	+	•	+	+	•	+
URINARY BLADDER		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ENDOCRINE SYSTEM																									
PITUITARY		•	_	-			•			•	•	÷	+	÷	•	-	÷	÷	-		•	+	•	+	
ADRENAL CORTICAL ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+	* x	+	+	+
THYROID	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	÷	+	+	÷	+	+	+	÷	÷	+
PARATHYROID	+	+	+	-	-	-	-	+	+	+	-	-	+	+	+	+	+	+	+	+	+	+	-	+	+
REPRODUCTIVE SYSTEM	<u> </u>																							•	
MAMMARY GLAND	I N	N	N	N	N	N	N	N	N	N	н	N	н	N	N	N	N	N	N	N	N	N	N	N	N
TESTIS	+	+	+	+	+	•	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PROSTATE	÷	- <u>'</u>	+			+	 +	+	• •	+	+	•	+	+	+	+	•	÷	+	+	+	+	+	+	ź
SPECIAL SENSE ORGANS														•											_
LACRIMAL GLAND ADENOMA, NOS	н	N	N	N	N	N	н	N	N	N	N	N	N	N	N	N	N	N	н	N	N	N	N	N	N
ALL OTHER SYSTEMS					·									-				_							_
MULTIPLE DRGANS NOS MALIG.LYMPHOMA, HISTIOCYTIC TYPE MALIGNANT.LYMPHOMA, MIXED TYPE	н	N	N	N	H	N	H	N	N	н	N X	N X	н	N	N	N Y	N	N	N	N	N	N	N	H	N

CONTROL

TISSUE EXAMINED MICROSCOPICALLY
 REQUIRED TISSUE NOT EXAMINED MICROSCOPICALLY
 TUMOR INCIDENCE
 NECROPSY, NO AUTOLYSIS, NO MICROSCOPIC EXAMINATION

: NO TISSUE INFORMATION SUBMITTED C: Neckopsy, NO HISTOLOGY DUE TO PROTOCOL A: Autolysis M: Animal Missing B: No Necropsy Performed

.

ANIMAL NUMBER	026	0 2 7	0 21 8	2	0 3 0	31	032	0	0	0	0	0 3 7	0 3 8	0 3 9	040	4	0 4 2	0 4 3	0	0 4 5	0 4 6	0 4 7	0 4 8	4	0 5 0	TOTAL
WEEKS ON Study	0	1 0 5	0	1 01 5	1 0 5	1 0 5	11 01 51	01	0 6 0	11 01 5	0	1	11 0 5	0	1 0 5	01 71 71	0	0	0 5	1 0 5	0 9 7	0 5	0	1	105	TUMOR
INTEGUMENTARY SYSTEM Subcutaneous tissue	+	÷	+	+	÷	+	+	м	+	+	+	٠	+	+	+	+	* X	•	+	+	•	+	+	+	+	49*
HEMANGIOMA	1																<u> </u>								_	
RESPIRATORY SYSTEM LUNGS AND BRONCHI HEPATOCELLULAR CARCINOMA, METASTA ALVEOLAR/BRONCHIOLAR ADENOMA ALVEOLAR/BRONCHIOLAR CARCINOMA	۰	•	٠	٠	٠	٠	٠	M	+	٠	•	٠	•	٠	* x	* X X	٠	٠	•	٠	* ×	•	•	•	+ ×	49 5 4
TRACHEA	+	+	+	+	+	+	+	м	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	49
HEMATOPOIETIC SYSTEM	┞																									
BONE MARROW	+	+	+	+	+	+	+	м	+	+	+	+	+	+	+	÷	+	+.	÷	+	+	÷	+	+	+	47
SPLEEN	+	+	+	+	+	+	+	м	+	+	+	+	+	+	+	+.	+.	•	+	+	+	+	+	•		49
LYMPH NODES	+	+	+	+	+	+	+	м	4	÷	-	+	+	+	+	+	-	-	+	+	+	+	+	+	+	41
THYMUS	-	-	+	-	-	+	+	м	A	+	+	+	+	+	+	-	+	+	+	+	-	-	+	+	-	33
CIRCULATORY SYSTEM																									+	
HEART	.	÷	•	+	+	٠	•	м	+	÷	+	÷	÷	÷	٠	÷	+	+	+	+	+	٠	+	٠	+	49
DIGESTIVE SYSTEM	┨											··••													+	
SALIVARY GLAND	١.	+	÷	+	+	+	÷	м	+	+	+	+	÷	+	+	+	+	+	•	+	+	•	+	+	+	48
LIVER HEPATOCELLULAR ADENOMA HEPATOCELLULAR CARCINOMA	+	+	+	+	+	+	•	M	•	+	٠	* x	+	+	+ x	+ x	+	٠	+	+ x	+ x	• x	+	* x	* x	49 5 10
HEMANGIOSARCOMA BILE DUCT		•	•	÷	+			M	•	+	+	+		+	•											! 49
	, t	+	N	•	+	<u>.</u>	÷		<u>т</u>	+	+	. <u>.</u>	•	+	+	+	•	+	+	Ň	+	÷	<u>,</u>	+		<u>49×</u>
GALLBLADDER & COMMON BILE DUCT Pancreas		Ţ		Ţ	Ţ	Ţ	Ţ	M		Ţ	Ţ	Ţ	Ì	÷	Ţ	Ì			Ţ		Ţ	Ì		Ì]	47
ESOPHAGUS	- <u>·</u>		<u>.</u>	<u> </u>	÷		<u>.</u>	M	<u> </u>	<u>.</u>	*	÷	<u></u>		+	<u> </u>	<u>.</u>			<u>.</u>	 +	<u> </u>	÷		Ť	49
STOMACH	Ť	<u> </u>	- <u>*</u> -	. <u>.</u>	· ·	•	<u>.</u>	M	<u>+</u>	÷	<u>.</u>	<u>.</u>		÷.	+	<u> </u>	-	<u>.</u>	<u> </u>	<u>.</u>	<u>.</u>	*	• •	<u> </u>	Ť	47
SMALL INTESTINE ADENOCARCINOMA, NOS	+	+	+	+	+	+	+	M	A	+	+	+	+	+	+	+	+	+	+	+	•	•	+	+	·	48 1
MALIGNANT LYMPHOMA, MIXED TYPE		·		•	+	+							+	+		+	+	+	+	+	+	+	+	+	1	
LARGE INTESTINE	-	+			*	•	+	м	A	+	+	+	-	_	-	<u>.</u>	-		_	<u> </u>	-		<u> </u>	-	1	45
JRINARY SYSTEM																										
KIDNEY	+	•	•	•	•	+				+	÷	<u>+</u>	<u>+</u>	•	<u>.</u>		÷	+	<u>.</u>	<u>+</u>	<u>.</u>	•	<u>.</u>	÷	+	
URINARY BLADDER	+	+	•	•	+	+	+	M	+	•	+	+	*	+	+	+	*	+	+	+	+	+	*	+	-	49
ENDOCRINE SYSTEM																										
PITUITARY	-	+	+	+	+		~	<u> </u>	+		<u>+</u>	+		+	<u> </u>		•	+	+	*		*	<u>*</u>		4	38
ADRENAL Cortical Adenoma	+	+	+	+	+	•	+	M	<u>.</u>	<u>*</u>	+	+	+		<u>*</u>	•	<u>*</u>	<u>*</u>	*	<u>*</u>	<u>+</u>	*	*	+	4	48
THYROID	٠	+	•	+	+	+	+	M	+	+	+	•	+	÷	+	+	+	•	÷	٠	t	+	+	t	+	49
PARATHYROID	÷	+	~	+	+	+	÷	м	A	٠	+	+	-	-	+	-	-	÷	+	-	+	+	+	-	-	33
EPRODUCTIVE SYSTEM																		~							+	
MAMMARY GLAND	Ν.	+	N	N	N	N	N	m	N	N	N	N	N	N	Ν.	N	<u>N_</u>	N	N	N.	N	N	N	N	N	49×
TESTIS	+	+	+	•	+	+	+	M	۸.	+	<u>+</u>	+	t	<u>ب</u>	•	+	<u>.</u>	•	+	+	÷	+	+	+	+	48
PROSTATE	+	+	+	+	+	+	+	m	A	÷	+	+	÷	+	•	+	+	+	÷	+	+	+	+	÷	•	48
PECIAL SENSE ORGANS	<u> </u>																				•				-+	
LACRIMAL GLAND Adenoma, Nos	N	N	н	N	N	N	N	M	N	H	H X	ĸ	N	N	N	N	H	N	N	н	H	N	N	H	۳	49× 1
LL OTHER SYSTEMS																									1	
MULTIPLE ORGANS NOS Malig.lymphoma, histiocytic type Malignant lymphoma, mixed type	N	N	N	N	N	N	H	M	N	H X	N	H	H	N	N	N	H	N	H	N	N	N	H	N	۲	49× 3

TABLE B3. MALE MICE: TUMOR PATHOLOGY (CONTINUED) CONTROL

HISSUE EXAMINED MICROSCOPICALLY
 REQUIRED TISSUE NOT EXAMINED MICROSCOPICALLY
 TUMOR INCIDENCE
 HECROPSY, NO AUTOLYSIS, NO MICROSCOPIC EXAMINATION

: NO TISSUE INFORMATION SUBMITTED C: Necropsy, no mistology due to protocol A: Autolysis M: Animal missing B: No Necropsy performed

~

.

TABLE B3.

INDIVIDUAL ANIMAL TUMOR PATHOLOGY IN MALE MICE FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

				L	.U	W	U	U:	SE																
ANIMAL NUMBER	8	0	:	ê	0	8	8	0	0	1	1	1	1	1	1	0	!	1	1	2	2	2	2	2	020
WEEKS ON STUDY		-1		1	-		1	8	1	1	1	1	1	1	1	1	1	1	9	1		1	-	1	1
INTEGUMENTARY SYSTEM	-21	5	. 51	51	21	-51	12	-51	_51	او	.51	51	<u>ei</u>	51	-51	51	51	31	٤	51	51	5	.51	51	1
SUBCUTANEOUS TISSUE Sarcoma, nos Fibrosarcoma Hemangiosarcoma	•	+ X	* ×	٠	٠	+	٠	٠	٠	+	٠	٠	٠	+	٠	٠	•	•	٠	٠	٠	٠	٠	٠	•
RESPIRATORY SYSTEM	-																								
LUNGS AND BRONCHI Hepatocelular Carcinoma, metasta Alveolar/Bronchiolar Adenoma Alveolar/Bronchiolar Carcinoma	ŀ	• x	•	٠	٠	٠	•	* ×	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	*	•
TRACHEA	<u></u> ++	+	+	+	+	.	+	+	+	+	•	٠	+	•	٠	+	+	+	+_	•	+	+	+	<u>+</u>	
MASAL CAVITY Olfactory Neuroblastoma	"	N	N	*	H	M	N	N	H	N	N	N	H	N	N	Η	N	N	N	N	N	H	N	N	N
HEMATOPOIETIC SYSTEM					-	-			_	_														-	-
BONE MARROW	++		+	+	•		+	+	•	+	+	+	+	-	+	.+	•	+	•	•	•	•	•	+	+
SPLEEN Malig.lymphoma, histiocytic type .	Ľ	•		+	•	+	•	•	•	*	•	+	•	+	+	+	+	•	•	•	•	+	+	*	_
LYMPH NODES Fibrosarcoma	+	•	•	•	+	+	+	+	+	•	+	+	•	•	+	+	+	•	+	•	•	•	•	•	•
THYMUS	-	-	-	-	-	٠	+	+	+	٠	+	+	-	-	٠	+	+	•	-	٠	•	-	+	-	+
CIRCULATORY SYSTEM																									-
HEART	+	+	+	+	+	+	•	+	+	+	•	+	+	+	*	+	+	+	+	+	•	•	+	+	•
DIGESTIVE SYSTEM																									
SALIVARY GLAND	+	•	•	+	+	+	+	•	+	•	+	•		• •	<u>+</u>	+	+	*	. <u>+</u> +	• •	+	<u>.</u>	÷	<u>.</u>	-
LIVER HEPATOCELLULAR ADENOMA HEPATOCELLULAR CARCINGMA HEMANGIOMA HEMANGIOSARCOMA		•	•	•	•	•	•	• ×	•	•	•	•	•	•	•	* X	•	×	•	•	* ×	* x	•	×	•
BILE DUCT	+	+	+	+	÷	+	+	+	+	+	+	•	+	÷	•	+	+	÷	•	+	+	+	+	÷	+
GALLBLADDER & COMMON BILE DUCT	÷	+	+	+_	+	+	+	+	+	+	+	+	+	+	•	+	+	+	+	+	+	+	•	+ .	+
PANCREAS	+	+	+	+	+	+	+	+	+	+	+	•	+	÷	+	+	+	+	+	•	+	+	+	+	•
ESOPHAGUS	+	+	+		+	+	.t.	ŧ.	+	+	+	+	<u>+</u>	<u>+</u>	•	+	+	•	<u>+</u>	•	+	•	.+	-	•
STOMACH	+	+		+	-	+	+	+	<u>.</u>	+	<u>+</u>	+	+	•	ŧ	+	+	+	+	+	+	+	+	•	+
SMALL INTESTINE Adenocarcinoma, nos	+	٠	٠	+	+	+	•	+	+	٠	٠	•	-	•	•	+.	•	+	+	•	*	+	•	•	+
LARGE INTESTINE	+	+	+	+	+	÷	٠	+	÷	+	٠	+	÷	+	÷	+	+	+	+	-	+	+	+	+	+
URINARY SYSTEM																					•				-
KIDNEY	+	•	<u>+</u>	+	•	•	÷	÷	÷	+	÷	ŧ.,	÷	+	+	•	٠	+	+	+	+	+	+	+	•
KIDNEY/PELVIS Hemangioma	+	+	+	+	+	+	+	+	*	٠	٠	+	٠	+	+	+	٠	+	+	٠	+	+	+	+	+
URINARY BLADDER	+	•	-	+	-	+	+	+	+	•	+	+	-	•	+	+	+	+	+	+	+	+	+	÷	•
ENDOCRINE SYSTEM	<u> </u>																								_
PITUITARY	+	-	+	+	-	+	+	+	+	<u>+</u>	+	+	•		+	+	-		÷	•	+	•	•	÷	-
ADRENAL	+	+	٠	+	٠	+	+	+	+	<u>+</u>	+	+	+	+	•	+	+	•	<u>+</u>	+	+	+	+	+	•
THYROID Follicular-cell Adenoma	٠	٠	+	+	+	*	+	+	+	+	+	+	•	+	+	•	+	+	+	+	+	+ .	•	•	+
PARATHYROID	+	-	+	+	+	+	+	+	+	+	•	-	-	+	-	+	÷	-	÷	-	٠	+	-	-	
REPRODUCTIVE SYSTEM																									-
MAMMARY GLAND	N	N	N	N	N	N	N.	N	N	N	H	N	N	<u>N</u>	N	N	N	Ν.	N	N	N	N	N	N	N
TESTIS INTERSTITIAL-CELL TUMOR	٠	٠	٠	٠	+	+	٠	٠	+	٠	* x	•	+	•	+	•	+	•	•	+	٠	٠	•	•	•
PROSTATE	+	+	٠	٠	÷	+	٠	+	+	+	+	•	+	+	+	+	+	+	-	•	٠	+	+	•	+
ALL OTHER SYSTEMS				~																	_				-
MULTIPLE ORGANS NOS Sarcoma, Hos. Metastatic Fibrosarcoma, invasive Malignant Lymphoma, nos Malig.Lymphoma, lymphocytic type Malig.Lymphoma, histiocytic type	н	N X	N	N	N X	N	N X	N	M	н	N	N	N S	H	H		H X	H X	N X	N	M	H	N	H	H
MALIG.LYMPHOMA, LYMPHOCYTIC TYPE MALIG.LYMPHOMA, HISTIOCYTIC TYPE +: TISSUE EXAMINED MICROSCOPI	CALI				x		x				;	NO	x	SUE	IN			101	x su	BMI	TTE				

LOW DOSE

 +:
 TISSUE EXAMINED MICROSCOPICALLY
 :
 NO TISSUE INFORMATION SUBMITTED

 -:
 REQUIRED TISSUE NOT EXAMINED MICROSCOPICALLY
 C:
 NCROPY, NO HISTOLOGY DUE TO PROTOCOL

 X:
 IMMOR INCIDENCE
 AUTOLYSIS
 AUTOLYSIS

 N:
 HECROPSY, NO AUTOLYSIS, NO MICROSCOPIC EXAMINATION
 MICAL MISSING

 N:
 HECROPSY, NO AUTOLYSIS, NO MICROSCOPIC EXAMINATION
 NO MECROPSY PERFORMED

AN IMAL NUMBER	0 2 6	2	0 2 8	0 2 9	0 3 0	0 3 1	3	0 3 3	3	3	3	0 3 7	0 3 8	0 3 9	4		0 0	044	0457-	0 4 6	0 4 7	0 4 8 1	849	0 5 0	TOTAL
WEEKS ON Study	0	0	0	0	0	0	0	0	0	0	0	8	0	0	0	1	0 0		1 0 5	1 0 5	0	5	9 0 0 3	0	TUMOR
INTEGUMENTARY SYSTEM		-	_																						
SUBCUTANEOUS TISSUE Sarcoma, nos Fibrosarcoma Hemangiosarcoma	+	•	٠	•	•	٠	•	•	•	٠	•	٠	•	•	•	•	+ • ×	• •	+	+	•	٠	٠	+	50+
RESPIRATORY SYSTEM												-					-							-	· · · ·
LUNGS AND BRONCHI Hepatocelular Carcinoma, metasta Alveolar/Bronchiolar Adenoma Alveolar/Bronchiolar Carcinoma	+ X	+	+	•	+	•	+ x	•	•	×	• ×	•	•	+	•	•	+ +		+	•	+	+ x	•	•	50
TRACHEA	ŀ	÷	+	+	+	+	+	+	+	+	+	+	+	+	+		<u>+ -</u>	<u>+</u>	<u>+</u>	+	•	+	-	+	<u>49</u>
NASAL CAVITY Olfactory neuroblastoma	н	N	N	N	N	N	M	N	N	N	N	N	N	N	N	N	N P	4 14	N	N	N	H	N	M	50
NEMATOPOIETIC SYSTEM													-											-	
BONE MARROW	+	+	+	*	+	<u>+</u>	+	+	-	+	+	+	+	+	+	•	+ +	• •	+	+		+	•	-1	48
SPLEEN Malig.lymphoma, histiocytic type _	•	•	•	+	+	+	+	+	+	•	+	•	•	+	•	•	+ •	+	+	+	•	ż	+	1	50
LYMPH NODES Fibrosarcoma	l.	+	+	+	+	+	+	+	•	•	+	•				_	• •		+		+	×.	-	-	46
THYMUS	+	+	•	+	*	*	*	•	-	-	*	-	÷	•	+	-	• •	• •	+	-	+	+	-	-	31
CIRCULATORY SYSTEM																									_
HEART	+	+	•	+	+	+	+	+	+	+	+	+	+	+	+	•	• •	+ +	*	+	+	+	+	1	50
DIGESTIVE SYSTEM																									•
SALIVARY GLAND	+	÷	. <u>*</u>	<u>+</u>	<u>.</u>	<u>+</u>	+		<u>+</u>		*	<u>+</u>	<u> </u>	<u>+</u>	_	<u>.</u>	<u>• •</u>	<u>+</u>	_ <u>+</u>	•	•	•	+	-	48
LIVER HEPATOCELLULAR ADENDMA HEPATOCELLULAR CARCINOMA HEMANGIOMA HEMANGIOSARCOMA		+	××	•	•	•	•	•	•	* ×	•	* ×	*	•		н . К	• •	• •	.•	* X	•	×	•		50
BILE DUCT	+	+	+	٠	+		+	+	+	+	<u>+</u>	<u>+</u>	+	+	+	<u> </u>	• •	•	+	•	+	•	•	+	50
GALLBLADDER & COMMON BILE DUCT	+	+	•	+	+	٠	ŧ	+	٠	+	+	H	÷	+	•	•	+ •	+	+	+	+	N	+	.*	50
PANCREAS	+	+	+	٠	+	+	٠	+	•	+	+	+	+	+	+	•	+ +	• •	+	٠		+	•	-4	50
ESOPHAGUS	<u> </u>	t	+	+	+		<u>+</u>	+	+	+	+	+	+	•	•	•	+ +	+ +	+	+	+	+	+	4	. 49
STOMACH	+	+	+	+	.+	+	<u>+</u>	+	+	+	-	+	+		*	<u>.</u>	<u>+ -</u>				<u> </u>	+		┦	48
SMALL INTESTINE Adenocarcinoma, NOS	•	•	•	•	+	+			•	+	+	<u>+</u>					+ •		<u> </u>		<u> </u>	•	•	-	49
LARGE INTESTINE	+	+	*	-	+	*	+	+	+	+	+	*	+	+	+	•	+ +	+ +	*	+	+	*	<u>.</u>	•	48
URINARY SYSTEM																									
KIDNEY KIDNEY/PELVIS	+	+	+	•	+	+	•	+	•	÷	*	÷	+	. <u>+</u>	•	•	•	<u>} +</u>	<u>+</u>	+	+	<u>+</u>	• •	-	50
KIDNETZPELVIS Hemangioma Urinary Bladder	Ļ.	•	• •		÷		• •	•	<u>.</u>	÷	• •	<u>.</u>					• •		• •		• •	•	• •	-	50 46
ENDOCRINE SYSTEM	Ľ										•	·	•						•			·		-	
PITUITARY	١.	-				-		•	•		•	-	•	•	•	•							-		37
ADRENAL	÷.	•	÷	÷	•	•	÷	•	÷		•	•	•				÷ .			•	•	•	•		50
THYROID	•	+	+	+	+	+	+	+	٠	+	÷	+	+	÷	+	•	• •	• •	+	+	+	+	-	-	48
FOLLICULAR-CELL ADENOMA																				·. ·.				-	
PARATHYROID	•	*	+	-	-	+	+	-	+	+	-	-	+	-	•	-	+ +		*	+	+	-	-	-	29
REPRODUCTIVE SYSTEM	١. ا																								
MAMMARY GLAND Testis Interstitial-cell tumor	•	+	+	+	<u>+</u>	+	+	<u>+</u>	.н. +	•	+	+	N .	<u>+</u>	+	•	<u>+</u>	<u> </u>	<u>N</u>	- N +	•	+	•	•	<u>50</u> 50
PROSTATE		•	•	•	•	•	•	+	•	•	•	•	+	÷	+		• •		•	•	•	•	•	_	47
ILL OTHER SYSTEMS	Ļ.	-	<u> </u>	-		. ·		<u> </u>	-	<u> </u>									-		_	<u> </u>		_	
MULTIPLE ORGANS NOS Sarcona, NOS, METASTATIC Fibrosarcona, invasive Maligant Lymphoma, nos Malig. Lymphoma, Lymphocytic type Malig. Lymphoma, Lymphocytic type Malig. Lymphoma, Lymphocytic type	N	N	N	N	N	м	N	N	H	M	N	N	N	N	N i	ĸ	N 1		N	N	N	H	N	×	50
MANUAL THERWINA, HISINGLING THE MANUALS MEEROPSIED 1 ISSUE EXAMINED Regures Tissue for exami Tomor incidence for exami Herropsi, Ho Autolysis, P	ICAI INED	MI	CRO: DSC	3C0 DP1	PIC. C E	ALL	Y INA	110			2 C: A: M: B:							T 1 01 OL DO RMEE		IBMI WE	TTE To	PRO	T D C	1 01	

TABLE B3. MALE MICE: TUMOR PATHOLOGY (CONTINUED) LOW DOSE

TABLE B3.

INDIVIDUAL ANIMAL TUMOR PATHOLOGY IN MALE MICE FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

				H	IG	iH	D	0	SE																
ANIMAL NUMBER	8	0	0	0	0	8	0	0	0	1	1	0	0	-	9	1	1	:	1	2	2	2	2	0	
WEERS ON Study	ļ	-1	-	븳	귀	1	-11	8		8	-11	1	킒	1	1	븳	뷞	9	뷞	╣	뷥	1	-3 -0 9	1	
INTEGUMENTARY SYSTEM	أفر	5	ŝ	اذ	اذ	أذ	il	لق	لغ	ĭ	š	اف	أف	أق	اذ	š	š	il	ĩ.	š	اد ا	š	8	اد	
SUBCUTANEOUS TISSUE Fibrosarcoma Rhabdomyosarcoma	•	٠	٠	+	+	٠	٠	• x	+	٠	+	+	٠	٠	+	٠	٠	٠	* ×	٠	٠	٠	٠	٠	
RESPIRATORY SYSTEM	<u>}</u>																								
LUNGS AND BRONCHI HEPATOCELULLAR CARCINOMA, METASTA Alveolar/bronchiolar Adenoma Fibrosarcoma, metastatic		*	•	+	•	•	•	•	+	•	* ×	•	+	+	•	* ×	•	×	•	+	•	• x	•	•	
TRACHEA	•	٠	•	+	+	٠	÷	÷	+	+	+	٠	+	+	٠	+	+	٠	٠	+	٠	+	+	٠	
EMATOPOIETIC SYSTEM	-							-																	
BONE MARROW	ŀ	+	+	-	+	•	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
SPLEEN Hemangiosarcoma Malignant Lymphoma, nos	•	*	+	•	•	•	•	+	•	•	•	+	+	•.	•	+	•	+	+	•	+	+ x	•	+	
LYMPH HODES Fibrosarcoma, invasive Malig.lymphoma, lymphocytic type	•	+	-	•	+	•	+		-	•	•	•	•	•	+	•	•	•	*	•	•	٠	•	•	
THYMUS	-	٠	-	-	٠	+	٠	-	٠	-	٠	+	-	٠	-	-	+	٠	-	-	+	+	-	+	
CIRCULATORY SYSTEM																									-
HEART	+.	+	٠	٠	٠	+	٠	+	+	٠	+	٠	+	+	٠	٠	+	٠	٠	٠	+	+	٠	+	
DIGESTIVE SYSTEM													_						_						
SALIVARY GLAND	+	+	+	+	+	+	•	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	
LIVER Hepatocellular Adenoma Hepatocellular Carcinoma Hemangioma Hemangiosarcoma	•	* ×	٠	•	•	•	+	•	+	٠	٠	٠	•	* X	* x	+	+	+ x	٠	* ×	+	+	٠	+ x	
BILE DUCT		+	+	+	+	+	+	+	+	+	+	+	•	+	+	+	+	+	+	+	+	+	+	+	
GALLBLADDER & COMMON BILE DUCT		+	+	•	+	+	+	+	÷	+	+	+	+	+	+	+	÷	+	+	+	+	•	+	+	
PANCREAS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•	-	.+	
ESOPHAGUS	+	+	+	+	+	+	+	+	+	•	+	+	+	+	+	+	+	+	÷	ŧ	+	+	÷	+	
STOMACH Squamous cell papilloma Squamous cell carcinoma	-	٠	+	+	* x	÷	٠	•	÷	٠	+ x	+	+	+	+	+	+	•	+ X	•	•	•	٠	+	
SMALL INTESTINE	-	+	•	+	+	٠	+	-	+	+	+	•	+	÷	+	+	+	+	-	+	+	+	+	+	
LARGE INTESTINE	-	+	+	+	+	•	•	-	+	+	+	+	+	÷	•	+	+	+	+	+	+	+	+	٠	
RINARY SYSTEM				_											-	-									
KIDNEY	+	+	+	+	+	+	•	+	+	+	<u>.</u>	+	•	+	<u>.</u> t.,	+	+	+	+	+	+	+	+	+	
URINARY BLADDER	÷	٠	+	٠	+	÷	٠	+	٠	÷	٠	٠	+	+	+	+	+	÷	÷	÷	+	٠	٠	+	•
NDOCRINE SYSTEM														-	-				_	-					
PITUITARY Chromophobe Adenoma	+	٠	٠	•	٠	•	•	•	٠	٠	•	•	•	٠	-	•	•	+	-	+	٠	•	-	+	_
ADRENAL Pheochromocytoma	<u> </u>	•	•	+	<u>*</u>	+	+	*	+	+	+	*	+	+	+	+	+	+	+	+	+	*	<u> </u>	+	
THYROID Follicular-cell Adenoma Follicular-cell Carcinoma	•	•	+	+	+	+	+	•	+	•	+	•	•	+	•	٠	•	٠	*	+	٠	+ x_	+	+	
PARATHYROID	-	-	-	-	+	٠	-	-	-	-	٠	-	-	-	-	٠	-	-	-	-	-	-	٠	٠	-
EPRODUCTIVE SYSTEM															_					· -					
MAMMARY GLAND Adengcarcinoma, Nos	N	N	N	н	N	N	N	H	N	N	H	N	N	N	N	N	N	N	H	N	N	N	N	N	1
TESTIS	•	+	+	÷	÷	+	+	+	+	•	+	+	+	+	•	•	÷	•	+	+	+	+	•	+	
PROSTATE	•	+	÷	+	+	+	+	+	+	-	+	+	+	+	+	+	•	+	+	+	+	•	+	÷	
PECIAL SENSE ORGANS																									-
LACRIMAL GLAND Adenoma, Nos	N	N	N	N	н	N	н	H	N	H	N	N	N	н	X	N	N X	N	H	N	N	N	N	H	1
ODY CAVITIES										-															-
MEDIASTINUM HEPATOCELLULAR CARCINOMA, METASTA LL OTHER SYSTEMS	N	N	N	N	н	N	H	N	N	N	N	N	N	м	N	H	н	N	N	N	N	N	N	H	
MULTIPLE ORGANS NOS Adenocarcinoma, Nos, metastatic malig.lynphoma, lynphocytic type malig.lynphoma, histiocytic type	N	N	н	N	N	н	H	H	N	N X	N	N	N	N	N	N	н	N	N	N	н	N	N	N	,
MALIG.LYMPHOMA, HISTIOCYTIC TYPE GRANULOCYTIC LEUKEMIA					×		x	x															x		
 *: TISSUE EXAMINED MICROSCOPJ -: REQUIRED TISSUE NOT EXAMIN X: Tungr incidence N: Necropsy, NO Autolysis, NC 	CALI IED 1	LY MIC CRO	ROS	COP PIC	EX	AMIN	NATI	104		i	: C: A: M: B:	AU	TIS CROF	(SIS M)	5 I 5 5 1	ING				UBMI		PR	010	COL	-

TABLE B3. MALE MICE: TUMOR PATHOLOGY (CONTINUED)	HIGH DOSE
--	-----------

ANIMAL NUMBER	0	2	0 2 8	0 2 9	0 3 0	0 3	0 3 2	0 3 3	0 3 4	0 3 5	0 3 6	0 31 7	3	0 3 9	0 4 0	4	4	0 4 3	4	6	0	41	0 4 8	0	0 5	TOTAL
WEEKS ON STUDY		1	- Î O	1	9	- i I	0	1	1	1	0	1	8	3	1	0	-2	1	0	1		0	0	0 9	1	TOTA TISSU TUMD
INTEGUNENTARY SYSTEM	1 21	5	5	5	41	5	5	_5	_51	_51	5	_5	5	41	_ <u>5</u> [51	5	5	5	5	_51	-31	<u>.5i</u>	_11	-51	
SUBCUTANEOUS TISSUE Fibrosarcoma Rhabdonyosarcoma	+	٠	+	+	+	+	* ×	٠	٠	+	٠	٠	٠	+	+	٠	٠	٠	٠	N	٠	+	٠	٠	•	50
RESPIRATORY SYSTEM																										
LUNGS AND BRONCHI HEPATOCELLULAR CARCINOMA, METASTA Alveolar/Bronchiolar Adenoma Fibrosarcoma, metastatic	+	×	+ ×	+	×	+	* .×	•	•	•	•	+	•	+	•	•	•	•	* ×	•	•	+	•	+	+ ×	50
TRACHEA	+	٠	+	+	+	٠	+	٠	٠	+	٠	+	+	٠	٠	٠	÷	٠	٠	٠	٠	+	+	٠	•	50
HEMATOPOIETIC SYSTEM	1																								_	
BONE MARROW	+	+	+	+.	+	+	+	+	+	+	+	+	+	+	. <u>+</u> -	. t	+	+	+	+	+	+	+	+	-+	49
SPLEEN Hemangiosarcoma Malighant Lymphoma, NOS	• 	•	+	•.	•	+	•	+	•	•	•	*	•	•	•	•	•	•	•	*	•	•	+	•		50
LYMPH NODES Fibrosarcoma, invasive Malig.lymphoma, lymphocytic type	+ 	•	•	-	-	•	+	+	+	•	+	-	•	•	* x	+ x	•	+	+	•	•	• 	+		+	43
THYMUS	+	-	-	-	-	-	•	+	-	-	+	-	+	A	+	+	+	+	+	+	+	-	+	-	٠	27
CIRCULATORY SYSTEM																										
HEART	+	+	+	+	+	+	+	+	+	+	+	•	+	+	+	+	+	*	+	<u>.</u>	<u>+</u>	-	+	+	-	49
DIGESTIVE SYSTEM				*		+						÷	•		•		•	•	÷			÷		4		49
SALIVARY GLAND	ļ,	÷	- <u>,</u>	• •		÷	+	÷.	+	+	+	÷	- <u></u>	+	+	+	+	+	•	+	÷	+	+	÷	Ţ	50
HEPATOCELLULAR ADENOMA HEPATOCELLULAR CARCINOMA HEMANGIOSARCOMA HEMANGIOSARCOMA	×				×	x				×	×	×				x	x			×	x		×	x	×	1
BILE DUCT	+	+	+	+	+	+	+	+	÷	÷	+	÷	•	+	+	÷	+	+	+	+	+	+	+	•	+	50
GALLBLADDER & COMMON BILE DUCT	+	+	+	+	+	N	+	+	+	+	+	+	+	N	+	+	N	+	+	+	+	÷	+	+	+	50,
PANCREAS	+	+	+	+	+	+	+	•	<u>+</u>	+	+	+	+	+_	+	+	+	+	+	+	÷	+	•	÷	٠	49
ESOPHAGUS .	·	+	+	+		+	+	+	+	+	+	<u>+</u>	+	•	+	+	+	+	+	<u>+</u>	*	+	+	+	-+	50
STOMACH Squamous cell papilloma Squamous cell carcinoma	+	+	+	+	•	+	+	+	+	+	+	+	•	+	•	•	+	+	+	•	+	+	+	•	+	49
SMALL INTESTINE	. +	+	+	+	-	+	+	+	٠	+	+	+	+	+	+	+	+	+	+	+	+	-	+	÷	ᅪ	45
LARGE INTESTINE	+	٠	+	٠	+	٠	+	٠	+	٠	+	+	+	+	-	+	+	+	+	+	÷	٠	۰,	+	+	47
DRINARY SYSTEM																										
KIDNEY	+	+	+	+	+	+	<u>+</u>	+	+	+	+	+	+_	+	+	+	+	+	+	+	+	+	+	+	+	50
URINARY BLADDER	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•	+	+	+	*	+	-	+	•	-	49
ENDOCRINE SYSTEM		•		•	+	•	•	•		•		•	_		-			÷	•	•	•	•		+		
CHROMOPHOBE ADENOMA	•	-	-	÷	-		-	•	-	-		x		A		_	-	<u> </u>	<u> </u>	-	x	<u> </u>	<u> </u>	+	4	41
ADRENAL Pheochromocytoma	•	•	+	+	+	•				+		+	•	+	+	+	+	+	+	+	•	+	•	+	•	49
THYROID Follicular-Cell Adenoma Follicular-Cell Carcinoma	•	•	+	+	•	+	•	+	+	+	•	+	•	+	*	+	•	+	•	+	• 	+	+	•	+	50
PARATHYROID	+	+	+	-	-	-	+	-	-	+	-	+	-	A	-	-	-	+	-	-	-	+	-	+	-	15
REPRODUCTIVE SYSTEM Mammary Gland Adenocarcinoma, Nos	н	N	N	м	* ×	N	N	N	N	N	N	N	N	м	N	N	N	N	N	N	N	N	H	N	N	50* 1
TESTIS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	<u>+</u>	+	<u>+</u>	+	+	•	49
PROSTATE	+	٠	٠	٠	٠	٠	•	•	٠	٠	٠	٠	٠	٠	٠	٠	+	+	٠	+	٠	٠	+	+	•	48
PECIAL SENSE ORGANS																									1	
LACRIMAL GLAND Adengma, Nos Dody Cavities	H	N	N	N	N	N	N	N	N	N	H	N	N	N	N	H 	N	M	N	N	N	N	H	N	M	50× 2
MEDIASTINUM Hepatocellular carcinoma, metasta	N	N	н	N	H X	N	N	N	N	N	N	H	м	N	H	N	H	N	N	H	N	N	N	N	۳	50×
LL OTHER SYSTEMS MULTIPLE ORGANS NOS ADENGCARCINOMA, NOS, METASTATIC MALIG.LYNPHOMA, LYMPHDCYTIC TYPE MALIG.LYNPHOMA, HISTIGCYTIC TYPE GRAHULGCYTIC LEUKEMIA	N	н	N	N	NX	H	N	N	N	N	N		H X	H	н	н	N	H	N	H		N X	N	н	N	50× 1 5
ANIMALS HECROPSIED +: TISSUE EXAMINED MICROSCOP -: REQURED TISSUE NOT EXAMI X: TUMOR INCIDENCE N: HECROPSY, NO AUTOLYSIS, N								10	1		: C: M: B:	Â	NIM	AL I	VE I Y, I IS MISS OPSI	5 I N	G			SUB	MITET	TED O P	ROT	000)L	

TABLE B4.

٠

INDIVIDUAL ANIMAL TUMOR PATHOLOGY IN FEMALE MICE FED DIETS CONTAINING **C.I. SOLVENT YELLOW 14**

CONTROL

ANIMAL NUMBER	1	ļ	0	į	0	0	9	l ě	ļ			1	1		5	į	;	1 8	1	Ž	2	22	2	2	
WEEKS ON Study	1	1	3 8	9	6	1	6	F١	6	1		0	Ŏ 9		1	0 9	Ì	0	0 9	0	0	2	9	0	
INTEGUMENTARY SYSTEM	+*	1.5	10	L 6	1.5	12	1.2	1.5	1.2			2	01	-21		31	_21	51	2			1.2	<u> </u>	1.2	1
SKIN Basal-Cell Carcinoma	Ŀ	+	•	+	+	•	•	+	+	+	•	•	+	*	•	+	+	+	+	+	•	+	* x	+	
SUBCUTANEDUS TISSUE	+	•	+	÷	+	+		+	+	+	•	+	+	+	+	+	+	+	٠	+	+	•	+	+	
SARCOMA, NOS RESPIRATORY SYSTEM	-			X																			····		_
	1.	•	٠	+	٠		÷	+	+	•	٠	,	•	٠	•	٠		٠	•	٠	,	•	÷	٠	
LUNGS AND BRONCHI Alveolar/bronchiolar Adenoma Alveolar/bronchiolar carcinoma	1													-				×							
TRACHEA	•	٠	٠	٠	٠	٠	٠	٠	٠	+	٠	٠	٠	٠	٠	٠	٠	٠	٠	+	٠	٠	٠	+	
HEMATOPOIETIC SYSTEM	1	_																							
BONE MARROW	++	<u>.</u>			÷		•	<u>+</u>	·	•	+	•	+	+	*	<u>+</u>	+	+	+	+		+	<u>.</u>		
SPLEEN Hemangiosarcoma Malig.lymphoma, histiocytic type		•	•	•	•	•	•	+	+	•	•	•	+	•	* 	+	•	•	•	•	+	•	+	*	
LYMPH HODES	<u> </u>	+	+	+	•		+	+	•	•	+	+	+	. +	•	+	+	+	+	+	+	•		+	_
THYMUS	+	+	-	-	+	+	+	٠	٠	٠	+	٠	-	٠	٠	~	+	-	-	٠	٠	+	-	+	
CIRCULATORY SYSTEM	1																								
HEART	1.	*	+	*	*	+	+		+	•		•	<u> </u>	<u>.</u>	•	*	•	•	+	+	+	+	+	*	_
DIGESTIVE SYSTEM SALIVARY GLAND				_								•		+					-		,				
LIVER	t.	+	+			+	- <u>;</u>	÷		+	- <u>-</u>	+	+	+	÷	÷	+	•	+	<u>,</u>	*	+	÷		-
HEPATOCELLULAR CARCINOMA	+																·								_
BILE DUCT	*	٠	٠	+	٠	٠	٠	+	٠	+	٠	٠	٠	+	+	٠	•	•	٠	+	+	٠	٠	٠	
GALLBLADDER & COMMON BILE DUCT	+	•		•	+	•	. +			•	+ 	*	.*	. *	.*	+	+	•	•	+	+	•	<u>+</u>	<u>+</u>	-
PANCREAS	+	.			<u> </u>	<u> </u>	*	<u>_</u>	<u>+</u>	+	_ <u>+</u>		<u>+</u>	*	<u>+</u>	+	+		+	+	<u>+</u>	+	<u>+</u>	<u>.</u>	
ESOPHAGUS Stomach	f:	÷	•	•	+	•	÷	+	<u>.</u>	•	•	<u>.</u>	•	÷	•	<u>+</u>	÷	<u>.</u>	•	<u>.</u>	+	•	<u>.</u>	<u>.</u>	-
SMALL INTESTINE	†÷	- <u>-</u>	<u> </u>	<u> </u>	<u> </u>	_ <u>_</u>	<u> </u>		<u> </u>	<u>*</u>	÷	<u>*</u> -	<u> </u>	÷	-		<u> </u>	- <u>*</u>	<u>.</u>		<u> </u>	<u> </u>		<u> </u>	-
LARGE INTESTINE	t.	•	<u>-</u>	- <u>-</u> -		•	•				+	- <u>+</u>	-	•	•	÷		•	•	<u>,</u>		÷	+	÷	-
JRINARY SYSTEM	<u> · </u>									<u> </u>										-	-				_
KIDNEY	+	+	+	+	+	÷	+	+	+	+	+	÷	•	+	•	+	÷	÷	+	•	÷	+		•	
URINARY BLADDER	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	
ENDOCRINE SYSTEM	+							-																	-
PITUITARY Chromophobe Adenoma Chromophobe Carcinoma	•	٠	٠	٠	٠	+	+	+	+	+	٠	+	٠	٠	+	+	٠	٠	-	٠	٠	+	٠	٠	
ADRENAL	1.	•	÷		+	+	+	+	+	+	+	+	+	÷	+.	+	+	+	+	+	+	+	•	+	
THYROID	+	÷	+	÷	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	-	+	+	÷	+	+	
ADENOMA, NOS	┢																								-
PARATHYROID REPRODUCTIVE SYSTEM	<u> </u>	+	+	<u> </u>	+	-	+	-	•	-		+	+	*				+		+		_	*	+	
MAMMARY GLAND ADENOCARCINOMA, NOS	•	N	N	÷	÷	+	* X	+	+	+	N	м	٠	÷	+	N	÷	+	•	+	÷	+	•	٠	
UTERUS Adenocarcinoma, nos Fibroma	+	•	٠	+	+	+	+	٠	+	+	+	+	+	+	+	+	٠	+	٠	+	+	٠	+	+	
OVARY Papillary Adenoma Papillary Cystadenoma, Nos	•	+	+	+	+ x	+	+	+	+	+	+	٠	+	+	+	+	+	+	+	+	+	+	+	+	
FACILLART CISTADERONA, ROS	i—																								_
EYE	Í n	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	н	N	N	N	N	
MALIGNANT MELANOMA	+×-															_									_
LACRIMAL GLAND ADENOMA, NOS	X	н	N	N	N	N	н	N	N	N	H	N	H	н	H	N	N	N	N	N	N	N	N	N	_
DDY CAVITIES Pleura	N									N															
LIPUSARCOMA, METASTATIC	 -							-										N					н		_
PERITONEUM Sarcoma, NDS	N	N	N	N	N	H	N	N	N	N	N	H	N	N	N	N	N	N	N	N	H	N	N	N	
LL OTHER SYSTEMS]																								
MULTIPLE ORGANS NOS Adenocarcinoma, nos, metastatic Sarcoma, nos, metastatic Malignant lymphoma, nos	N	N	N	H X	H	N	н	н	N	N	H	N	N X	N	N	N	N	H	H	N	H	H	N	H	
MALIG LYMPHOMA, LYMPHOCYTIC TYPE Malig.lymphoma, Histiocytic type Malignant Lymphoma, Mixed Type Leukemia,Nos			×					x			x	x							x				x		
LYMPHOCYTIC LEUKEMIA																							^		

TABLE B4. FEMALE MICE: TUMOR PATHOLOGY (CONTINUED) CONTROL

ANIMAL	1 2	9	2	2	03	0	03	0	0	0	01	Q	01	Ö 3	4	21		21	2	9	0	0	0	9	0	
WEEKS ON	16	3	ŝ	Į	ļļ	1	2	3	4	5	ا	-7	- 6	9	-1	귀	2	긝	4	- 2		-1	-8	-1	-	TOTAL
STUDY	0	ļġ	ļ	5	0 5	0 S	0	0	8	8 7	0	6		0	0	0	0 5	0 5	ġ	7	5	0	0	0	0	TUMOR
INTEGUMENTARY SYSTEM	Τ.																	+		N	•		•	÷		50+
SKIN Basal-Cell Carcinoma	Ŀ		+	<u> </u>		•	<u> </u>	*	N	N	+	н	N	*	+	+	<u> </u>	-	<u>.</u>		<u> </u>	-		÷	_	50
SUBCUTANEOUS TISSUE Sarcoma, nos	1 *	٠	٠	+	٠	+	+	+	N	H	+	N	N	+	+	٠	+	+	+	N	+	+	٠	+	•	50
RESPIRATORY SYSTEM	+																									
LUNGS AND BRONCHI	1+	÷	+	+	÷	٠	٠	÷	٠	٠	٠	+	٠	÷	+	+	+	+	+	٠	+	+	÷	+	•	50
ALVEOLAR/BRONCHIOLAR ADENOMA ALVEOLAR/BRONCHIOLAR CARCINOMA	 		_									x		×												1
TRACHEA	•	+	+	+	٠	+	٠	+	+	+	+	+	٠	٠	+	٠	+	٠	+	٠	٠	٠	+	٠	•	50
HEMATOPOIETIC SYSTEM	T																									
BONE MARROW	+	+	-		+	<u>+</u>	+	+	<u>.</u>	*	<u>+</u>	+	<u>+</u>	+	+	•	+	+	<u>+</u>	•	÷	+	<u>+</u>	+	+	47
SPLEEN Hemangiosarcoma Malig.lymphoma, histiocytic type	1.	•	+	+	+	+	+	+	+	+	+	+	+	+	+	•	•	•	+	•	•	•	*	•		50
LYMPH NODES	+	-	•	+	+	+	+	•	•	+	+	-	•	+	+	+	+	+	+	•	-	+	+	+	+	45
THYMUS	-		+	+	+	+	+	+	-	+	-	-	-	+	+	+	+	÷	+	-	÷	+	+	+	+	36
CIRCULATORY SYSTEM	+																								+	
HEART	+	+	٠	٠	+	÷	+	+	+	٠	+	٠	٠	٠	٠	+	٠	+	÷	٠	•	٠	+	+	+	50
DIGESTIVE SYSTEM	1										~~~															
SALIVARY GLAND	++		•	+	. +	+	t	+	+	+			+	+	+	•	.+	+	•	+	•	+	+	+	-+	45
LIVER HEPATOCELLULAR CARCINOMA	L.	+	+	+	+	+	+	*	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
BILE DUCT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	50
GALLBLADDER & COMMON BILE DUCT	+	•		_+	+	t	+	+	N	.+	+	N	+	+	+	+	+.	+	+	N	+	+	+	+	.+	50×
PANCREAS	+	+		+	.+	+	•		+	+	+			+	+	•	+	+	+	+	-	+	+	+	+	47
ESOPHAGUS	++	<u>.</u>	+	+	•	•	+	•		+	+	<u>+</u>	<u>+</u>	+.	.†	+	+.	+	+	<u>+</u>	+	+	<u>+</u>	+	4	_ 5.0
STOMACH	+-	+	+	+	+	+	+	<u>+</u>	.+	+	+	+	+	ŧ	+	+	+	+	.+	+	-		+	+	╇	49
SMALL INTESTINE	+	+	<u>+</u>	·_+	<u>+</u>	*	+		+	+	. <u>+</u>	-		+	+	. *	<u>+</u>	<u>+</u>	*	<u>+</u>	-	<u>+</u>	<u>+</u>	+	+	48
LARGE INTESTINE	+	+	+	+	+	+		•	*	+	+	-	+	+	+	+	+	+	*	+		+	+	•	4	47
KIDNEY	1.		+	÷	+	+	+	+	+	+	+	+	•	+	÷	÷	+	÷	÷	+	•	+	+	•	+	_ 50
URINARY BLADDER	+	+	+	+	+	+	+	+	+	-	+	-	+	+	÷	-	+	÷	÷	+	+	+	+	+	+	46
NDOCRINE SYSTEM	+				•		-																		-+	
PITUITARY CHROMOFHOBE ADENOMA	+	-	٠	+	+	+	* x	+	+	-	+	~	-	+	٠	+	-	٠	+	• •	-	٠	٠	+	+	43
CHROMOPHOBE CARCINOMA							<u> </u>				x														-+	<u> i</u>
ADRENAL	++	+	+	+	+	+	+	+	+	+	+	+	. <u>+</u>	+	+	+ .	+	<u>+</u>	+	+	+	+	+	+	┿	49
THYROID Adenoma, Nos	Ľ	+	•	+	+	+	+	+	+	+	+	+	•	+	*	*	+	+	+	+	.+	+	+	*	*	49
PARATHYROID	-	-	+	+	+	÷	-	+	+	-	+	-	-	+	٠	+	+	-	+	-	٠	+	٠	+	-	30
EPRODUCTIVE SYSTEM	1											-													+	
MAMMARY GLAND Adenocarcinoma, Nos	+	N	N	N	+	٠	٠	+	N	N	N	N	N	+	٠	٠	+	+	+	+	+	N	N	+	•	50×
UTERUS	1.	+	+	+	+	+	+	÷	+	+	+	-	+	+	+	+	+	+	+	+	+	÷	+	+	7	49
ADENOCARCINOMA, NOS Fibrona	L	_		x		_												x								1
OVARY PAPILLARY ADENOMA	+	-	٠	,+	٠	+	-	٠	٠	٠	+	-	٠	+	*	+	٠	٠	٠	٠	-	٠	٠	٠	+	46,
PAPILLARY CYSTADENOMA, NOS	1														Ŷ											i
PECIAL SENSE ORGANS	1																									
EYE • Malignant Melanoma	N I	N	N	H	N	N	N	N	N.	н	N	N	N	N	N	N	N	N	H	N	H	H	N	N	N	50×
LACRIMAL GLAND	N	N	N	N	N	N	N	N	N	N	N	N	N	N	н	N	N	N	N	N	N	N	н	N	н	50×
ADENOMA, NOS ODY CAVITIES	1							_																	-+	·'
FLEURA	N	N	м	м	N	м	N	N	м	н	N	н	N	N	N	N	N	н	N	N	N	N	N	N	N	58×
LIPOSARCOMA, METASTATIC	\vdash								X																+	1
PERITONEUM Sarcoma, NOS	N	N	N	N	N	H	N	N	N	N	N	н	N	н	н	N	N	н	н	N X	N	N	н	H	*	50× 1
LL OTHER SYSTEMS	1-																	••			-			_	╉	
MULTIPLE OPCANE NOS	н	N	н	N	N	н	N	N	N	N	N	н	N	N	н	N	N	N	N	N	N	N	N	N	N	50×
HOLIFICE URGANS HUS ADENOCARCINONA, NOS, METASTATIC SARCCHA, NOS, METASTATIC MALIGHANT LYMPHOMA, NOS MALIG, LYMPHOMA, LYMPHOCYTIC TYPE MALIG, LYMPHOMA, MISTOCYTIC TYPE MALIGHANT LYMPHOMA, MIXED TYPE LEUVENTA NOS																		^							1	1
MALIG.LYMPHOMA, LYMPHOCYTIC TYPE MALIG.LYMPHOMA, HISTINCYTIC TYPE	1										x			×												2 4
MALIGMANT LYMPHOMA, MIXED TYPE LEUKEMIA,NOS LYMPHOCYTIC LEUKEMIA																										i
LEUKEMIA, NOS	1									x											x					1

Ŵ

ANIMALS NECROPSIED
 * ANIMALS NECROPSIED
 * INSUE EXAMINED MICROSCOPICALLY
 * NO TISSUE INFORMATION SUBMITTED
 * REQUIRED TISSUE NOT EXAMINED MICROSCOPICALLY
 * HECROPSY, NO HISTOLOGY DUE TO PROTOCOL
 * AUTOLYSIS
 * NECROPSY, NO AUTOLYSIS, NO MICROSCOPIC EXAMINATION
 * ANIMAL MISSING
 B: NO NECROPSY PERFORMED

TABLE B4.

-

INDIVIDUAL ANIMAL TUMOR PATHOLOGY IN FEMALE MICE FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

LOW DOSE

ANIMAL				- 61			- 61							1		-	- 61	- 11							
NUMBER	ļ	ů 2	03	Ő	ů S	Ů	į	į	ŝ	į	<u>i</u>	ž	j.	į	ŝ	i	<u>i</u>	i	j	Ž	2	Ž	2 3	ž	_
WEEKS ON Study	0	1	0	0	0	0	?	ė	0	0	0	0	0	0		0	?	0	0	0	0	0		į	
INTEGUMENTARY SYSTEM	12	2.	_2		2	21		21	_21	-21	-21	-21	41	21	-21.	21	- 14	-21	21	-21	-21	21	-21	-21	-
SKIN Mast-cell tumor	•	٠	٠	٠	+	N	٠	+	+	٠	+	•	+	+	٠	•	•	+	•	+	٠	٠	٠	٠	•
SUBCUTANEOUS TISSUE	1.	+	+	•	+	N	+	•	+	+	+	+	+	+	+	+	•	+	+	+	+	+	+	+	Ξ,
FIBROSARCOMA													×	×											
RESPIRATORY SYSTEM																									
LUNGS AND BRONCHI Alveolar/Bronchiolar Adenoma Alveolar/Bronchiolar Carcinoma	1	•	•	•	x	•	ţ	•	•	•	•	•	•	•	•	•	•	•	x	•	•	•	•	•	;
TRACHEA	1.	•	•	•	•	•	- <u>^</u> -	•	•	+	•	•	•		•	•	•	•	•	•	•	•	•	•	_
HEMATOPOIETIC SYSTEM	–																								
BONE MARROW	Ŀ	+	•	•	•	•	•	•	•	+	•	•	÷	+	•	•	•	•	+	•	•	•	+	•	_
SPLEEN	+	+	÷	٠	٠	+	+	+	٠	٠	٠	٠	٠	٠	+	٠	•	٠	٠	٠	٠	+	+	٠	
MALIGNANT LYMPHOMA, MIXED TYPE Lymph Nodes	<u> </u>	+	•	•	•	•	•	•	•	•	•	•	-	•	•	•	+	•	•	•	•	•	•	•	-
MALIG.LYMPHOMA, LYMPHOCYTIC TYPE	Ļ.	-		_	<u> </u>								· · ·			<u> </u>			<u> </u>					<u> </u>	_
THYMUS	•	+	٠	-	٠	+	-	-	-	•	+	٠	-	+	•	+	-	+	٠	+	+	+	+	٠	•
CIRCULATORY SYSTEM	—																								
HEART	+	+	.	. <u>+</u> .	. +	•	<u>.</u>	•		*	•	<u>+</u>	•	•	+	•	•	+	•.	•		. .	_ +	*	-
BLOOD VESSELS Sarcoma, Nos, metastatic	н	N	н	N	N	N	N	N	N	N	N	н	N	N	N	N	H	NX	N	н	N	H	N	H	۴
DIGESTIVE SYSTEM	-																								
SALIVARY GLAND	ł۰	+	+	+	+	+	+	+	+	+	+	•	+	+	+	•	+	+	+	+	+	+	+	+	
LIVER Hepatocellular adenoma	1 *	٠	+	+	+	+	+	*	•	+	+	+	•	•	+	•	+	+	+	+	+	+	+	+	1
HEPATOCELLULAR CARCINOMA	+		·								<u>×</u>							_			<u>×</u>				_
BILE DUCT Gallbladder & Common Bile Duct	ا :	÷	•	÷	<u>,</u>	÷	<u>,</u>	<u>,</u>	÷.	<u>.</u>	<u>.</u>	<u>.</u>	<u>.</u>		<u>.</u>	÷	<u>.</u>	÷	÷	÷.	N.		<u>.</u>	÷	_
PANCREAS	ļ,	÷	÷	+	÷	•	÷	÷	÷	+	÷	+	+	+	•	+	+	_	+	•	*	÷	•	÷	_
ESOPHAGUS	1.	•	+	٠	÷	+	+	÷	+	•	+	+	+	÷	+	÷	-	+	÷	+	+	+	•	+	
SQUAMOUS CELL PAPILLOMA	+						<u> </u>											<u>×</u>							
STOMACH SMALL INTESTINE	<u> </u>	+	+	<u>.</u>	+	<u>.</u>	÷	+	÷	<u>+</u>	• •	+ +		<u>+</u> +		+	<u>+</u>	+	+ •	<u>+</u>	+	<u>+</u>	÷.	•	-
MALIG.LYMPHOMA, HISTIOCYTIC TYPE	<u> -</u>											·	<u> </u>	×.		·		-		_			•	•	_
LARGE INTESTINE	+	•	•	+	•	+	+	+	*	+	+	•	٠	+	•	+	+	+	٠	*	+	+	+	٠	٠
URINARY SYSTEM																									
KIDNEY	†÷	÷	÷	. <u>.</u>	÷.	+	+	•	*	. <u>+</u>	+	<u>.</u>	+	<u>+</u>	•	+	•	•	•	• •	<u>.</u>	<u>+</u>	. <u>+</u>	. *	-
URINARY BLADDER ENDOCRINE SYSTEM	Ļ	<u> </u>	·	•	•	•	-	<u> </u>	•	*	*	+	•	+	+	+		+	•	<u>.</u>	<u>.</u>	+	+	+	
PITUITARY	.		•	-	•	-	•	•	•	•			•	•			_	_	_	•	•	•		_	
ADRENAL	T.	+	+	•	+	+	+	+	+	+	+	+	+.	+	+	+	•	+	•	•	÷	+	+	+	•
THYROID	1.	+	+	+	+	+	+	•	+	+	+	+	•	+	+	÷	+	+	÷	٠	+	+	+	+	+
FOLLICULAR-CELL ADENOMA	 				- • • •													X		<u>x</u>			··		
PARATHYROID	<u> </u>	-	-	-	<u>+</u>	<u>+</u>	-	<u>+</u>	-	<u>+</u>	<u>+</u>	<u>+</u>	<u> </u>		. <u>+</u>			+	<u>-</u>	<u>+</u>	•	<u>+</u>		<u>+</u> _	
PANCREATIC ISLETS ISLET-CELL ADENOMA	ľ	•	Ť	•	٠	•	•	•	·	•	•	Ť	•	•	•	•			•	x	•	x	Ť	•	
REPRODUCTIVE SYSTEM																									-
MAMMARY GLAND Adenocarcinoma, nos	+	N	*	N	N	N	N	N	•	+	+	•	•	+	+	*	N	N	+	•	*	*	N	*	+
UTERUS Leionyoma Endometrial stromal Polyp	+ ×	٠	٠	٠	+	٠	+	+	•	٠	٠	٠	+	•	٠	+	-	•	* ×	•	+	٠	+	٠	•
OVARY CHORIDCARCINOMA	•	+	٠	٠	٠	+	-	٠	+	٠	٠	٠	•	•	٠	٠	+	•	٠	+	+	+	٠	+	٠
USCULOSKELETAL SYSTEM	┣—																								-
BONE	н	N	N	N	N	N	N	н	N	N	N	N	N 1	N	N	N	N	N	N	N	N	N	N	N	N
SARCOMA, NOS, INVASIVE														_				×							
DODY CAVITIES Pleura	N	N	м	N	м	N	N	N	м	н	N	N	N 1	N	N	N	N	N	N	N	N	N	N	N	
SARCOMA, NOS			11	.4	.,	н	п	ы	н	n				•	^	.1		X		"	a	n	n	"	1
LL OTHER SYSTEMS																									
MULTIPLE ORGANS NOS FIBROSARCOMA, METASTATIC HEMANGIOSARCOMA Malighant Lymphoma, Nos	н	N		N	N	н	н	н	N	м	N	H	N 1	ĸ	N I	H	N	н	N	N	H	N	N	N	N
MALIGNANT LYMPHOMA, NOS Malignant Lymphoma, Nos Malig.Lymphoma, Undiffer-Type Malig.Lymphoma, Hisidcytic Type Malignant Lymphoma, Mixed Type	×	×	×	×			x			×						×	×			×		×			×
+: TISSUE EXAMINED MICROSCOP									-						I I N										1

 +:
 TISSUE EXAMINED MICROSCOPICALLY
 :
 NO TISSUE INFORMATION SUBMITTED

 -:
 REQUIRED TISSUE NOT EXAMINED MICROSCOPICALLY
 C
 NECROPSY, NO HISTOLOGY DUE TO PROTOCOL

 X:
 TUMOR INCIDENCE
 AUTOLYSIS
 AUTOLYSIS

 N:
 NECROPSY, NO AUTOLYSIS, NO MICROSCOPIC EXAMINATION
 MISSING

 B:
 NO NECROPSY PERFORMED

.

TABLE B4. FEMALE MICE: TUMOR PATHOLOGY (CONTINUED) LOW DOSE

ANIMAL Number Weeks on	2	27	2	Ž	ŝ	3	3	j i	3	3	3	ł	3	j	i		2	43	•	1	4	4		-	-9	TOTAL
STUDY	Å	0	0	0	?	ŝ	0	ŝ	ŝ	ġ	2	ŝ	0	ŝ	ŝ	5	5	Ž	ŝ	5	3	0	5	ŝ	5	TUMO
NTEGUMENTARY SYSTEM	Τ.															•										
SKIN Mast-Cell Tumor	1.	*	+	<u> </u>	•	•	•	•	•	<u> </u>	N		•	+	•	x	+	+	<u>.</u>	N	+	•	•	•	-1	50
SUBCUTANEOUS TISSUE Fibrosarcoma	•	٠	+	٠	٠	+	٠	+	+	+	N	+	+	٠	٠	٠	٠	•	•	N	+	+	+	+	•	50
ESPIRATORY SYSTEM	+											-													-	
LUNGS AND BRONCHI Alveolar/Bronchiolar Adenoma Alveolar/Bronchiolar Carcinoma	ŀ	•	•	×	•	+	*	•	•	•	+	•	+	•	•	•	+	٠	+	•	•	•	•	•	•	50
TRACHEA	+	٠	٠	٠	+	٠	+	+	٠	٠	A	٠	٠	٠	٠	٠	٠	+	٠	+	+	٠	٠	٠	+	49
EMATOPOIETIC SYSTEM	1								_													_			1	
BONE MARROW	++	+	•		*	+	<u>+</u>	*	+	*	<u> </u>	•	+	<u>+</u>	•	*	•	+	•	•	+	<u>+</u>	•	+	+	48
SPLEEN Malignant Lymphoma, Mixed Type	Ļ	•	+	<u>.</u>	-	*	*	+	+	•	A	+	<u>+</u>		*	+	*	+	+	*	*	+	*	*	-	49
LYMPH NODES Malig.lymphoma, lymphocytic type	-	٠	•	٠	* ×	-	٠	٠	٠	٠	۸	٠	٠	٠	٠	٠	٠	٠	-	-	٠	+	+	٠	•	45
THYMUS	-	+	+	٠	-	+	+	+	+	+	٨	+	+	•	+	-	+	-	+	+	-	•	+	+	+	38
IRCULATORY SYSTEM	+												·												-+	
HEART	++	•	+	+		+	+	+	+	+	A	+	+	+	•	+	+	+	+	+	+	+	+	+	4	49
BLOOD VESSELS Sarcoma, NOS, METASTATIC	N	N	N	N	N	N	H	H	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	H	M	50
ICESTIVE SYSTEM	1-					_										_							_			
SALIVARY GLAND	++	+	+	+	•	+	+	+	÷	*		+	+	+	. <u>+</u>	+	+	•	+	+	+	+	<u>+</u>	•	╇	49
LIVER Hepatocellular Adenoma Hepatocellular carcinoma	+	•	•	•	•	+	•	+	•	•	•	•	•	•	•	+	•	•	* .	•	•	×	•	+	+ 	50
BILE DUCT	1.	+	+	.+	*	+	+	•	. .		+	+	•	+	•	+	+_	+	+	+	+	+	+	+		50
GALLBLADDER & COMMON BILE DUCT	++	•	+	+	•	+	+	+	+	+	N	+	•	+	•	•	+	N	•	+	+	+	+	+	4	50
PANCREAS	+-	+	•	<u>.</u>	÷	+	+	<u>.</u>	÷	+	+	+	+	+	+	+	+	•	•	+	+	+	*	+	+	48
ESOPHAGUS Squamous cell papilloma	Ļ	•	•	•	•	*	•	•	•	-	A	*	+	•	+	+	+	•	+	+	*	*	*	+	-	47
STOMACH	<u></u> ∔+	+	•	+	+	+	+	+	+	+	.A.	. +.	+	<u>+</u>	. •	<u>+</u>	+	+	+	+	+	+	+	+	4	49
SMALL INTESTINE Malig.lymphoma, Histiocytic type	ļ.	+	+	•	•	•	•		+	+	+	+	+	•	•	+	+	+	+	*	+	+	+	*	+	49
LARGE INTESTINE RINARY SYSTEM	<u>+</u>	•	+	+	+	+	+	+		+	A	+	+	+	+	+	+	•	•	+	+	+	•	+	4	49
KIDNEY	1.	+	•	÷	÷	÷	+	٠	+	•	A	÷	÷	+	÷	÷	+	÷	+	+	+	+	÷	+	+	49
URINARY BLADDER	+	+	÷	+	+	+	+	+	+	÷	A	+	+	+	+	-	+	+	÷	+	+	+	+	+	+	46
NDOCRINE SYSTEM																									-	
PITUITARY	Ŀ	•	+	+	+	+	+	+	-	+	A	-	+	+	+	-	+	-	+	+	+	+	+	٠	4	38
ADRENAL	<u> -</u>	+	•	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
THYROID FOLLICULAR-CELL ADENOMA	1 *	+	٠	٠	٠	٠	+	+	+	-	A	+	٠	٠	٠	٠	+	-	+	+	+	٠	٠	* ×	+	47
PARATHYROID		-	+	+	+	-	+	-	+		A	-	-		+	+	+		+	-	+	+	-	+	+	26
PANCREATIC ISLETS	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+.	+	+	48
ISLET-CELL ADENOMA EPRODUCTIVE SYSTEM	ļ																								-	
MAMMARY GLAND ADENOCARCINOMA, NOS	м	•	+	+	•	N	+	•	•	•	N	•	•	N	N	+	+	+	•	N	+	•	+	+	٠	50
UTERUS LEIOMYOMA ENDOMETRIAL STROMAL POLYP	+	٠	٠	٠	٠	٠	٠	٠	٠	•	A	٠	٠	+	+	-	٠	•	٠	+	٠	٠	+	٠	+	47
OVARY CHORIOCARCINOMA	+	٠	٠	٠	٠	٠	٠	٠	٠	+	A	+	-	٠	٠	-	٠	* x	٠	+	÷	٠	٠	٠	+	46
USCULOSKELETAL SYSTEM	+																							-	+	
BONE Sarcoma, Nos, Invasive	N	N	N	N	N	N	N	N	N	N	N	N	N	N	м	н	N	N	N	н	N	N	N	N	N	50
ODY CAVITIES																									T	
PLEURA Sarcoma, NOS	N N	N	N	н	н	N	N	н	н	N	N	М	N	N	N	м	N	M	N	N	N	H	N	N	М	50
LL OTHER SYSTEMS	1	-			-																				+	
MULTIPLE ORGANS NOS FIBROSARCOMA, METASTATIC HEMANGIOSARCOMA Malionant lymphoma, Nos	н	N	H	N	N X	N	N	н	N	N	N	N	N	N	N	H	H	N	N	N	N	H	н	H	N	50
MALIG.LYMPHOMA, UNDIFFER-TYPE MALIG.LYMPHOMA, HISTIOCYTIC TYPE MALIGNANT LYMPHOMA, MIXED TYPE	x		x	x					x						¥						×			x	×	14

TABLE B4.

INDIVIDUAL ANIMAL TUMOR PATHOLOGY IN FEMALE MICE FED DIETS CONTAINING **C.I. SOLVENT YELLOW 14**

								03																. <u></u> .	
AN IMAL NUMBER	0	jó					0 0 7	0 0 8	0	0	0	0 1 2	0	0	0 1 5	0	01	0 1 8	01	0 2	0 2 1	0 2 2	0 2 3	024	
WEEKS ON STUDY	0		3			0	10.5	8 0 8 6	1	9	0	0	ļ	ŝ	0	0	0	e 5	8	0	01		0	8	
INTEGUMENTARY SYSTEM					1F.															_					
SUBCUTANEOUS TISSUE Sarcoma, nos Liposarcoma	ŀ	•	+	•	•	•	•	N	+	•	•	•	+	*	•	•	N	*	+	•	+	•	•	•	
RESPIRATORY SYSTEM																									
LUNGS AND BRONCHI Alvedlar/Bronchidlar Adenoma Alvedlar/Bronchidlar Carcinoma Sarcoma, Nos, Metastatic Liposarcoma, Metastatic		•	•	•	×	-	•	•	•	•	•	•	•	•	×	•	•	•	•	•	•	•	•	•	
TRACHEA	+	+	+	+	+	+	+	A	+	+	+	•	+	+	٠	+	٠	٠	+	٠	+	+	+	•	
TEMATOPOLETIC SYSTEM	Γ																								
BONE MARROW Hemangioma	ŀ	•	•	•	+		<u>+</u>	+	<u>+</u>	*	*	*	<u> </u>	<u> </u>	+	+	•	+	+	•	-	*	+	+	
SPLEEN Hemangiosarcoma Malig.lymphoma, histiocytic type	•	*	+	+	•	•	+	•	•	+	•	•	+	•	•	٠	+	•	•	•	•	•	•	+	
LYMPH NODES Liposarcoma, metastatic Malig.lymphoma, lymphocytic type .	ŀ	+	+	+	•	+	+	•	•	+	•	•	•	•	+	•	•	+	•	•	•	•	•	•	
THYMUS	+	-	÷	-	٠	٠	٠	A	٠	+	٠	٠	+	+	٠	-	+	٠	-	+	-	-	-	•	
CIRCULATORY SYSTEM																									
HEART	+	+	+	+	•	+	+	+	*	+	*	+	+	+	+	+	*	+	+	•	+	*	+	•	
DIGESTIVE SYSTEM						-			•	•	•						•	+			•		•		
SALIVARY GLAND	Ţ.	<u>,</u>	-		- <u>-</u>	+	+	•	+	+	•	+	+	•	•	•	•	• •	•	<u>.</u>	*	•	<u> </u>	<u>*</u>	-
HEPATOCELLULAR ADENOMA Hepatocellular carcinoma Malig.lymphoma, histiocytic type .	ļ.						×		×					•			×								
BILE DUCT	ŀ	•	+	_+	+	+		. t	•	+	•	+	+	<u>+</u>	+	+	+	+	<u>+</u>	+	+		+	+	_
GALLBLADDER & COMMON BILE DUCT	ŀ	+	+		•	+	+	N	٠	N	+	+	+	+	+	+	+	+	t	<u>+</u>	*	+	.	N	_
PANCREAS	+	+	+		+	+	+	<u> </u>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-
ESOPHAGUS	+	+	+	+	•	+	+	<u> </u>	+	•	*	+	+	<u>+</u>	+	•	+	.+	<u>+</u>	. <u>+</u>	+	<u>+</u>	+	<u>+</u>	
STOMACH Squamous Cell Papilloma	•	*	•	+	+	+	•		+	*	+	+	+	*	•	*	*	•	+	*	+	+	•	+	_
SMALL INTESTINE ADENOCARCINOMA, NOS	•	+	+	+	+	+	+		+	•	+	•	+	•	•	•	+	+	•	•	+	+	•	•	-
LARGE INTESTINE JRINARY SYSTEM	ŀ	•	+	•	+	+	•	•	+	•	<u>+</u>	+	<u>+</u>	÷	•	÷	<u>+</u>	•	+	•	<u>+</u>	<u>+</u>	•	+	
KIDNEY	١.			•	•			+	•	•	•	-	•	•		•	÷	•	•	•	•	÷	•	•	
URINARY BLADDER		+	+	+	+	+	+		+	+	+	+	+			+	+	+	-	•	+	+	+	-	
NDOCRINE SYSTEM				-																					-
PITUITARY Chromophobe Adenoma	•	•	•	٠	•	٠	-		+	•	*	•	+	+	•	+	•	•	•	+	+	•	•	•	
ADRENAL Pheochromocytoma	+	+	+	•	+	+	+		•	•	•	+	*	•	<u>+</u>	•	•	+	-	•	•	+	٠	+	
THYROID Follicular-Cell Adenoma	+	•	+	•	•	•	•	۸	•	•	•	•	•	•	•	ż.	•	+	•	•	•	•	٠	•	
PARATHYRDID .	-	+	-	+	-	+	+	A	-	-	+	+	+	-	-	+	+	+	-	+	-	+	+	+	-
PANCREATIC ISLETS ISLET-CELL ADENOMA	•	•	•	+	•	•	•	*	.*	٠	•	+	•	•	•	•	•	+	•	+	•	•	•	•	
EPRODUCTIVE SYSTEM														-									·		-
MAMMARY GLAND . UTERUS LETOMYOMA	+	•	•	+	<u>н</u> •	• •	•	<u>N</u>	•	<u>+</u>	• •	•	+ +	+	++	<u>+</u> •	<u>+</u>	<u>+</u>	<u>+</u>	*	+ +	++	+	<u>н</u> +	-
ENDOMETRIAL STROMAL POLYP Malig.lymphoma, Histiocytic type ovary		-		•	•	×	•	•			•			×		-				<u>-</u>				-	_
PECIAL SENSE ORGANS		•	-			_			·				•		•		•		-		•				_
EAR Sarcoma, Nos	N	N	N	N	N	H	N	H	H	H	N	N	N	N	H	N	H	N	N	N	H	N	N	N	I
USCULÓSKELETAL SYSTEM											_														
BONE Sarcoma, Nos, Invasive	N	N	H	N	N	"	H	H	H	H	H	M	H	N	N	M	H	H	H	N	N	H	N	N	1
LL OTHER SYSTEMS	N	N	N	N	N	N	N	N	N	н	N	N	M	N	N	N	н	H	H	N	N	м.	N	N	
PULTIPLE ORGANS NOS Sarcoma, NOS. Metastatic Malioliyphona, UNDIFFER-Type Malioliynphona, Lynphocytic Type Malioliynphona, Misiocytic Type Malioliynphona, Mixed Type	n	X			"	×	-			×			.4			n X	-1		×	-1		N X		×	•
MALIGNANT LYMPHOMA, MIXED TYPE										<u>^</u>		X_				^			<u> </u>					^	_

HIGH DOSE

TABLE B4. FEMALE MICE: TUMOR PATHOLOGY (CONTINUED) HIGH DOSE

ÁNIMAL NUMBER	0	0 2 7	2 8	2	0 3 0	0 3 1	0 3 2	3	3	3	0 3 6	3	31	3	4	4	4	31	4	0 4 5	4	2	-	4	5	TOTAL
WEEKS ON STUDY	0	0	8	0	0	0	0	5	0	0	į	0		0	0	5	1 0 5	9	1 0 5	0	0	9	9	1 01 5	0 7 1	TUMOR
INTEGUMENTARY SYSTEM																										
SUBCUTANEOUS TISSUE Sarcoma, nos Liposarcoma	ŀ	+	٠	+	•	+	•	٠	•	+	* X	+	+	+	+	•	+	+	•	•	+	* ×	•	•	* ×	50× 2
RESPIRATORY SYSTEM																										
LUNGS AND BRONCHI Alveolar/Bronchiolar Adenoma Alveolar/Bronchiolar Carcinoma Sarcoma, Nos. Metastatic Liposarcoma, metastatic	•	•	•	+	•	+	•	•	•	•	+ x	+	•	•	•	•	×	+	•	+	+	•	+	* ×	+ X	49 3 1
TRACHEA	•	+	+	+	+	÷	٠	•	÷	+	+	•	+	+	+	+	٠	٠	ŧ	٠	٠	+	÷	-	+	48
IEMATOPOIETIC SYSTEM																									-	
BONE MARROW Hemangioma	+	+	+	+	+	+	+	٠	•	+	+	٠	•	•	+	•	+	•	*	•	+	+	+	+	+	49
SPLEEN Hemangidsarcoma Malig.lymphoma, histiocytic type	ŀ	•	+	•	+	+	•	•	+	•	+	•	•	•	•	+	•	•	+	•	+ x	+	+	+	-	49
LYMPH HODES Liposarcoma, metastatic Malig.lymphoma, lymphocytic type .	+	•	•	+	-	-	+ x	+	٠	+	•	•	•	٠	+	•	•	٠	+	+	٠	+	+	+	*	46
THYMUS	1.	+	+	÷	+	+	+	+	+	+	+	+	-	+	-	+	+	-	-	•	+	-	-	+	-	34
CIRCULATORY SYSTEM	┝																								+	
HEART	•	٠	+	٠	+	٠	÷	+	+	٠	+	٠	÷	•	+	÷	٠	÷	÷	+	٠	•	+	÷	+	50
DIGESTIVE SYSTEM																									-	
SALIVARY GLAND	+	+	•	+	٠	+		+	+_	+	+	•	+	+	+	•	+	•	•	•	•	•	÷	÷	+	49
LIVER HEPATOCELLULAR ADENOMA HEPATOCELLULAR CARCINOMA	•	•	+	•	+ X	+	•	+	+	+	+	+	+	٠	÷	* x	•		+ X	÷	٠	+	•	+	+	50
MALIG.LYMPHOMA, HISTIOCYTIC TYPE . Bile Duct	+	•	+	•	+	+	+	•	•	+	× +	•	•	•	+	+	+	+.	•	+	+	+	+	+		50
GALLBLADDER & COMMON BILE DUCT	+	•	+	÷	+	+	÷	•	+	+	+	+	•	+	+	+	+	÷	•	+	+	+	+	+	+	50
PANCREAS	•	+	+	+	•	+	+	Ŧ	•	+	÷	+	•	+	+	+	+	+	÷	+	+	+	+	+	•	49
ESOPHAGUS	1.	+	+	+	+	+	+	+	+	+	+	•	+	+	+	•	•	•	•	+	+	+	÷	+	+	49
STOMACH Squamous cell papilloma	•	•	•	•	•	+	+	+	٠	*	•	•	+	•	+	•	+	•	+	•	•	•	+	•	+	49
SMALL INTESTINE	+	+	+	t	+	-	+	+	+	٠	÷	٠	+	+	•	+	•	•	+	٠	+	٠	٠	+	+	48
ADENOCARCINOMA, NOS Large intestine	•	•	+	<u>×</u> +	+	•	•	+	+	•	+	+	•	+	•	٠	•	•	•	+	+	+	+	٠	-	48
JRINARY SYSTEM																										
KIDHEY .	+	+	+	.+	+	+	+	+	+	•	+	•	•	+	+	+	•	•	+	+	+	+	•	•	4	_ 49
URINARY BLADDER	1	+	*	+	+	*	+	+	•	+	•	•	+	+	*	•	+	•	•	•	•	+	+	*	_	46
ENDOCRINE SYSTEM																										
PITUITARY Chromophobe Adenoma	└	+	ż	•	•	•	<u>+</u>	•	<u>.</u>	•	•	•	•	•	-	+	•	•	•	<u>+</u>	<u> </u>	<u>.</u>	<u>.</u>	-	4	46
ADRENAL PHEOCHROMOCYTOMA	+	+	+	*	*	+	+	+	+	+	*	+	+	+	+	•	+	+	+	+	+	+	+	+	+	48
THYROID FOLLICULAR-CELL ADENDMA	·	+	٠	•	•	•	+	٠	•	•	•	•	+	•	٠	+	•	•	+	•	٠	٠	٠	-	-	47
PARATHYROID	-	+	7	+	-	-	-	÷	•	-	+	٠	-	•	•	•	•	٠	-	+	-	-	-	<u> </u>	+	24
PANCREATIC IGLETS ISLET-CELL ADENOMA	×	•	•	+	•	•	+	•	•	•	•	•	•	•	•	•	•	٠	•	•	•	•	•	•	٠	49 ₁
REPRODUCTIVE SYSTEM			,		,	,	,		,																	
MAMMARY GLAND Uterus Leionyoma Endonetrial Stromal Polyp	•	•	•	•	•	*	+	+	•	•	•	•	•	•	+	•	•	<u>+</u>	+	•	•	•	•	<u>+</u>	•	<u>504</u> 49 1
MALIG.LYMPHOMA, HISTIOCYTIC TYPE . Ovary	•	•	•	•	•	+	+	+	•	•	•	•	+	•	•	•	•	•	•	+	•	•	•	•	•	48
PECIAL SENSE ORGANS	 																		-						+	
EAR SARCOMA, NDS	N	N	N	N	н	н	N	н	N	N	N	ж	N	N	H	N	N	*	N	N	N	*	N	N	M	50*
RUSCULOSKELETAL SYSTEM																									ſ	
BONE SARCOMA, NOS, INVASIVE	M	M	N		H	н 	N 	м	M	N	N	м	N	и		N	M	M	N	N	N 	N X	H	*	-	50%
MULTIPLE ORGANS HOS SARCOMA, HOS, METASTATIC Malig.Lymphoma, undiffer-type Malig.Lymphoma, Lymphocytic type Malig.Lymphoma, Mistidcytic type Malig.Lymphoma, Mistidcytic type	N	M	H	H	H	H	H	H	N X	N	N	H		N X	H X	H		H X	N	M	H	NX	N X	H	•	50 4 1 3

APPENDIX C

Summary of the Incidence of Nonneoplastic Lesions in Rats Fed Diets Containing C. I. Solvent Yellow 14

108

.

TABLE C1.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY ANIMALS NECROPSIED ANIMALS EXAMINED HISTOPATHOLOGICALLY	50 50 50	50 50 50	50 50 50 50
INTEGUMENTARY SYSTEM			
*SKIN EPIDERMAL INCLUSION CYST INFLAMMATION, FOCAL GRANULOMATOU FIBROSIS, DIFFUSE	(50) 1 (2%)	(50) 1 (2%)	(50) 1 (2%)
*SUBCUT TISSUE INFLAMMATION, FOCAL GRANULOMATOU GRANULOMA, FOREIGN BODY	(50) 1 (2%) 1 (2%)	(50)	(50)
RESPIRATORY SYSTEM			
#TRACHEA INFLAMMATION, DIFFUSE INFLAMMATION, ACUTE/CHRONIC	(49) 1 (2%)	(50) 1 (2%)	(50)
#LUNG/BRONCHUS Inflammation, acute/chronic Hyperplasia, epithelial	(50)	(50)	(50) 1 (2%) 1 (2%)
#LUNG/BRONCHIOLE Hyperplasia, nos	(50) 1 (2%)	(50) 3 (6%)	(50) 1 (2%)
#LUNG CONGESTION, NOS CONGESTION, PASSIVE EDEMA, NOS	(50)	(50) 2 (4%) 3 (6%)	(50) 1 (2%) 1 (2%)
HEMORRHAGE INFLAMMATION, INTERSTITIAL PNEUMONIA, ASPIRATION PERIVASCULAR CUFFING	1 (2%)	1 (2%) 1 (2%)	1 (2%) 3 (6%) 1 (2%)
HYPERPLASIA, ALVEOLAR EPITHELIUM	1 (2%)	3 (6%)	1 (2%)

	CONTROL	LOW DOSE	HIGH DOSE
HEMATOPOIETIC SYSTEM			
#BONE MARROW Congestion, NOS Hyperplasia, granulocytic Hyperplasia, reticulum cell Hypoplasia, erythroid	(49) 1 (2%)	(46) 1 (2%)	(58) 1 (2%) 2 (4%) 1 (2%)
#SPLEEN INFLAMMATION, FOCAL GRANULOMATOU FIBROSIS, FOCAL FIBROSIS, MULTIFOCAL FIBROSIS, DIFFUSE LYMPHOID DEPLETION HYPERPLASIA, RETICULUM CELL HYPERPLASIA, LYMPHOID HEMATOPOIESIS	(50) 1 (2%) 2 (4%) 1 (2%)	(50) 1 (2%) 3 (6%) 1 (2%)	(50) 1 (2%) 2 (4%) 3 (6%) 1 (2%) 1 (2%)
#SPLENIC RED PULP HEMATOPOIESIS	(50) 1 (2%)	(50) 5 (10%)	(50) 4 (8%)
#LYMPH NODE HEMORRHAGE INFLAMMATION, DIFFUSE INFLAMMATION, GRANULOMATOUS PLASMACYTOSIS HEMATOPOIESIS	(47) 1 (2%) 1 (2%)	(45) 1 (2%) 1 (2%)	(41) 1 (2%)
#MANDIBULAR L. NODE HEMORRHAGE INFLAMMATION, GRANULOMATOUS INFLAMMATION, FOCAL GRANULOMATOU PLASMACYTOSIS HYPERPLASIA, LYMPHOID	(47) 1 (2%)	(45) 1 (2%) 1 (2%) 2 (4%)	(41) 1 (2%) 1 (2%) 3 (7%) 1 (2%)
#CERVICAL LYMPH NODE PIGMENTATION, NOS Lymphoid depletion	(47)	(45)	(41) 1 (2%) 1 (2%)
<pre>#PANCREATIC L.NODE INFLAMMATION, FOCAL GRANULOMATOU</pre>	(47)	(45) 2 (4%)	(41)
#MESENTERIC L. NODE INFLAMMATION, GRANULOMATOUS	(47)	(45)	(41) <u>1 (2%)</u>

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

-

	CONTROL	LOW DOSE	HIGH DOSE
INFLAMMATION, FOCAL GRANULOMATOU Lymphoid depletion	1 (2%) 1 (2%)	7 (16%)	4 (10%) 1 (2%)
<pre>#RENAL LYMPH NODE INFLAMMATION, GRANULOMATOUS PIGMENTATION, NOS LYMPHOID DEPLETION</pre>	(47) 1 (2%)	(45)	(41) 1 (2%) 1 (2%)
<pre>#TRACHEAL SUBMUCOSA Hyperplasia, lymphoid</pre>	(49)	(50)	(50) 1 (2%)
#LUNG/BRONCHUS Hyperplasia, lymphoid	(50)	(50)	(50) 1 (2%)
<pre>#LUNG/BRONCHIOLE HYPERPLASIA, LYMPHOID</pre>	(50) 1 (2%)	(50)	(50)
#LUNG Hyperplasia, lymphoid	(50) 12 (24%)	(50) 28 (56%)	(50) 23 (46%)
#PEYER'S PATCH Hyperplasia, lymphoid	(47) 1 (2%)	(45)	(47)
#THYMUS Congestion, Nos Congestion, Passive Hemorrhage	(37) 1 (3%)	(34) 1 (3%) 1 (3%)	(35)
PIGMENTATION, NOS ATROPHY, DIFFUSE Lymphoid Depletion	1 (3%)	1 (3%) 1 (3%)	
CIRCULATORY SYSTEM			
*MEDIASTINUM Thrombus, Mural	(50)	(50) 1 (2%)	(50)
#LYMPH NODE Lymphangiectasis	(47)	(45)	(41) 1 (2%)
#MANDIBULAR L. NODE Lymphangiectasis	(47)	(45)	(41) 1 (2%)
#HEART MINERALIZATION	(50)	(50)	(50) 1 (2%)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

`

	CONTROL	LOW DOSE	HIGH DOSE
DEGENERATION, NOS PIGMENTATION, NOS	43 (86%)	44 (88%) 1 (2%)	41 (82%)
#LEFT ATRIUM Thrombosis, nos Thrombus, organized	(50)	(50) 1 (2%) 1 (2%)	(50)
THROMBUS, MURAL #MYOCARDIUM MINERALIZATION DEGENERATION, NOS	2 (4%) (50)	(50) 1 (2%)	1 (2%) (50) 1 (2%)
#CARDIAC VALVE FIBROSIS, MULTIFOCAL	(50) 3 (6%)	(50) 8 (16%)	(50) 11 (22%)
*BLOOD VESSEL Congestion, Nos	(50)	(50)	(50) 1 (2%)
*AORTA PERIARTERITIS	(50)	(50) 1 (2%)	(50)
*PANCREATIC ARTERY Inflammation, Chronic	(50)	(50)	(50) 1 (2%)
*MESENTERIC ARTERY Thrombosis, Nos	(50)	(50) 1 (2%)	(50)
#PANCREAS PERIARTERITIS	(50) 1 (2%)	(48) 1 (2%)	(46) 2 (4%)
#KIDNEY Arteriosclerosis, Nos	(50)	(50)	(50)
#PROSTATE PERIARTERITIS	(48) 1 (2%)	(42)	(47)
DIGESTIVE SYSTEM			
#LIVER CONGESTION, PASSIVE CONGESTION, CHRONIC PASSIVE INFLAMMATION, ACUTE FOCAL	(50) 1 (2%)	(50) 1 (2%) 2 (4%) 1 (2%)	(50)
INFLAMMATION, FOCAL GRANULOMATOU Degeneration, nos Degeneration, cystic	2 (4%) 1 (2%)	6 (12%) 1 (2%)	6 (12%) 1 (2%)
BASOPHILIC CYTO CHANGE Focal cellular change	12 (24%) <u>1 (2%)</u>	27 (54%)	20 (40%)

TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

	CONTROL	LOW DOSE	HIGH DOSE
EOSINOPHILIC CYTO CHANGE Clear-Cell Change Cytologic Degeneration	6 (12%) 1 (2%)	10 (20%)	1 (2%) 17 (34%)
ANGIECTASIS	(24)		2 (4%)
#LIVER/CENTRILOBULAR	(50)	(50)	(50)
CONGESTION, NOS Degeneration, nos			1 (2%)
NECROSIS, NOS NECROSIS, FOCAL NECROSIS, DIFFUSE	1 (2%) 5 (10%) 7 (14%)	1 (2%) 4 (8%) 2 (4%)	1 (2%)
#LIVER/HEPATOCYTES Degeneration, nos	(50)	(50)	(50) 1 (2%)
#BILE DUCT	(50)	(50)	(50) 1 (2%)
CYST, NOS Hyperplasia, Nos Hyperplasia, Focal	2 (4%) 35 (70%)	36 (72%)	1 (2%) 1 (2%) 39 (78%)
#PANCREAS DILATATION/DUCTS	(50) 1 (2%)	(48) 1 (2%)	(46)
	1 (2%)		1 (2%)
FIBROSIS, DIFFUSE Cytoplasmic vacuolization		1 (2%)	1 (2%)
*PANCREATIC ACINUS	(50)	(48)	(46)
NECROSIS, NOS Atrofhy, focal Atrophy, diffuse	15 (30%) 1 (2%)	1 (2%) 19 (40%) 2 (4%)	22 (48%) 2 (4%)
#STOMACH Mineralization Inflammation, Chronic	(50)	(50)	(49) 1 (2%) 1 (2%)
#GASTRIC MUCOSA	(50)	(50)	(49)
CYST, NOS Congestion, Nos	1 (2%)	1 (2%)	
#GASTRIC SUBMUCOSA CYST, NOS	(50) 1 (2%)	(50)	(49) 1 (2%)
#GASTRIC SEROSA MINERALIZATION	(50)	(50)	(49)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

,

· · · · · · · · · · · · · · · · · · ·	CONTROL	LOW DOSE	HIGH DOSE
#CARDIAC STOMACH Ulcer, Focal Ulcer, Acute Hyperplasia, Nos Hyperplasia, Focal Hyperplasia, Basal Cell	(50) 1 (2%)	(50) 1 (2%) 1 (2%) 1 (2%)	(49) 1 (2%) 1 (2%) 1 (2%) 1 (2%)
#GASTRIC FUNDUS ~ EMBRYONAL REST ULCER, NOS	(50) 2 (4%)	(50) 1 (2%)	(49) 1 (2%)
#JEJUNUM Inflammation, acute/chronic	(47) 1 (2%)	(45)	(47)
#ILEAL MUCOUS MEMBRAN ULCER, FOCAL	(47) 1 (2%)	(45)	(47)
#COLON NEMATODIASIS	(50)	(48) 1 (2%)	(47)
URINARY SYSTEM			
#KIDNEY NEPHROPATHY NEPHROSIS, NOS PIGMENTATION, NOS	(50) 47 (94%) 1 (2%)	(50) 46 (92%) 1 (2%) 1 (2%)	(50) 49 (98%)
#KIDNEY/CORTEX CYST, NOS MULTIPLE CYSTS	(50)	(50) 1 (2%)	(50) 1 (2%)
#KIDNEY/TUBULE CYST, NOS PIGMENTATION, NOS REGENERATION, NOS	(50) 1 (2%) 1 (2%)	(50) 1 (2%) 1 (2%)	(50) 2 (4%)
#KIDNEY/PELVIS HYPERPLASIA, EPITHELIAL	(50) 1 (2%)	(50)	(50)
ENDOCRINE SYSTEM			
#PITUITARY HEMORRHAGE	(44)	(45)	(43)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

•

	CONTROL	LOW DOSE	HIGH DOSE
HYPERPLASIA, CHROMOPHOBE-CELL ANGIECTASIS	4 (9%)	9 (20%) 1 (2%)	9 (21%)
<pre>#PITUITARY ACIDOPHIL HYPERPLASIA, NOS</pre>	(44)	(45) 1 (2%)	(43)
#ADRENAL NECROSIS, HEMORRHAGIC METAMORPHOSIS FATTY	(50) 1 (2%)	(49) 1 (2%) 1 (2%)	(50)
#ADRENAL CORTEX HEMORRHAGIC CYST METAMORPHOSIS FATTY HYPERPLASIA, NODULAR HYPERPLASIA, FOCAL	(50) 3 (6%) 2 (4%) 2 (4%)	(49) 3 (6%) 1 (2%)	(50) 1 (2%) 2 (4%) 2 (4%)
#ZONA RETICULARIS CYTOPLASMIC VACUOLIZATION	(50)	(49) 1 (2%)	(50)
#ADRENAL MEDULLA Hyperplasia, nodular Hyperplasia, nos Hyperplasia, focal	(50) 2 (4%) 1 (2%)	(49) 1 (2%) 2 (4%)	(50) 1 (2%) 1 (2%)
<pre>#THYROID FOLLICULAR CYST, NOS HEMORRHAGE HYPERPLASIA, C-CELL HYPERPLASIA, FOLLICULAR-CELL</pre>	(50) 33 (66%)	(49) 1 (2%) 30 (61%)	(50) 2 (4%) 33 (66%) 2 (4%)
#THYROID FOLLICLE Multilocular cyst Multiple cysts	(50) 1 (2%)	(49) 1 (2%)	(50)
#PARATHYROID HYPERPLASIA, NODULAR HYPERPLASIA, NOS HYPERPLASIA, FOCAL HYPERPLASIA, DIFFUSE	(38) 1 (3%) 1 (3%)	(41) 1 (2%)	(42) 1 (2%)
<pre>#PANCREATIC ISLETS Hyperplasia, Focal</pre>	(50)	(48) 3 (6%)	(46)
REPRODUCTIVE SYSTEM			
*MAMMARY GLAND DILATATION/DUCTS	(50) 12 (24%)	(50) <u>4 (8%)</u>	(50) <u>4 (8%)</u>

٠

TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

	CONTROL	LOW DOSE	HIGH DOSE
CYST, NOS HYPERPLASIA, CYSTIC	1 (2%)		1 (2%)
*MAMMARY ACINUS DILATATION, NOS Hyperplasia, focal	(50) 6 (12%)	(50) 1 (2%) 2 (4%)	(50) 3 (6%) 1 (2%)
*PREPUTIAL GLAND CYST, NOS	(50)	(50) 2 (4%)	(50)
#PROSTATE CONGESTION, NOS INFLAMMATION, FOCAL INFLAMMATION, MULTIFOCAL INFLAMMATION ACUTE AND CHRONIC INFLAMMATION, ACUTE/CHRONIC INFLAMMATION, CHRONIC HYPERPLASIA, EPITHELIAL	(48) 4 (8%) 1 (2%) 1 (2%) 1 (2%)	(42) 1 (2%) 9 (21%) 1 (2%) 1 (2%)	(47) 1 (2%) 4 (9%)
*SEMINAL VESICLE Inflammation, acute/chronic	(50)	(50) 2 (4%)	(50)
#TESTIS MINERALIZATION HEMATOMA, NOS DEGENERATION, NOS ATROPHY, NOS ATROPHY, FOCAL ATROPHY, DIFFUSE HYPERPLASIA, INTERSTITIAL CELL	(50) 1 (2%) 2 (4%) 1 (2%)	(50) 2 (4%) 4 (8%) 1 (2%) 1 (2%) 8 (16%)	(50) 1 (2%) 7 (14%) 1 (2%)
#TESTIS/TUBULE DEGENERATION, NOS ATROPHY, DIFFUSE	(50) 1 (2%)	(50) 1 (2%)	(50)
*EPIDIDYMIS MINERALIZATION	(50)	(50) 1 (2%)	(50)
ERVOUS SYSTEM	•		
#BRAIN/MENINGES Hemorrhage	(50) 1 (2%)	(50)	(50)
#CEREBRUM MINERALIZATION	(50)	(50)	(50)

.

	CONTROL	LOW DOSE	HIGH DOSE
HEMORRHAGE Atrophy, pressure	2 (4%)	1 (2%)	
#BRAIN Hydrocephalus, Nos Necrosis, Hemorrhagic	(50) 1 (2%)	(50) 1 (2%)	(50) 1 (2%) 1 (2%)
ATROPHY, PRESSURE #CEREBELLUM Hemorrhage	(50) 2 (4%)	1 (2%) (50)	1 (2%) (50)
*CEREBELLAR WHITE MAT Cytoplasmic vacuolization	(50)	(50) 1 (2%)	(50)
*SPINAL CORD INFLAMMATION, NOS DEGENERATION, WALLERIAN	(50)	(50) 1 (2%) 1 (2%)	(50)
PECIAL SENSE ORGANS			
*EYE/RETINA Degeneration, Nos	(50)	(50)	(50) 1 (2%)
*EYE/CRYSTALLINE LENS MINERALIZATION	(50)	(50)	(50) 1 (2%)
USCULOSKELETAL SYSTEM			
*RIB OSTEOPOROSIS	(50)	1 (2%)	(50)
ODY CAVITIES			
*ABDOMINAL CAVITY Inflammation, focal granulomatou	(50)	(50) 1 (2%)	(50)
*PLEURA Inflammation, Chronic	(50) 1 (2%)	(50)	(50)
<pre>*MESENTERY STEATITIS INFLAMMATION, GRANULOMATOUS</pre>	(50) 1 (2%)	(50)	(50) 3 (6%)

TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)	

-

•

	CONTROL	LOW DOSE	HIGH DOSE
INFLAMMATION, FOCAL GRANULOMATOU NECROSIS, FAT	1 (2%)	3 (6%)	4 (8%) 1 (2%)
ALL OTHER SYSTEMS			
CRANIOBUCCAL POUCH EMBRYONAL REST		1	1
SPECIAL MORPHOLOGY SUMMARY			
NONE			
# NUMBER OF ANIMALS WITH TISSUE EXAMIN * NUMBER OF ANIMALS NECROPSIED	ED MICROSCOPIC	ALLY	

TABLE C2.

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY ANIMALS NECROPSIED ANIMALS EXAMINED HISTOPATHOLOGICALLY	50 50 50	49 49 49	50 49 48
NTEGUMENTARY SYSTEM			
*SKIN ACANTHOSIS	(50)	(49) 1 (2%)	(49)
*SUBCUT TISSUE	(50)	(49)	(49)
EDEMA, NOS Inflammation, Necro gran	1 (2%)		1 (2%)
ESPIRATORY SYSTEM			
#TRACHEA DILATATION/DUCTS	(48)	(49)	(48) 1 (2%)
#LUNG/BRONCHIOLE Inflammation, chronic focal	(50)	(49)	(48) 1 (2%)
HYPERPLASIA, NOS	1 (2%)	1 (2%)	1 (24)
#LUNG CONGESTION, NOS	(50) 1 (2%)	(49)	(48)
EDEMA, NOS	1 (2%)		2 (4%)
INFLAMMATION, INTERSTITIAL PNEUMONIA INTERSTITIAL CHRONIC	1 (2%)	2 (4%)	2 (4%) 1 (2%)
INFLAMMATION, FOCAL GRANULOMATOU Perivascular cuffing	1 (2%)		1 (2%)
HEMOSIDEROSIS Hyperplasia, Alveolar epithelium	1 (2%)	1 (2*)	
nirekriasia, alveolak eriinelion		1 (2%)	
EMATOPOIETIC SYSTEM			
#BONE MARROW Hypoplasia, nos Depletion	(47)	(49) 2 (4%)	(46) 1 (2%) 1 (2%)

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

	CONTROL	LOW DOSE	HIGH DOSE
HYPERPLASIA, DIFFUSE		1 (2%)	
HYPERPLASIA, GRANULOCYTIC	1 (2%)	4 (8%)	
HYPERPLASIA, RETICULUM CELL	4 (9%)	4 (8%)	6 (13%)
#SPLEEN	(50)	(49)	(48)
CONGESTION, NOS			1 (2%)
FIBROSIS, FOCAL		1 (2%)	2 (4%)
FIBROSIS, DIFFUSE			1 (2%)
PIGMENTATION, NOS			1 (2%)
ATROPHY, FOCAL	1 (24)	1 (2%)	1 (2))
LYMPHOID DEPLETION Hyperplasia, lymphoid	1 (2%)	1 (2%)	1 (2%)
HTEERELASIA, LINEHUID		1 (24)	
#SPLENIC RED PULP	(50)	(49)	(48)
PIGMENTATION, NOS		3 (6%)	2 (4%)
HEMATOPOIESIS	1 (2%)	2 (4%)	2 (4%)
#LYMPH NODE	(49)	(46)	(46)
HEMORRHAGE	1 (2%)		
INFLAMMATION, FOCAL GRANULOMATOU	4 (8%)	2 (4%)	8 (17%)
#MANDIBULAR L. NODE	(49)	(46)	(46)
INFLAMMATION, DIFFUSE			1 (2%)
INFLAMMATION, FOCAL GRANULOMATOU		1 (2%)	1 (2%)
PLASMACYTOSIS	2 (4%)	1 (2%)	1 (2%)
#PANCREATIC L.NODE	(49)	(46)	(46)
INFLAMMATION, FOCAL GRANULOMATOU		1 (2%)	
HEMATOPOIESIS	1 (2%)		
#MESENTERIC L. NODE	(49)	(46)	(46)
INFLAMMATION, FOCAL GRANULOMATOU	1 (2%)	2 (4%)	2 (4%)
#LUNG/BRONCHUS	(50)	(49)	(48)
HYPERPLASIA, LYMPHOID			1 (2%)
#LUNG	(50)	(49)	(48)
HYPERPLASIA, LYMPHOID	25 (50%)	36 (73%)	35 (73%)
ADODTAL TRACT	(
#PORTAL TRACT Hyperplasia, lymphoid	(50)	(49)	(48)
#KIDNEY	(50)	(49)	(48)
HYPERPLASIA, LYMPHOID	1 (2%)		
#KIDNEY/PELVIS	(50)	(49)	(48)
HEMATOPOIESIS		1 (2%)	

TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

	CONTROL	LOW DOSE	HIGH DOSE
CIRCULATORY SYSTEM			
#HEART Degeneration, Nos	(50) 43 (86%)	(49) 46 (94%)	(48) 44 (92%)
#HEART/ATRIUM Thrombosis, NOS Thrombus, organized	(50)	(49)	(48) 2 (4%) 1 (2%)
#LEFT ATRIUM Thrombosis, Nos Thrombus, Mural	(50) 1 (2%)	(49) 1 (2%) 1 (2%)	(48)
<pre>#RIGHT VENTRICLE FIBROSIS, DIFFUSE</pre>		(49)	(48) 1 (2%)
#MYDCARDIUM Fibrosis, focal	(50) 1 (2%)	(49)	(48)
INFLAMMATION, ACUTE/CHRONIC Inflammation, Chronic Inflammation, Chronic Focal	1 (2%)	(49) 2 (4%)	6 (13%)
FIBROSIS, MULTIFOCAL *PERIAORTIC TISSUE INFLAMMATION, FOCAL GRANULOMATOU	10 (20%) (50)	17 (35%) (49) 1 (2%)	18 (38%) (49)
DIGESTIVE SYSTEM			
#SALIVARY GLAND Atrophy, focal	(50)	(49) 2 (4%)	(48) 1 (2%)
CONGESTION, CHRONIC PASSIVE INFLAMMATION, CHRONIC DIFFUSE		(49)	(48) 1 (2%) 1 (2%)
INFLAMMATION, FOCAL GRANULOMATOU Degeneration, cystic Metamorphosis fatty		1 (2%)	
METAMORPHOSIS FATTY Cytoplasmic vacuolization Basophilic cyto change Focal cellular change	1 (2%) 31 (62%)	1 (2%) 45 (92%) 1 (2%)	2 (4%) 33 (69%) 1 (2%)

	CONTROL	LOW DOSE	HIGH DOSE
CLEAR-CELL CHANGE Angiectasis		9 (18%) 1 (2%)	11 (23%)
#PORTAL TRACT Lymphocytic inflammatory infiltr fibrosis	(50) 1 (2%) 2 (4%)	(49)	(48)
#LIVER/CENTRILOBULAR CONGESTION, NOS	(50)	(49) 1 (2%)	(48)
CONGESTION, ACUTE NECROSIS, FOCAL NECROSIS, DIFFUSE Cytoplasmic Vacuolization	1 (2%) 1 (2%) 2 (4%) 1 (2%)	1 (2%)	1 (2%)
#LIVER/HEPATOCYTES Necrosis, focal	(50) 2 (4%)	(49)	(48)
#BILE DUCT	(50)	(49)	(48)
FIBROSIS, MULTIFOCAL Hyperplasia, focal	23 (46%)	1 (2%) 37 (76%)	38 (79%)
#PANCREAS Dilatation/ducts	(49)	(49)	(48)
INFLAMMATION, ACUTE/CHRONIC Inflammation, Chronic Diffuse	1 (2%)	1 (2%)	
#PANCREATIC ACINUS	(49)	(49)	(48)
ATROPHY, NOS Atrophy, focal Atrophy, diffuse	3 (6%) 1 (2%)	20 (41%) 2 (4%)	1 (2%) 21 (44%) 3 (6%)
#CARDIAC STOMACH Ulcer, Nos Hyperplasia, Nos	(50)	(49)	(47) 1 (2%) 1 (2%)
#GASTRIC FUNDUS Hyperplasia, focal	(50)	(49)	(47) 1 (2%)
#COLON NEMATODIASIS	(49)	(49)	(48) 1 (2%)
URINARY SYSTEM			
#KIDNEY LYMPHOCYTIC INFLAMMATORY INFILTR	(50)	(49)	(48)

.

TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

.

	CONTROL	LOW DOSE	HIGH DOSE
NEPHROPATHY	11 (22%)	16 (33%)	25 (52%)
INFARCT, ACUTE Pigmentation, nos	t (2%) t (2%)		1 (2%)
#KIDNEY/CORTEX GLOMERULOSCLEROSIS, NOS	(50.)	(49) 1 (2%)	(48)
INFARCT, FOCAL	1 (2%)	((24)	1 (2%)
#KIDNEY/TUBULE DILATATION, NOS	(50) 7 (14%)	(49) 2 (4%)	(48) 1 (2%)
CYST, NOS PIGMENTATION, NOS	1 (2%)	1 (2%)	1 (2/4)
REGENERATION, NOS	7 (14%)	3 (6%)	7 (15%)
#KIDNEY/PELVIS MINERALIZATION	(50) 2 (4%)	(49)	(48)
#URINARY BLADDER HYPERPLASIA, EPITHELIAL HYPERPLASIA, DIFFUSE METAPLASIA, SQUAMOUS	(47)	(46)	(47) 1 (2%) 1 (2%) 1 (2%)
#U. BLADDER/MUCOSA DEGENERATION, HYDROPIC	(47) 1 (2%)	(46)	(47)
NDOCRINE SYSTEM			
#PITUITARY	(44)	(45)	(46)
CYST, NOS Hyperplasia, NOS	1 (2%)	2 (4%) 2 (4%)	1 (2%)
HYPERPLASIA, CHROMOPHOBE-CELL	3 (7%)	6 (13%)	7 (15%)
#ADRENAL METAMORPHOSIS FATTY	(49)	(48)	(48) 1 (2%)
HYPERPLASIA, NODULAR Angiectasis	1 (2%)	1 (2%)	
#ADRENAL CORTEX CYST, NOS	(49)	(48) 2 (4%)	(48) 2 (4%)
CONGESTION, PASSIVE HEMORRHAGIC CYST		2 (4%)	1 (2%)
DEGENERATION, NOS METAMORPHOSIS FATTY	5 (10%)	1 (2%) 8 (17%)	6 (13%)
PIGMENTATION, NOS	1 (2%)	0 (17%)	0 (13%)

	CONTROL	LOW DOSE	HIGH DOSE
FOCAL CELLULAR CHANGE ATROPHY, NOS Hyperplasia, Nodular Hyperplasia, Nos	2 (4%) 1 (2%) 4 (8%)	4 (8%) 1 (2%)	1 (2%)
HYPĒRPLAŠIA, FOCAL Angiectasis		2 (4%)	2 (4%) 4 (8%)
#ZONA GLOMERULOSA Inflammation, chronic diffuse	(49)	(48)	(48) 1 (2%)
<pre>#THYROID HYPERPLASIA, C-CELL</pre>	(50) 41 (82%)	(49) 40 (82%)	(48) 41 (85%)
#THYROID FOLLICLE Multilocular cyst Multiple cysts	(50)	(49)	(48) 1 (2%) 1 (2%)
<pre>#PARATHYROID CYTOPLASMIC VACUOLIZATION Hyperplasia, focal</pre>	(40)	(38)	(35) 1 (3%) 1 (3%)
#PANCREATIC ISLETS Hyperplasia, focal	(49)	(45) 1 (2%)	(48)
REPRODUCTIVE SYSTEM			
*MAMMARY GLAND DILATATION, NOS DILATATION/DUCTS CYST, NOS Hyperplasia, NOS Hyperplasia, Cystic	(50) 1 (2%) 20 (40%) 1 (2%) 6 (12%)	(49) 18 (37%) 1 (2%)	(49) 20 (41%)
*MAMMARY ACINUS Dilatation, Nos Hyperplasia, Nos Hyperplasia, Focal	(50) 18 (36%) 1 (2%)	(49) 22 (45%) 1 (2%) 4 (8%)	(49) 19 (39%) 3 (6%)
*CLITORAL GLAND CYST, NOS	(50) 1 (2%)	(49)	(49)
#UTERUS Embryonal Rest Dilatation, Nos	(49)	(47)	(48) 1 (2%) <u>4 (8%)</u>

	CONTROL	LOW DOSE	HIGH DOSI
INFLAMMATION, FOCAL GRANULOMATOU			1 (2%)
#CERVIX UTERI FIBROSIS FIBROSIS, DIFFUSE	(49)	(47) 1 (2%)	(48) 1 (2%)
#UTERUS/ENDOMETRIUM Hyperplasia, cystic Hyperplasia, stromal	(49) 1 (2%)	(47)	(48) 2 (4%) 1 (2%)
<pre>#ENDOMETRIAL GLAND DILATATION, NOS HYPERPLASIA, DIFFUSE</pre>	(49) 1 (2%) 1 (2%)	(47)	(48)
HYPERPLASIA, CYSTIC Hyperplasia, adenomatous	6 (12%)	14 (30%) 1 (2%)	6 (13%)
#OVARY CYST, NOS	(49) 1 (2%)	(47) 1 (2%)	(48)
IERVOUS SYSTEM			
*CEREBRAL VENTRICLE Hydrocephalus, Nos	(50) 1 (2%)	(49)	(48)
#CEREBRUM Hemorrhage Infarct, Nos	(50) 1 (2%) 1 (2%)	(49)	(48)
ATROPHY, PRESSURE	4 (8%)	4 (8%)	4 (8%)
#BRAIN Hemorrhage Atrophy, pressure	(50) 1 (2%) 4 (8%)	(49)	(48)
PECIAL SENSE ORGANS			
*EYE/RETINA Degeneration, nos	(50) 2 (4%)	(49) 1 (2%)	(49)
*EYE/CRYSTALLINE LENS MINERALIZATION Degeneration, Nos	(50) 1 (2%)	(49) 1 (2%)	(49)

.

NONE

	CONTROL	LOW DOSE	HIGH DOSE
BODY CAVITIES			
*MESENTERY Inflammation, focal granulomatou	(50) 1 (2%)	(49)	(49)
ALL OTHER SYSTEMS			
ADIPOSE TISSUE Inflammation, focal granulomatou	1		
SPECIAL MORPHOLOGY SUMMARY			
ACCIDENTAL DEATH Auto/Necropsy/No histo			1 1
NUMBER OF ANIMALS WITH TISSUE EXAMINE NUMBER OF ANIMALS NECROPSIED	NED MICROSCOPI	CALLY	

APPENDIX D

.

'Summary of the Incidence of Nonneoplastic Lesions in Mice Fed Diets Containing C. I. Solvent Yellow 14

128

a

.

TABLE D1.

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY ANIMALS MISSING	50 1	50	50
ANIMALS NECROPSIED ANIMALS EXAMINED HISTOPATHOLOGICALLY	49	50 50	50 50
INTEGUMENTARY SYSTEM			
*SKIN ULCER, ACUTE FIBROSIS, FOCAL	(49) 1 (2%) 2 (4%)	(50)	(50)
METAPLASIA, OSSEOUS		2 (4%)	
	(49)	(50) 1 (2%)	(50)
RESPIRATORY SYSTEM			
#LUNG/BRONCHIOLE Hyperplasia, nos Hyperplasia, epithelial	(49) 7 (14%)	(50) 2 (4%) 1 (2%)	(50) 3 (6%) 1 (2%)
#LUNG Edema, Nos Hemorrhage, Chronic	(49)	(50) 1 (2%) 1 (2%)	(50)
LYMPHOCYTIC INFLAMMATORY INFILTR Inflammation, interstitial		1 (2%)	1 (2%)
INFLAMMATION ACUTE AND CHRONIC PNEUMONIA INTERSTITIAL CHRONIC	1 (2%) 9 (18%)	3 (6%)	14 (28%)
INFLAMMATION, CHRONIC FOCAL HYPERPLASIA, ALVEOLAR EPITHELIUM HISTIOCYTOSIS	7 (14%)	1 (2%) 6 (12%) 3 (6%)	3 (6%) 2 (4%)
HEMATOPOIETIC SYSTEM			
*MULTIPLE ORGANS PLASMACYTOSIS	(49)	(50)	(50)
HYPERPLASIA, LYMPHOID		1 (24)	1 (2%)
#BONE MARROW Hyperplasia, reticulum cell	(47)	(48)	(49)

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

	CONTROL	LOW DOSE	HIGH DOSE
#SPLEEN AMYLOIDOSIS LYMPHOID DEPLETION ANGIECTASIS HYPERPLASIA, HEMATOPOIETIC HYPERPLASIA, RETICULUM CELL HYPERPLASIA, LYMPHOID	(49) 1 (2%)	(50) 1 (2%) 1 (2%) 1 (2%)	(50) 1 (2%) 1 (2%) 1 (2%)
	(49)	(50)	(50)
#MANDIBULAR L. NODE INFLAMMATION, ACUTE DIFFUSE Lymphoid depletion Hyperplasia, reticulum cell Hyperplasia, lymphoid	(41) 1 (2%) 1 (2%)	(46) 1 (2%) 1 (2%) 1 (2%)	(43)
#PANCREATIC L.NODE Hemorrhage Hyperplasia, lymphoid	(41) 1 (2%)	(46)	(43) 1 (2%) 1 (2%)
#MESENTERIC L. NODE DILATATION, NOS EDEMA, NOS HEMORRHAGE INFLAMMATION, ACUTE DIFFUSE INFLAMMATION ACUTE AND CHRONIC INFLAMMATION, GRANULOMATOUS INFLAMMATION, PYOGRANULOMATOUS HYPERPLASIA, RETICULUM CELL HYPERPLASIA, LYMPHOID		(46) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	(43) 1 (2%) 2 (5%) 1 (2%)
#LIVER/CENTRILOBULAR ERYTHROPHAGOCYTOSIS	(49)	(50) 1 (2%)	(50)
#PEYER'S PATCH Hyperplasia, lymphoid	(48)	(49)	(45) 1 (2%)
#KIDNEY Hyperplasia, lymphoid	(48)	(50) 1 (2%)	(50)
#U.BLADDËR/SUBMUCOSA Hyperplasia, lymphoid	(49)	(46)	(49)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

74

	CONTROL	LOW DOSE	HIGH DOSE
#THYMUS Lymphoid depletion	(33) 1 (3%)	(31)	(27)
CIRCULATORY SYSTEM			
#LUNG Thrombosis, Nos	(49)	(50) 2 (4%)	(50)
#HEART Thrombosis, Nos	(49)	(50)	(49) 1 (2%)
#LEFT ATRIUM Thrombosis, Nos	(49)	(50) 1 (2%)	(49)
#MYOCARDIUM Inflammation, chronic focal	(49)	(50) 1 (2%)	(49)
*CORONARY ARTERY Inflammation acute and chronic Inflammation, chronic focal	(49)	(50) 1 (2%)	(50) 1 (2%)
*PULMONARY ARTERY Inflammation, chronic focal	(49)	(50) 1 (2%)	(50)
#HEPATIC SINUSOID Congestion, Nos	(49)	(50)	(50) 1 (2%)
#PANCREAS PERIARTERITIS	(47)	(50)	(49) 1 (2%)
*MESENTERY Thrombosis, Nos	(49)	(50) 1 (2%)	(50)
#URINARY BLADDER PERIARTERITIS	(49)	(46)	(49) 1 (2%)
DIGESTIVE SYSTEM			
#SALIVARY GLAND Inflammation, focal granulomatou	(48) 1 (2%)	(48)	(49)
#LIVER MULTILOCULAR CYST	(49)	(50)	(50)

TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

-

	CONTROL	LOW DOSE	
INFLAMMATION ACUTE AND CHRONIC GRANULOMA, NOS INFLAMMATION, NECRO GRAN NECROSIS, COAGULATIVE AMYLOIDOSIS FOCAL CELLULAR CHANGE CLEAR-CELL CHANGE	2 (4%) 1 (2%)	3 (6%) 1 (2%)	1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)
#LIVER/HEPATOCYTES DEGENERATION, NOS NECROSIS, NOS NECROSIS, FOCAL REGENERATION, NOS	(49) 1 (2%) 2 (4%) 1 (2%)	(50) 1 (2%) 3 (6%)	(50) 3 (6%)
#BILE DUCT CYST, NOS HYPERPLASIA, NOS	(49) 1 (2%)	(50)	(50) 1 (2%)
#PANCREATIC ACINUS Atrophy, focal	(47) 3 (6%)	(50) 1 (2%)	(49) 1 (2%)
#STOMACH Cyst, Nos Inflammation Acute and Chronic Hyperplasia, epithelial	(47) 1 (2%) 1 (2%) 1 (2%)	(48)	(49)
#CARDIAC STOMACH Ulcer, focal	(47)	(48)	(49) 1 (2%)
#PEYER'S PATCH Inflammation, focal granulomatou	(48)	(49) 1 (2%)	(45)
#COLON NEMATODIASIS	(45)	(48) 2 (4%)	(47) 3 (6%)
URINARY SYSTEM			
#KIDNEY LYMPHOCYTIC INFLAMMATORY INFILTR PYELONEPHRITIS, ACUTE GLOMERULONEPHRITIS, SUBACUTE INFLAMMATION, CHRONIC FOCAL NEPHROPATHY	1 (2%) 1 (2%)	(50) 1 (2%) 1 (2%) 1 (2%)	(50) 1 (2%)
	1 (2%)	1 (2%)	

TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED) <u>_____</u>

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

.

	CONTROL	LOW DOSE	HIGH DOSE
HYPERPLASIA, TUBULAR CELL METAPLASIA, OSSEOUS	1 (2%) 2 (4%)		
#KIDNEY/CORTEX CYST, NOS INFLAMMATION, CHRONIC FOCAL NECROSIS, FOCAL	(48)	(50) 2 (4%) 1 (2%)	(50) 1 (2%)
#KIDNEY/TUBULE DILATATION, NOS DEGENERATION, NOS REGENERATION, NOS	(48) 3 (6%)	(50) 3 (6%)	(50) 1 (2%) 2 (4%) 3 (6%)
*PERIURETERAL TISSUE LYMPHOCYTIC INFLAMMATORY INFILTR	(49)	(50) 1 (2%)	(50)
#URINARY BLADDER NECROSIS, FOCAL	(49) 1 (2%)	(46)	(49)
#U.BLADDER/SUBMUCOSA INFLAMMATION, ACUTE/CHRONIC	(49) 1 (2%)	(46)	(49)
*URETHRA Obstruction, Nos	(49) 1 (2%)	(50)	(50)
*PROSTATIC URETHRA INFLAMMATION, ACUTE DIFFUSE INFLAMMATION, ACUTE SUPPURATIVE	(49) 1 (2%)	(50) 1 (2%)	(50)
ENDOCRINE SYSTEM			
#ADRENAL FOCAL CELLULAR CHANGE	(48)	(50)	(49) 1 (2%)
#ADRENAŁ CORTEX Focal cellular change	(48)	(50)	(49) 6 (12%)
#ZONA FASCICULATA Focal cellular change	(48) 2 (4%)	(50)	(49) 1 (2%)
#THYROID THYROGLOSSAL DUCT CYST CYST, NOS MULTILOCULAR CYST	(49) 2 (4%)	(48)	(50) 1 (2%) <u>1 (2%)</u>

TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED) _____

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
HYPERPLASIA, FOLLICULAR-CELL			2 (4%)
HYPERPLASTA, NOS	(47)	(50)	(49) 1 (2%)
REPRODUCTIVE SYSTEM			
*PENIS Obstruction, Nos	(49) 1 (2%)	(50)	(50)
<pre>#PROSTATIC GLAND ECTOPIA</pre>	(48)	(47)	(48) 1 (2%)
#TESTIS MINERALIZATION FIBROSIS ATROPHY, NOS	(48) 1 (2%) 1 (2%) 1 (2%)	(50)	(49)
#TESTIS/TUBULE MINERALIZATION ATROPHY, DIFFUSE	(48) 3 (6%)	(50) 1 (2%)	(49) 1 (2%)
*EPIDIDYMIS INFLAMMATION, CHRONIC FOCAL INFLAMMATION, FOCAL GRANULOMATOU	(49) 2 (4%)	(50)	(50) 2 (4%)
NERVOUS SYSTEM			
#LATERAL VENTRICLE Hydrocephalus, nos	(49) 1 (2%)	(50)	(50)
#HYPOTHALAMUS ATROPHY, PRESSURE		(50)	(50) 1 (2%)
SPECIAL SENSE ORGANS NONE			
MUSCULOSKELETAL SYSTEM			

TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED) _____

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

) (50) 1 (2%)) (50) 1 (2%)) (50) 1 (2%)	(50)
) (50)) (50)	(50)
) (50)	(50)
) (50) (2%)	(50)
7	5
	1
	(2%)

TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

TABLE D2.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE FED DIETS CONTAINING C.I. SOLVENT YELLOW 14

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY ANIMALS NECROPSIED ANIMALS EXAMINED HISTOPATHOLOGICALLY	50 50 50	50 50 50	50 50 50 50
INTEGUMENTARY SYSTEM			
FIRROSIS, DIFFUSE	(50)	(50) 1 (2%)	(50)
RESPIRATORY SYSTEM			
#LUNG Edema, NOS Lymphocytic inflammatory infiltr	(50) 1 (2%)	1 (2%) 1 (2%)	(49)
PNEUMONIA INTERSTITIAL CHRONIC PERIVASCULAR CUFFING Hyperplasia, alveolar epithelium	((2%)	7 (14%) 7 (14%)	
HEMATOPOIETIC SYSTEM			
*MULTIPLE ORGANS Hyperplasia, lymphoid	(50) 1 (2%)	(50)	(50)
*SKIN Mastocytosis	(50) 1 (2%)	(50)	(50)
#BONE MARROW Necrosis, focal	(47) 1 (2%)	(48)	(49)
#SPLEEN Inflammation, acute focal	(50)	(49)	(49) 1 (2%)
ANGIECTASIS HYPERPLASIA, RETICULUM CELL	1 (2%)		1 (2%)
HYPERPLASIA, LYMPHOID HEMATOPOIESIS	2 (4%) 1 (2%)	3 (6%)	1 (2%)
#MANDIBULAR L. NODE Hyperplasia, lymphoid	(45)	(45)	(46)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

- ,

	CONTROL	LOW DOSE	HIGH DOSE
#MEDIASTINAL L.NODE Inflammation, granulomatous	(45) 1 (2%)	(45)	(46)
#MESENTERIC L. NODE Plasmacytosis	(45)	(45)	(46) 1 (2%)
<pre>#PEYER'S PATCH HYPERPLASIA, LYMPHOID</pre>	(48) 4 (8%)	(49)	(48)
<pre>#THYMIC MEDULLA HYPERPLASIA, EPITHELIAL</pre>	(36) 1 (3%)	(38) 1 (3%)	(34)
IRCULATORY SYSTEM			
*MULTIPLE ORGANS PERIARTERITIS	(50) 1 (2%)	(50)	(50) 1 (2%)
#RENAL LYMPH NODE Lymphangiectasis	(45) 1 (2%)	(45)	(46)
#HEART MINERALIZATION THROMBOSIS, NOS	(50) 1 (2%)	(49)	(50) 1 (2%)
#RIGHT ATRIUM Thrombosis, Nos	(50)	(49) 1 (2%)	(50)
#RIGHT VENTRICLE Perivasculitis	(50)	(49) 1 (2%)	(50)
#MYOCARDIUM Inflammation, interstitial Inflammation, chronic focal	(50) 1 (2%) 1 (2%)	(49) 2 (4%)	(50)
*ARTERY Inflammation, Chronic Focal Metaplasia, Osseous	(50)	(50) 1 (2%) 1 (2%)	(50)
*SPLENIC ARTERY NECROSIS, FIBRINOID	(50) 1 (2%)	(50)	(50)
DIGESTIVE SYSTEM			
#LIVER INFLAMMATION ACUTE AND CHRONIC	(50)	(50)	(50) 1 (2%)

TABLE D2. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

.

137

	CONTROL	LOW DOSE	HIGH DOSE
INFLAMMATION, FOCAL GRANULOMATOU			1 (2%)
PERIVASCULAR CUFFING NECROSIS, FOCAL NECROSIS, COAGULATIVE NECROSIS, ISCHEMIC	1 (2%) 2 (4%) 1 (2%) 1 (2%)		1 (2%)
METAMORPHOSIS FATTY BASOPHILIC CYTO CHANGE		1 (2%)	1 (2%)
#LIVER/CENTRILOBULAR NECROSIS, FOCAL	(50) 1 (2%)	(50)	(50)
#LIVER/PERIPORTAL Inflammation, focal granulomatou	(50) 1 (2%)	(50)	(50)
#LIVER/HEPATOCYTES NECROSIS, FOCAL	(50) 2 (4%)	(50)	(50)
#PANCREAS DILATATION/DUCTS CYSTIC DUCTS	(47) 1 (2%)	(48) 1 (2%)	(49)
<pre>#PANCREATIC ACINUS ATROPHY, DIFFUSE</pre>	(47) 1 (2%)	(48)	(49)
#CARDIAC STOMACH Inflammation acute and chronic Hyperplasia, epithelial	(49)	(49)	(49) 1 (2%) 1 (2%)
#COLON NEMATODIÁSIS	(47) 4 (9%)	(49) 2 (4%)	(48) 2 (4%)
URINARY SYSTEM			
HYDRONEPHROSIS		(49)	(49) 1 (2%)
GLOMERULONEPHRITIS, SUBACUTE INFLAMMATION, CHRONIC DIFFUSE NEPHROSIS, NOS GLOMERULOSCLEROSIS, NOS	1 (2%)	1 (2%)	1 (2%) 1 (2%)
INFARCT, FOCAL Metaplasia, osseous	2 (4%)		1 (2%)
#KIDNEY/CORTEX MULTIPLE CYSTS	(50)	(49)	(49)

.

TABLE D2. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
LYMPHOCYTIC INFLAMMATORY INFILTR Degeneration, Nos		1 (2%)	1 (2%)
#KIDNEY/TUBULE Degeneration, nos Regeneration, nos	(50) 1 (2%)	(49) 1 (2%)	(49) 1 (2%)
#U.BLADDER/SUBMUCOSA Inflammation, acute focal	(46)	(46)	(46) 1 (2%)
ENDOCRINE SYSTEM			
<pre>#PITUITARY HYPERPLASIA, CHROMOPHOBE-CELL</pre>	(43) 1 (2%)	(38) 3 (8%)	(46) 1 (2%)
#ANTERIOR PITUITARY Cyst, Nos	(43)	(38)	(46) 1 (2%)
<pre>#THYROID COLLOID CYST INFLAMMATION, ACUTE FOCAL GRANULOMA, NOS HYPERPLASIA, FOLLICULAR-CELL</pre>	(49) 1 (2%) 1 (2%)	(47) 1 (2%)	(47) 1 (2%)
#PARATHYROID Hyperplasia, Nos	(30) 6 (20%)	(26) 2 (8%)	(24) 3 (13%)
#PANCREATIC ISLETS Hyperplasia, focal	(47)	(48) 1 (2%)	(49) 2 (4%)
REPRODUCTIVE SYSTEM			
#UTERUS CYST, NOS	(49)	(47)	(49) 1 (2%)
#UTERUS/ENDOMETRIUM Inflammation, acute diffuse	(49)	(47)	(49) 1 (2%)
#ENDOMETRIAL GLAND CYST, NOS MULTIPLE CYSTS INFLAMMATION ACUTE AND CHRONIC HYPERPLASIA, CYSTIC	(49) 1 (2%) 5 (10%) 30 (61%)	(47) 3 (6%) 1 (2%) 35 (74%)	(49) 5 (10%) 31 (63%)

TABLE D2, FEMALE MICE. NONNEOPLASTIC LESIONS (CONTINUED)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
#OVARY	(46)	(46) 2 (4%)	(48)
CYST, NOS Follicular cyst, Nos Multiple cysts	9 (20%)	2 (4%) 4 (9%)	4 (8%) 3 (6%) 1 (2%)
PAROVARIAN CYST Hemorrhagic Cyst Hyperplasia, epithelial	4 (9%)	1 (2%) 6 (13%)	3 (64)
HYPERPLASIA, NOS	(46)	(46)	(48) 1 (2%)
NERVOUS SYSTEM			
#BRAIN	(49)	(49)	(50) 1 (2%)
NECROSIS, FOCAL	1 (2%)		1 (2%)
#HYPOTHALAMUS ATROPHY, PRESSURE	(49) 1 (2%)	(49)	(50)
SPECIAL SENSE ORGANS			
NONE		*	
MUSCULOSKELETAL SYSTEM			
NONE			
BODY CAVITIES			
*MEDIASTINUM Lymphocytic inflammatory infiltr	(50) 1 (2%)	(50)	(50)
*PERITONEUM	(50)	(50) 1 (2%)	(50)
INFLAMMATION, ACUTE FIBRINOUS Inflammation, chronic focal Inflammation, focal granulomatou	1 (2%) 1 (2%)		
*MESENTERY GRANULOMA, FOREIGN BODY	(50)	(50)	(50)

TABLE D2. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED) _____

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED

	CONTROL	LOW DOSE	HIGH DOSE
ALL OTHER SYSTEMS			
*MULTIPLE ORGANS Lymphocytic inflammatory infiltr	(50)	(50)	(50) 1 (2%)
SITE UNKNOWN Abscess, Chronic			1
SPECIAL MORPHOLOGY SUMMARY			
AUTO/NECROPSY/HISTO PERF		1	1
# NUMBER OF ANIMALS WITH TISSUE EXAMIN NUMBER OF ANIMALS NECROPSIED	NED MICROSCOPI	CALLY	

TABLE D2. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

.

•

٠

142

.

•

APPENDIX E

Analysis of C. I. Solvent Yellow 14 (Lot No. PY112075) Midwest Research Institute

APPENDIX E

Analysis of C. I. Solvent Yellow 14

(Lot No. PY112075)

A. Elemental Analysis

Element	C	н	N
Theory	77.40	4.87	11.29
Determined	76.66 76.71	4.71 4.72	11.04 10.94

B. Water Analysis

(Karl Fisher) $0.5 + 0.1 (\delta)$ %

C. Titration with Titanous Chloride (Horwitz, 1975)

94.1 + 0.5 (8)%

D. Melting Point

Determined

Literature Values

m.p. 131^o-134^oC, dec. (visual; sealed, evacuated capillary) 133°-134°C (Ernsberger and Brode, 1941)

E. Thin-Layer Chromatography

Plates: Silica Gel 60F-254 Amount Spotted: 100 and 300 µg Ref. Standard: Azobenzene Visualization: Visual Ultraviolet, 254 and 366 nm	
System 1: CH ₂ Cl ₂ (100%)	System 2: CC1 ₄ (100%)
R _f : 0.90 (trace) 0.77 (major) 0.66 (trace) 0.13 (trace) Origin (trace)	R _f : 0.36 (trace) 0.29 (trace) 0.16 (major) 0.04 (trace) Origin (trace)

R _{st} :	1.00, 0.85, 0.73,	R _{st} : 0.63, 0.51, 0.28,
	0.14, origin	0.08, origin

F. High-Pressure Liquid Chromatography

Instrument: Waters ALC 202 with Model 660 Solvent Programmer Column: C₁₈ µ-Bondapak, 300 x 4 mm I.D. Detector: Ultraviolet, 254 nm Solvent: 75% B + 25% A A: 0.005 M tetrabutyl ammonium hydroxide and 1% acetic acid in water. B: 0.005 M tetrabutyl ammonium hydroxide and 1% acetic acid in methanol. Flow: 1.5 ml/min


Results: Major peak and 2 minor peaks

Peak	Retention Time (min.)	Retention Time Relative to Solvent Yellow 14	Area Relative to Solvent Yellow 14
minor	3.1	0.23	0.5
minor	4.1	0.30	0.2
major	13.6	1.00	100

G. Spectral Data

(1) Infrared:

Instrument: Beckman IR-12	Consistent with
Cell: 0.75% in potassium bromide	literature spectrum
Results: See Figure 5.	(Sadtler Standard Spectra)



,

Figure 5. Infrared Absorption Spectrum of C.I. Solvent Yellow 14

(2) Ultraviolet/Visible:

Instrument:	Cary 118		lues (Przybylski McKeown, 1960)
λ max (nm)	<u>e x 10</u> -3	λ max (nm)	$\epsilon \times 10^{-3}$
229.5	$35.9 + 0.3 (\delta)$	230	36.84
254.5	10.75 + 0.04 (8)	254(a)	11.0
260(a)	$10.06 + 0.04(\delta)$	263(a)	9.9
264(a)	9.55 + 0.08 (b)	280	6.43
279.5	$6.26 + 0.04(\delta)$	303	6.62
304	$6.40 + 0.04(\delta)$	314(a)	6.4
316(a)	$6.11 + 0.04 (\delta)$	363(a)	6.3
360(a)	$6.28 + 0.05(\delta)$	380(a)	7.5
380(a)	$7.18 + 0.07 (\delta)$	430	12.28
433	$11.88 + 0.06 (\delta)$	462	12.60
463	$12.2 + 0.1 (\delta)$	492(a)	9.6
495(a)	$9.31 \pm 0.08 (\delta)$		
Solvent:	n-Hexane	Solvent: n	-Hexane

(a) Denotes point of inflection.

(3) Nuclear Magnetic Resonance:

Instrument: Varian HA-100 Solvent: Benzene-d₆ with internal tetramethylsilane Assignments: (See Figure 6): (a and b) m, $\delta = 6.85-7.64$ ppm; (c) d, $\delta = 8.77$ ppm Integration Ratios: (a and b) 10.62; (c) 0.38 No literature reference found. Spectrum consistent with the structure.




Figure 6. Nuclear Magnetic Resonance Spectrum of C.I. Solvent Yellow 14

150

.

APPENDIX F

Analysis of Formulated Diets for Stability of C. I. Solvent Yellow 14

.

.

APPENDIX F

Analysis of Formulated Diets for Stability of C. I. Solvent Yellow 14

1. MIXING AND STORAGE

C. I. Solvent Yellow 14 (2.551 g) and Wayne Lab-Blox[®] Rodent Feed (21.103 g) were mixed in a mortar. Samples of the mixture were removed and stored for 2 weeks at -20° , 5° , 25° , and 45° C, respectively. These samples were then analyzed by high-pressure liquid chromatography, as described below.

2. EXTRACTION

One-gram samples of each of the above mixtures were mixed with 50 ml of methanol in an ultrasonic vibratory bath for 1 minute and then were triturated for 1 minute with a Polytron[®] high-speed blender. The mixture was centrifuged, and the supernatant solution was decanted into a 100-ml volumetric flask. This extraction was repeated on the feed residue, and the combined supernatant solutions were brought to volume with fresh methanol.

3. ANALYSIS

Instrument: Waters ALC 202 with Model 660 Solvent Programmer Column: C₁₈ μ-Bondapak, 300 x 4 mm I.D. Detection: Ultraviolet, 254 nm Solvent: 13% A + 87% B (see Appendix E, Section F for solvent compositions) Flow rate: 1.5 ml/min.

Sample (°C)	Average Percentage Compound (a)	
-20	10.6 + 0.2	
5	10.7 + 0.2	
25	10.4 + 0.2	
45	10.6 ± 0.2	

(a) Corrected for a spiked recovery yield of 97.8%; theoretical 100% value = 10.8%

There was no significant difference between samples stored at the various temperatures.

4. CONCLUSION

C. I. Solvent Yellow 14 mixed with feed is stable for 2 weeks at temperatures up to 45° C.

APPENDIX G

Analysis of Formulated Diets for Concentrations of C. I. Solvent Yellow 14

APPENDIX G

Analysis of Formulated Diets for Concentrations of C. I. Solvent Yellow 14

A 100-mg sample of the dye-feed mixture was mixed with 10 ml of solvent (100% acetone) and agitated on a vortex mixer for 30 seconds. The suspension was centrifuged at room temperature for 5 minutes at 2,000 rpm. Levels used in the chronic study permit direct reading of the supernatant at 473 nm without further dilution. Internal standards were prepared using control powdered feed and were assayed in the same manner. All samples and standards were run in triplicate. The absorbance was determined at 473 nm in a Gilford 2400-S spectrophotometer. The spectrophotometer was blanked with a 100-mg feed sample treated in the same manner as the test samples. The standard curve developed with feed-dye standards (triplicate) automatically incorporates a correction for recovery. The concentration of dye in a feed sample could be read directly from the curve without any further adjustment for recovery.

The results of these analyses are summarized in Table Gl.

		Concentration(b) of C. I. Solvent Yellow 14 for Target Concentration of		
Date Mixed(a)	Date Used	250 ppm	500 ppm	1,000 ppm
4/17/77	week of 4/21	- -	510	1,060
8/15/77	week of 8/19	250	510	1,000
		240	480	
			470	
10/21/77	week of 10/25	230	480	1,000
		250	520	-
			490	
1/28/78	week of $2/1$	270	490	1,000
		270	500	
			500	
4/6/78	week of $4/10$		495	99 5
6/22/78	week of 6/26	256	471	1,020
		252	481	
			482	
7/12/78	week of 7/16	225	502	1,018
•		245	494	
			498	
9/13/78	week of 9/16	240	480	1,000
		260	500	
			510	
11/13/78	week of 11/17	240	500	950
		250	490	
1 /00 /70			500	0/0
1/23/79	week of 1/26	240	480	960
		250	510	
0/10/70	1 6 9 / 1 6		520	070
3/12/79	week of 3/16		495	970
Mean (ppm)		248	495	998
Standard Deviation Coefficient of		12.5	13.7	30.5
Variation (%)		5.	2.7	3
Range (ppm)		230-270	470-520	950-106
Number of Samples		16	27	11

Table G1. Analyses of Formulated Diets

ŧ

(a) 4/8/77 was the start date for mice and 3/10/77 was the start date for rats.

(b) The data presented are the average of duplicate analysis.

APPENDIX H

ł

Feed Consumption by Rats and Mice Receiving C. I. Solvent Yellow 14

160

,

	Control	I	WO	Hi	gh
	GRAMS	GRAMS	LOW/	GRAMS	HIGH/
	FEED/	FEED/	CONTROL	FEED/	CONTROL
Week	DAY(a)	DAY(a)	(b)	DAY(a)	(b)
5	19.0	19.6	1.0	18.3	1.0
10	15.9	16.7	1.1	15.0	0.9
14	17.7	16.1	0.9	18.6	1.1
18	17.3	17.4	1.0	17.7	1.0
22	18.3	16.4	0.9	16.9	0.9
26	18.4	17.4	0.9	17.7	1.0
30	20.0	18.1	0.9	18.9	0.9
36	20.3	17.7	0.9	19.9	1.0
41	19.0	17.6	0.9	18.3	1.0
46	24.6	22.7	0.9	25.3	1.0
50	12.0	17.1	1.4	19.1	1.6
54	21.0	19.1	0.9	21.7	1.0
58	24.6	23.3	0.9	23.9	1.0
62	19.7	18.0	0.9	20.1	1.0
67	19.9	23.1	0.9	24.3	1.2
70	22.0	22.7	1.0	23.6	1.1
75	19.9	17.0	0.9	19.7	1.0
81	19.4	16.9	0.9	16.9	0.9
84	21.6	21.0	1.0	22.4	1.0
88	20.9	25.0	1.2	23.6	1.1
92	18.6	18.3	1.0	21.4	1.2
97	18.1	21.9	1.2	23.4	1.3
98	21.0	21.3	1.0	25.4	1.2
101	23.9	20.7	0.9	16.3	0.7
Mean	19.7	19.4	1.0	20.3	1.0
SD (c)	2.7	2.6	0.1	3.1	0.2
CV (d)	13.7	13.4	10.0	15.3	20.0

Table H1. Feed Consumption by Male Rats Receiving C. I. Solvent Yellow 14

(a) Grams of feed consumed per animal per day.(b) Ratio of feed consumed per day for the dosed group to that for the controls.

(c) Standard deviation.

(d) (Standard Deviation/Mean) x 100.

	Control	L	WO	Hi	gh
	GRAMS	GRAMS	LOW/	GRAMS	HIGH/
	FEED/	FEED/	CONTROL	FEED/	CONTROL
Week	DAY(a)	DAY(a)	(b)	DAY(a)	(b)
3	12.6	13.6	1.1	12.7	1.0
8	13.3	12.9	1.0	12.4	0.9
12	13.4	10.1	0.8	12.1	0.9
16	13.0	12.7	1.0	12.0	0.9
20	13.0	12.6	1.0	12.0	0.9
24	12.7	12.1	1.0	11.0	0.9
28	12.7	13.4	1.1	12.3	1.0
34	13.6	12.7	0.9	12.7	0.9
39	12.0	11.3	0.9	12.6	1.1
44	17.1	19.0	1.1	18.1	1.1
48	20.4	12.0	0.6	11.6	0.6
52	15.3	12.1	0.8	14.0	0.9
56	20.3	18.6	0.9	21.3	1.0
60	13.9	12.4	0.9	13.6	1.0
65	16.3	15.6	1.0	17.3	1.1
68	13.6	17.3	1.3	16.7	1.2
73	13.9	12.9	0.9	13.0	0.9
79	12.6	11.3	0.9	11.1	0.9
82	15.3	13.4	0.9	14.0	0.9
86	16.0	14.3	0.9	16.0	1.0
90	14.9	13.7	0.9	17.4	1.2
95	12.3	12.3	1.0	12.7	1.0
99	13.7	12.7	0.9	13.6	1.0
Mean	14.4	13.4	0.9	13.9	1.0
SD (c)	2.3	2.2	0.1	2.6	0.1
CV (d)	16.0	16.4	11.1	18.7	10.0

(a) Grams of feed consumed per animal per day.(b) Ratio of feed consumed per day for the dosed group to that for the controls.

.

(c) Standard deviation.(d) (Standard Deviation/Mean) x 100.

	Control	I	WOL	Hi	gh
	GRAMS	GRAMS	LOW/	GRAMS	HIGH/
	FEED/	FEED/	CONTROL	FEED/	CONTROL
Week	DAY(a)	DAY(a)	(b)	DAY(a)	(b)
1	7.7	7.6	1.0	7.7	1.0
5	7.3	7.9	1.1	7.7	1.1
10	3.3	3.9	1.2	3.6	1.1
14	5.7	6.0	1.1	5.9	1.0
19	8.3	8.1	1.0	7.9	1.0
23	8.4	8.7	1.0	8.3	1.0
27	8.4	8.9	1.1	8.4	1.0
33	8.0	8.3	1.0	8.4	1.1
37	8.3	8.3	1.0	8.1	1.0
42	7.9	8.1	1.0	8.3	1.1
46	8.3	8.3	1.0	8.3	1.0
50	8.7	8.4	1.0	8.6	1.0
54	8.6	8.6	1.0	8.6	1.0
58	7.9	8.3	1.1	8.6	1.1
62	9.4	9.0	1.0	9.1	1.0
66	8.9	8.9	1.0	9.0	1.0
71	9.7	9.0	0.9	9.0	0.9
77	8.9	8.6	1.0	8.9	1.0
79	11.1	9.7	0.9	10.6	1.0
84	8.7	8.6	1.0	9.3	1.1
88	9.7	9.1	0.9	9.6	1.0
92	9.1	9.0	1.0	9.7	1.1
96	8.6	8.6	1.0	9.1	1.1
100	10.6	9.6	0.9	11.9	1.1
Mean	8.4	8.3	1.0	8.5	1.0
SD (c)	1.5	1.2	0.1	1.5	0.1
CV (d)	17.9	14.5	10.0	17.6	10.0

Table H3. Feed Consumption by Male Mice Receiving C. I. Solvent Yellow 14

(a) Grams of feed consumed per animal per day.(b) Ratio of feed consumed per day for the dosed group to that for the controls.

(c) Standard deviation.

(d) (Standard Deviation/Mean) x 100.

	Control	ntrol Low		High	
Week	GRAMS FEED/ DAY(a)	GRAMS FEED/ DAY(a)	LOW/ CONTROL	GRAMS FEED/	HIGH/ CONTROL
week	DAI(a)	DAI(a)	(b)	DAY(a)	(b)
1	7.4	7.3	1.0	7.0	0.9
4	7.4	7.0	0.9	7.7	1.0
9	2.1	1.9	0.9	1.7	0.8
13	4.9	2.4	0.5	4.7	1.0
18	8.0	7.9	1.0	7.4	0.9
22	7.6	8.9	1.2	7.7	1.0
26	8.1	8.1	1.0	7.9	1.0
32	8.0	7.4	0.9	8.3	1.0
36	8.3	8.3	1.0	8.1	1.0
41	8.0	8.1	1.0	7.7	1.0
45	8.4	7.1	0.8	8.1	1.0
49	8.0	8.1	1.0	8.3	1.0
53	8.1	8.0	1.0	7.4	0.9
57	8.3	8.6	1.0	8.4	1.0
61	8.6	8.1	0.9	8.3	1.0
65	8.4	8.3	1.0	8.7	1.0
70	8.7	8.6	1.0	9.4	1.1
76	8.4	8.3	1.0	8.4	1.0
78	10.3	10.4	1.0	9.9	1.0
83	9.1	8.3	0.9	7.9	0.9
87	9.0	9.3	1.0	8.3	0.9
91	9.3	9.3	1.0	8.7	0.9
95	10.7	9.0	0.8	9.0	0.8
99	11.1	10.4	0.9	10.3	0.9
Mean	8.2	7.9	1.0	7.9	1.0
SD (c)	1.8	2.0	0.1	1.7	0.1
(b) VO	22.0	25.3	10.0	21.5	10.0

Table H4. Feed Consumption by Female Mice Receiving C. I. Solvent Yellow 14

(a) Grams of feed consumed per animal per day.(b) Ratio of feed consumed per day for the dosed group to that for the controls.

(c) Standard deviation.

(d) (Standard Deviation/Mean) x 100.

☆[U.S. GOVERNMENT PRINTING OFFICE: 1982-381-132:683

NIH Publication No. 82-1782 September 1982